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ABSTRACT ABSTRACT ABSTRACT ABSTRACT       
       
The intestinal spirochaete Brachyspira hyodysenteriae is the causative agent of swine 
dysentery  (SD),  a  diarrhoeal  disease  of  pigs  which  has  significant  economic  impact 
worldwide.  Controlling  SD  remains  problematic,  particularly  as  there  is  no  effective 
vaccine and there are few definitive diagnostic methods available. In this study, a partial 
genomic sequence of B. hyodysenteriae was screened in silico. A total of 19 putative 
open reading frames (ORFs) encoding outer-membrane proteins then were selected and 
these were subjected to a laboratory screening process. To select potential universal 
vaccines, a preliminary study was conducted using PCR to determine the distribution of 
the putative genes in 23 strains of B. hyodysenteriae. A total of 17 of the 19 ORFs were 
considered to be suitable for further testing as they were found to be present in the 
majority  of  strains  investigated.  After  molecular  cloning  and  protein  expression  and 
purification, of 19 cloned candidate molecules derived from 17 genes (one large gene 
was divided into two parts encoding N and C terminal proteins, respectively), 14 were 
expressed in E. coli and the recombinant proteins were successfully produced. A variety 
of sera from pigs naturally and experimentally infected with B. hyodysenteriae were 
tested  for  reactivity  with  the  14  recombinant  proteins  in  an  immunoblotting  assay. 
Seven molecules from six genes reacted strongly with the tested sera, and therefore 
were  selected  and  used  to  immunize  mice.  All  these  proteins  generated  a  specific 
antibody response. Post-immunization sera raised against each recombinant protein had 
the capacity to agglutinate B. hyodysenteriae cells, and also recognized the cognate 
proteins of B. hyodysenteriae in cell extracts. Further sequencing analysis demonstrated 
that  these  molecules  were  highly  conserved  in  the  genomes  of  different  B.   v 
hyodysenteriae strains. Therefore, from the genomic-based study, the products of six 
genes were identified as promising candidates for vaccines or as diagnostic targets. 
 
Four  genes  were  expressed  on  a  large  scale,  the  products  (NAV-H7,  NAV-H17  C-
terminal, NAV-H34 and NAV-H42) were combined into one vaccine, and then this 
preparation  was  used  to  immunise  pigs  that  subsequently  were  challenged  with  B. 
hyodysenteriae. These antigens generate systemic and colonic antibody responses, and 
vaccination  tended  both  to  delay  the  onset  of  clinical  signs  and  attenuate  lesion 
development. Hence these recombinant proteins showed promise as components for 
further SD vaccines. 
 
Recombinant proteins from the selected genes also were used as antigens in class-specific 
ELISAs  used  as  serological  assays  for  SD.  Three  antigens  (NAV-H8,  NAV-H42  and 
Bhlp29.7) were selected as good indicators of seroconversion in IgM ELISAs, and these 
were evaluated further using a large range of serum samples. The NAV-H8 IgM ELISA 
using a cut-off value 2.5 times the mean value of all negative pigs could be used as a 
herd test for SD, and both the NAV-H8 and NAV-H42 IgM ELISAs had potential for 
detecting exposure to B. hyodysenteriae at the pig level. 
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CHAPTER ONE: LITERATURE REVIEW CHAPTER ONE: LITERATURE REVIEW CHAPTER ONE: LITERATURE REVIEW CHAPTER ONE: LITERATURE REVIEW       
               
1.1. FOREWORD 1.1. FOREWORD 1.1. FOREWORD 1.1. FOREWORD       
       
Swine dysentery (SD) is a severe mucohaemorrhagic colitis of weaner, grower and 
finisher  swine,  resulting  from  infection  with  the  anaerobic  intestinal  spirochaete 
Brachyspira hyodysenteriae (Harris and Lysons, 1992). The control of SD remains 
problematic for pig production worldwide. Whilst the disease can be eradicated by 
a combination of depopulation, thorough cleaning and disinfection, this procedure 
is  not  always  effective.  Control  can  be  achieved  using  antimicrobials,  although 
resistance to these agents is increasing (Hampson et al., 1997). The availability of an 
effective vaccine would be a useful adjunct to control. Unfortunately, whole cell 
bacterins have shown limited efficacy, so attention recently has been focused on 
identification of surface proteins for use as subunit vaccines. However, conventional 
methods  to  identify  potential  targets  have  had  limited  success.  In  recent  years 
functional  genomic  studies  have  been  successfully  applied  to  several  infectious 
diseases, using an analysis of entire genomes to identify vaccine candidates on a 
global genome basis. The present study is the first application of a genomic study for 
vaccine development for SD.  
 
This literature review consists of two major parts: “reverse vaccinology”, describing 
the  background  to  the  methodology  applied  in  this  project,  and  “Brachyspira 
hyodysenteriae, the causative agent of swine dysentery”, describing the pathogenic 
spirochaete and the disease it causes. In relation to the reverse vaccinology section, 
useful information was derived from several excellent reviews by Grandi (2001),   - 2 - 
Serruto et al (2004), Rappuoli (2000 and 2001), Mora et al (2003), and Adu-Bobie 
et al (2003). The author acknowledges their insight, which is reflected in parts of the 
review.  
 
1.2. 1.2. 1.2. 1.2.   REVERSE  VACCINOLOGY  REVERSE  VACCINOLOGY  REVERSE  VACCINOLOGY  REVERSE  VACCINOLOGY:  A  GENOMIC :  A  GENOMIC :  A  GENOMIC :  A  GENOMIC- - - -BASED  APPROACH  FOR  V BASED  APPROACH  FOR  V BASED  APPROACH  FOR  V BASED  APPROACH  FOR  VACCINE  ACCINE  ACCINE  ACCINE 
DISCOVERY            DISCOVERY            DISCOVERY            DISCOVERY                                                                                                                                                                        
       
1.2.1. Introduction 1.2.1. Introduction 1.2.1. Introduction 1.2.1. Introduction       
 
Pathogenic  microorganisms  remain  one  of  the  most  important  threats  to  global 
health.  Many  infectious  disease  agents  have  never  been  eliminated,  or  have  re-
occurred,  whereas  others  have  emerged  as  a  new  threat  (Wren,  2000).  On  the 
other  hand,  the  development  of  resistance  to  antimicrobials  has  rendered  the 
control  of  a  variety  of  infections  much  more  difficult  and  expensive.  However, 
vaccination  can  be  an  effective  tool  both  to  prevent  diseases  and  limit  the 
development of  microbial  resistance.  The  remarkable  decline  in  the  incidence of 
many diseases following immunisation demonstrates that vaccines can be efficacious. 
Unfortunately, there are still many infectious diseases without efficacious vaccines, 
and for most of them the traditional approaches to vaccine discovery have proved 
ineffective (Rappuoli, 2001). 
 
Most vaccines currently in clinical use were generated a long time ago, and are based 
on killed or lived-attenuated microorganisms, toxin components detoxified by chemical 
treatment, purified antigens or polysaccharides conjugated to proteins (Serruto et al., 
2004). For the vaccines that use highly purified protective antigens,  considerable efforts   - 3 - 
were made to clarify the pathogenesis of the infections to identify the main virulence 
factors and  to characterise the immune response before the target components were 
located (Del Giudice and Rappuoli, 1999). Using this approach, advanced genetic tools 
are required to purify the antigens in quantities suitable for vaccine testing, since the 
most abundant antigens often  tend not to be appropriate vaccine candidates (Adu-
Bobie et al., 2003). These methods have been successful in many cases, but they require 
the pathogens to be cultured in laboratory conditions, which makes them unsuitable for 
vaccine development for non-cultivatable microorganisms (Mora et al., 2003). 
 
The availability of complete bacterial genome sequences has allowed a new approach 
to  developing  vaccines  with  high  efficiency  and  rapidity.  This  novel  genome-based 
approach, which has been termed “Reverse Vaccinology” (Rappuoli, 2000; Rappuoli, 
2001), enables the design of vaccines regardless of antigen abundance and without the 
need  to  grow  the  pathogen  in  vitro.  It  has  been  successfully  applied  to  Neisseria 
meningitidis serogroup B for which conventional strategies have failed to provide an 
efficacious vaccine (Pizza et al., 2000). The concept of reverse vaccinology can be easily 
applied  not  only  to  bacteria  but  also  to  parasites  and  viruses.  In  addition,  novel 
technologies, such as bioinformatics, random mutagenesis, microarrays and proteomics 
can be configured into a complete genomic database to strengthen the approach to 
vaccine development and provide a new impetus to microbial research. 
       
1.2.2. Classical  1.2.2. Classical  1.2.2. Classical  1.2.2. Classical vaccinology in the 20 vaccinology in the 20 vaccinology in the 20 vaccinology in the 20th th th th century  century  century  century       
       
Classical vaccines in the 20th century consisted of two broad groups: whole-cell vaccines 
and subunit vaccines. Whole-cell vaccines use killed or attenuated pathogens to induce   - 4 - 
protective immunity. However, this type of vaccine is not always successful, and the 
potential reversion of live vaccine to the original virulent phenotype has always been a 
major concern. In the last few decades many of the newer vaccines have been based on 
the subunit approach. Like the genomic based approach, vaccines of this sort contain 
one or several protective antigens selected from immunogenicity studies. However, the 
traditional  subunit  vaccine  strategy  uses  biochemical,  microbiological  and  serological 
methods  on  laboratory-grown  pathogens  to  identify  individual  antigen  components 
(Rappuoli 2001, Fig 1.1), and each antigen is then assessed for its ability to induce an 
immune response. Although recombinant-DNA techniques have facilitated purifying the 
characterised  antigens,  using  this  approach  only  a  few  antigens  are  analysed 
simultaneously,  and  therefore  it  often  needs  iterative  cycles  to  obtain  useful  target 
protein components.  Also this method is not applicable to non-cultivable organisms, as 
the pathogens must be grown in vitro to characterise the candidate antigens for further 
genetic  manipulation.  To  date  two  very  efficacious  recombinant  vaccines,  the  anti-
Hepatitis B Virus vaccine (Andre, 1990) and the anti-Bordetella pertussis vaccine (Greco 
et al., 1996) have been produced by this approach, and are used for human vaccination. 
 
Fig. 1.1. Conventional approach to vaccine development, adapted from Rappuoli (2001)   - 5 - 
Most of the existing vaccines for humans and animals are safe and effective, but there is 
a proportion of infectious diseases for which the traditional approaches have failed and 
for which vaccines still need to be developed. Moreover, regulatory authorities now 
required  vaccines  to  meet  extremely  high  standards  of  safety  and  chemical-physical 
characterisation (Grandi, 2001). Therefore there is a clear need for a new approach to 
vaccine development. 
       
1.2.3. Reverse vaccinology 1.2.3. Reverse vaccinology 1.2.3. Reverse vaccinology 1.2.3. Reverse vaccinology 
       
           The  technology  for  sequencing  entire  genomes  of  microorganisms  is  a  recent 
development. The publication in 1995 of the first complete bacterial genome sequence 
for Haemophilus       influenzae represented the beginning of a “genomic era” (Fleischmann 
et al., 1995). The pace of genomic sequencing and analysis is increasing dramatically. As 
of 2007, around 941 completed genome sequences of pathogens and non-pathogens 
are  available  in  the  ERGO  database  (Online  database  at 
http://wit.integratedgenomics.com/GOLD/).  With  the  advent  of  various  sophisticated 
bioinformatics tools, the gene repertoire of a given pathogen can be screened by a 
series  of  computer  algorithms  to  select  antigens  with  vaccine  potential,  supplying 
valuable  information  for  follow-up  experimental  assessment.  This  novel  approach, 
reverse  vaccinology  (Figure  1.2)  comprises  in  silico  selection  and  wet  laboratory 
screening. 
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Fig. 1.2. Schematic representation of the “reverse vaccinology” genome-based approach   
to vaccine development, modified from Serruto et al (2004). 
            
           1.2.3.1.  1.2.3.1.  1.2.3.1.  1.2.3.1. In silico In silico In silico In silico analysis of genomes  analysis of genomes  analysis of genomes  analysis of genomes 
       
           1.2.3.1.            1.2.3.1.            1.2.3.1.            1.2.3.1.1. Secreted or surface 1. Secreted or surface 1. Secreted or surface 1. Secreted or surface- - - -exposed proteins exposed proteins exposed proteins exposed proteins       
       
           Secreted  or  surface-exposed  proteins  are  the  most  favoured  candidates  for  vaccine 
development because these proteins are most easily accessible to the immune system, 
and may be able to induce protective immunity in host species. A search for homologies 
to  known outer-membrane  proteins  is  a  common  method  to  identify  open  reading 
frames (ORFs) with a surface location. Various algorithms are  also available to identify   - 7 - 
proteins with a subcellular localization spanning the cytoplasm to the outer membrane, 
with an accuracy of 76%-91% (Zagursky and Russell, 2001). In addition, several other 
approaches  can  be  used  to  mine  genomic  sequences  to  predict  features  typical  of 
surface-associated  proteins,  such  as  transmembrane  domains,  leader  peptides, 
lipoprotein signatures, outer membrane anchoring motifs and host-cell binding domains 
(Chakravarti  et  al.,  2000).  The  success  of  the  genomic-based  strategies  for  vaccine 
development is highly dependent on the criteria used for the in silico selection of the 
potential antigens. Therefore, the appropriate combination of the various algorithms 
and  a  critical  evaluation  of  the  information  generated  are  essential  for  the  proper 
selection of antigens. 
 
1.2.3.1.2. Virulence factors  1.2.3.1.2. Virulence factors  1.2.3.1.2. Virulence factors  1.2.3.1.2. Virulence factors        
 
As virulence factors are crucial components for a pathogen to gain access to and survive 
in its niche within the host, neutralization of these factors by a vaccine-induced immune 
response may elicit protection (Allan and Wren, 2003). Moreover, in practice, some 
bacterial exotoxins are the basis of effective toxoid vaccines. For these reasons, bacterial 
virulence  factors,  particularly  surface-located  molecules  and  secreted  toxins,  are  also 
considered good vaccine candidates. 
 
In the search for virulence genes, the most common strategy is to compare putative 
coding  sequences  with  recognised  virulence  genes  recorded  in  databases.  However, 
sequence comparison cannot be used for the prediction of new families of virulence 
factors because from the bacterial genome sequences available so far, it appears that   - 8 - 
∼20% of the predicted ORFs in a genome do not match anything in the databases, and 
an additional 15-20% have homologies with genes of unknown function (Grandi, 2001).  
 
Another approach to virulence gene discovery is to search for tandem repeats at the 5’ 
ends  of  genes,  as  these  are  associated  with  certain  virulence  genes.  Because  of  the 
recombination events often occurring within the repeated regions, the expression of 
such genes contributes to an attenuated or virulent phenotype under phase variation 
(Saunders et al., 1998). Some clusters of virulence factors are known to share common 
regulatory sites. Novel virulence factors can also be identified by searching for unknown 
genes that are co-regulated with known virulence genes (Grandi, 2001). 
   
Finally, the virulence of many pathogens often correlates with the presence of DNA 
tracts  encoding  disease-related  factors,  the  so-called  “pathogenicity  islands”  (PAIS). 
These  fragments  are  usually  acquired  by  genetic  horizontal  transfer  (GHT)  and  are 
absent  from  non-pathogenic  species  (Hacker  and  Kaper,  2000).  Thus,  comparative 
genomics analysis easily can be carried out in silico to search for the complete set of 
genes potentially responsible for virulence, which then can be used as purified antigens 
in subunit-based vaccines (Scarselli et al., 2005). 
 
1.2.3.2. Experimental strategies 1.2.3.2. Experimental strategies 1.2.3.2. Experimental strategies 1.2.3.2. Experimental strategies       
       
           A large range of genes coding for potential vaccine candidates can be obtained from in 
silico selection, covering as much as 25% of the total number of ORFs in the genome 
(Mora et al., 2003). Whether the selected putative coding sequences are useful has to 
be  further  examined  and  refined  by  various  experiments.  The  routine  procedure   - 9 - 
requires  each  ORF  to  be  expressed  and  the  target  recombinant  protein  purified. 
Recombinant proteins can easily be prepared using recombinant DNA technology. To 
optimise utilization of the valuable information extracted from genomic analysis, gene 
cloning  and  expression  analysis  have  recently  started  to  be  implemented  in  a  high 
throughput format  (Dieckman  et  al.,  2002),  and  this  has  accelerated  the  process of 
vaccine development. Nevertheless, the traditional process remains useful, particularly 
when  dealing  with  a  small  number  of  candidate  antigens  produced  from  in  silico 
analysis, or with bacterial genomes of small size. 
  
           Once  purified,  the  recombinant  proteins  are  evaluated  by  in  vitro  and  in  vivo 
immunogenicity  assays  to  select  highly  immunodominant  proteins.  This  may  be  by 
fluorescence-activated  cell  sorter  (FACS)  or  immunofluorescence  assay  to  confirm 
subcellular  localization,  and  by  serology,  using  Western  blots  to  choose  conserved 
antigens which react with most heterologous strains. After multiple screening steps, a 
small number of antigens are selected and tested in an animal model in a protection 
study. Often, due to the lack of  a reliable animal model,  alternative methods have to 
be developed, such as in vitro assays that are known to correlate with vaccine efficacy 
in hosts (e.g. assays that measure bactericidal activity and opsonophagocytosis) (Mora 
et al., 2003). 
                         
           The  major  differences  regarding  vaccine  development  between  the  conventional 
approach and reverse vaccinology are summarized in Table 1.1.   
 
            
   - 10 - 
 
           Table.  1.1.  Comparison  of  conventional  and  genomic  approaches  to  vaccine 
development, modified from Rappuoli (2000). 
Conventional va Conventional va Conventional va Conventional vaccinology ccinology ccinology ccinology        Reverse vaccinology Reverse vaccinology Reverse vaccinology Reverse vaccinology       
Cultivable microorganism                 
Cultivable and non-cultivable 
microorganisms 
Antigens expressed in vitro  Antigens expressed in vitro and in vivo 
Most abundant antigens during disease  All antigens 
Animal models essential  Animal models important 
Structural components of microorganisms 
Non-structural components, including 
early proteins of viruses 
 
Correct folding in recombinant expression 
important 
High throughput expression/analysis 
important 
Correlates of protection useful  Correlates of protection very important 
Polysaccharides may be used as antigens 
Lipoplysaccharide-based vaccines are 
possible, glycolipids and other CD1- 
restricted antigens can be used 
Non-protein antigen cannot be used  
(polysaccharides, LPS, glycolipids  
and other CD1 restricted antigens) 
 
Antigens which are not immunogenic 
during infection can be identified 
       
       
         - 11 - 
1.2.4. Application of reverse vaccinology to vaccine discovery 1.2.4. Application of reverse vaccinology to vaccine discovery 1.2.4. Application of reverse vaccinology to vaccine discovery 1.2.4. Application of reverse vaccinology to vaccine discovery       
 
Group B meningococcus (Neisseria meningitidis: MenB), a major infectious pathogen in 
humans, was the first example of a successful application of reverse vaccinology. Since 
the MenB capsule shares chemical structures with many human tissues, it cannot be used 
in a conventional approach to preparation of vaccines due to its potential to cause 
autoimmunity.  Hence  surface  antigens  have  been  given  priority  for  vaccine 
development. Nevertheless, antigens identified by the traditional methods present high 
sequence  and  antigenic  variability  and  only  elicit  protective  antibodies    against  the 
homologous strains (de Moraes et al., 1992; Tappero et al., 1999) 
         
The  availability  of  the  complete  genome  sequence  of  MenB  (Tettelin  et  al.,  2000) 
provided an opportunity to take a different, genomic-based approach (Figure 1.3). A 
primary screening in silico involved using database and computer programmes such as 
PSORT or SignalP, to predict the signal peptide sequences, TMPRED to identify putative 
hydrophobic membrane regions and MOTIFS to discover lipoproteins. ORFs coding for 
proteins  with  homology  to  known  virulence  factors  of  other  bacteria  were  also 
identified. The computer prediction resulted in identification of 600 potentially useful 
ORFs,  all  of  which  were  cloned  in  an  E.  coli  mediated  expression  system.  Three 
hundred and fifty recombinant proteins were expressed, purified and used to immunise 
mice. The post-immunisation sera were analysed in Western blot, ELISA and FACS assays 
to test whether each protein was really expressed in vivo and localized in the outer 
membrane.  Ninety  one  novel  surface-exposed  proteins  were  identified  and  further 
examined by bactericidal activity, which correlates with protection in the host species. 
From this screening, 28 were positive in the bactericidal assay, and five proteins showed   - 12 - 
relatively  complete  conservation  of  their  amino  acid  sequence  across  heterologous 
MenB strains (Pizza et al., 2000).  
 
 
 
 
 
 
                      
Fig. 1.3. Neisseria meningitidis serogroup B as an example of reverse vaccinology, demonstrating 
how complete microbial genome sequence data can accelerate vaccine development (modified from 
Rappuoli 2005, www.meningitis.org/assets/pdf/conference_2005/C05_2_15_Rappuoli.pdf).       
 
The  success  of  reverse  vaccinology  for  MenB  stimulated  research  to  utilize  the  novel 
approach  to  identify  new  candidates  in  other  bacteria.  So  far,  bacteria  that  have  been 
studied include Bacillus anthracis (Ariel et al., 2002), Chlamydia pneumoniae (Montigiani et 
al., 2002), Streptococcus pneumoniae (Wizemann et al., 2001),  Porphyromonas gingivalis 
(Ross et al., 2001) and  Leptospira interrogans (Gamberini et al., 2005). All of these used 
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the same genomic-based concept, analysing the whole genome to identify candidates for 
clinical trial (Table 1.2). Each research group used slightly different specific prediction tools 
and experimental strategies.  
 
Pathogens Pathogens Pathogens Pathogens        Genome size Genome size Genome size Genome size       
           No. of No. of No. of No. of       
Candidates Candidates Candidates Candidates       
Examples of the described candidates Examples of the described candidates Examples of the described candidates Examples of the described candidates 
Neisseria meningitidis  2.27Mb 
(2158 ORFs) 
5  NadA: A new adhesion vaccine candidate 
NarE:  A novel mono-ADP-ribosyltransferase 
GNA 1870: Surface-exposed lipoprotein 
GNA 33:  Membrane-bound lytic transglycosylase 
App: A new adhesion with autocatalytic serine 
protease activity 
 
Bacillus anthracis  181Kb (Plasmid) 
(143 ORFs) 
 
3  ORF54: S-layer (N terminus) 
ORF90: S-layer plus DNA repair, repeats 
ORF130: Adhsin, enzyme 
 
Chlamydia  pneumoniae  1.23Mb 
(1130 ORFs) 
28  78.0 kDa: Predicted OMP 
57.5 kDa: Oligopeptide binding protein 
39.3 kDa: ompA (Major Outer Membrane Protein) 
34.4 kDa: porB (Outer Membrane Protein analog) 
17.3 kDa: OmpH-like outer membrane protein 
57.3 kDa: omcB (60 kDa Cysteine, rich Lipoprotein) 
28.0 kDa: fliY (Glutamine binding protein) 
71.3 kDa: dnaK (hsp 70 heat shock protein) 
Streptococcus  pneumoniae  2.16Mb 
(2236 ORFs) 
6  Sp36: Spase II 
Sp46: Choline-binding protein 
Sp91: Choline-binding protein 
Sp130: Cell wall anchor 
Porphyromonas  gingivalis  2.34Mb 
(1990 ORFs) 
2  PG32: Outer membrane porcin OprF 
PG33: Outer membrane porcin OprF 
 
Leptospira  interrogans  
   
   
4.6Mb 
(4768 ORFs) 
 
4  MPL36: Putative Lipoprotein 
OMPAL21: Membrane protein, peptidoglycan related 
OMPL15: Hypothetical protein   
Table 1.2. Examples of application of reverse vaccinology to bacterial pathogens         - 14 - 
1.2.5. Functional genomics in vaccine discovery 1.2.5. Functional genomics in vaccine discovery 1.2.5. Functional genomics in vaccine discovery 1.2.5. Functional genomics in vaccine discovery       
       
Complementary  to  the  in  silico  antigen  discovery  approach,  new  disciplines  in 
molecular biology have emerged and have been referred to as “functional genomics”. 
These  techniques,  including  mutational  analysis  (In  vivo  expression  technology  and 
Signature-tagged  mutagenesis),  microarray  technology  and  proteomics  analysis,  have 
been  incorporated  into  reverse  vaccinology  to  accelerate  the  process  of  identifying 
vaccine targets as well as validating and extending the range of available candidate 
antigens (Figure 1.2). In addition, by characterising a functional relationship for genes 
and proteins with phenotypes such as the presence and mode of pathogenicity, they 
offer new perspectives for identification of virulence factors. This information could 
lead to the production of  attenuated mutants, which might be used as live vaccines or 
delivery systems for heterologous antigens (Scarselli et al., 2005).  
       
1.2.6. Compa 1.2.6. Compa 1.2.6. Compa 1.2.6. Comparative genome analysis in vaccine discovery rative genome analysis in vaccine discovery rative genome analysis in vaccine discovery rative genome analysis in vaccine discovery       
 
As  described  in  section  1.2.3.1.2,  in  silico  comparative  genome  analysis  between 
pathogens  and  closely  related  non-pathogenic  microorganisms  offers  a  valuable 
guideline  in  the  search  for  virulence-associated  genes,  or  for  conserved  vaccine 
candidates  stably  maintained  within  the  natural  population  of  the  target  pathogen 
(Scarselli  et  al.,  2005).  Recently,  other  new  techniques  including  microarray-based 
comparative  genomic  hybridization  (array  CGH)  and  comparative  proteomics  have 
been introduced, and have been widely used as tools for antigen discovery in many 
pathogens (Grifantini et al., 2002; Jungblut et al., 1999; Jungblut et al., 2000; Mattow 
et al., 2001).   - 15 - 
1.2.7. Conclusions 1.2.7. Conclusions 1.2.7. Conclusions 1.2.7. Conclusions       
       
The use of whole genome sequences of bacteria has changed the approach taken to the 
investigation of bacterial pathogens, and is being used to augment the development of 
vaccines, therapeutics and diagnostics.  However, genome data alone cannot be used to 
accurately  predict  the  in  vivo  efficacy  of  candidate  vaccines.  Therefore,  many 
predictions generated based on in silico criteria need to be validated and narrowed 
down through various genetic technologies, and biochemical approaches, followed by 
the use of appropriate animal models, or, in the case of animal diseases, the host species. 
 
The  reverse  vaccinology  approach  offers  the  ability  to  undertake  a  rapid  and 
comprehensive  prediction  of  a  microorganism’s  surface  protein  repertoire,  and  has 
advantages over conventional approaches in identifying candidate antigens. Although 
most published studies have been conducted on human pathogens, the approach can 
also be  used  for  infectious  agents of  animals. Functional  genomics and  comparative 
genome analysis represent an alternative approach to gain a better understanding of 
pathogen  biology  and  likely  interactions  with  the  host  immune  system,  providing 
further scope to target key vaccine candidate antigens.  
 
       
       
       
       
       
         - 16 - 
1.3.  1.3.  1.3.  1.3.  BRACHYSPIRA  HYODYSEN BRACHYSPIRA  HYODYSEN BRACHYSPIRA  HYODYSEN BRACHYSPIRA  HYODYSENTERIAE TERIAE TERIAE TERIAE:  THE  AETIOLOGICAL  A :  THE  AETIOLOGICAL  A :  THE  AETIOLOGICAL  A :  THE  AETIOLOGICAL  AGENT  OF  SWINE  GENT  OF  SWINE  GENT  OF  SWINE  GENT  OF  SWINE 
DYSENTERY DYSENTERY DYSENTERY DYSENTERY       
       
1.3.1. General information on the spirochaetes 1.3.1. General information on the spirochaetes 1.3.1. General information on the spirochaetes 1.3.1. General information on the spirochaetes       
       
Spirochaetes are a group of morphologically distinct, helical coiled, rod-like bacteria, 
possessing  a  protoplasmic  cylinder  and  periplasmic  flagella  covered  by  an  outer 
envelope. Each flagellum is attached to one polar end of the cell, and winds down the 
length of the cell under the outer membrane. Periplasmic flagella allow spirochaetes to 
move in a corkscrew-like fashion, so enabling their movement in liquids, even those 
that are too viscous for externally flagellated bacteria (Greenberg and Canale-Parola, 
1977; Paster et al., 1991). 
 
Spirochaetes belong to the Kingdom Eubacteria, Order Spirochaetales, and are weakly 
Gram-negative. They utilize carbohydrates or amino acids as carbon and energy sources, 
and the DNA of various genera and species has a mol% guanine plus cytosine (G+C) 
content of between 25-65. They have been reported in a wide variety of habitats, and 
are  found  free-living  in  the  environment  in  soil,  mud  and  water,  as  well  as  in  the 
gastrointestinal tract, mouth, and genital areas of humans and animals (Johnson, 1977). 
They may be obligate or facultative anaerobes, aerobes or microaerophlic depending 
on  their  preferred  environment.  The  spirochaetes  have  been  divided  into  six  major 
phylogenetic  clusters,  comprising  the  genera  Spirochaete,  Treponema,  Borrelia, 
Leptospira, Leptonema and Brachyspira on the basis of the RNA sequence of their 16S 
ribosomal subunit (Paster et al., 1991) ( Figure 1.4).    - 17 - 
 
 
Figure 1.4. 16S rRNA dendrogram of the spirochaetes, demonstrating phylogenetic 
relationships between representatives of each genera. The scale bar represents a 5% 
difference in nucleotide sequence. Adapted from Paster et al. (1991) and Paster and 
Dewhirst (2000).   - 18 - 
This  thesis  concentrates  on  the  pathogenic  spirochaete  Brachyspira  hyodysenteriae, 
particularly in relation to vaccine development using a genome-based approach. Hence, 
the  rest  of  the  review  will  mainly  focus  on  giving  a  general  background  to  the 
spirochaete and the disease it causes, followed by more detailed information on the 
genetics and potential virulence factors of B. hyodysenteriae. 
 
1.3.2. Description of the genus  1.3.2. Description of the genus  1.3.2. Description of the genus  1.3.2. Description of the genus Brachyspira Brachyspira Brachyspira Brachyspira       
       
Originally,  species  in  the  genus  Brachyspira were  included  in  the  genus  Treponema, 
because of their anaerobic requirements, morphology and habitat (Harris et al., 1972; 
Kinyon  and  Harris,  1974).  Early  comparative  studies  between  the  genomes  of  T. 
pallidum and the current Brachyspira hyodysenteriae indicated that these two species 
were only distantly related (Miao et al., 1978). Later, both B. hyodysenteriae and the 
weakly haemolytic non-pathogen B. innocens were reclassified based on DNA: DNA re-
association and 16S rRNA gene sequencing as a unique genus Serpula (Stanton et al., 
1991).  It  was  then  realised  that  this  genus  name  was  already  used  for  a  fungus,  so 
Serpula was changed to Serpulina (Stanton, 1992). Finally, based on further molecular 
studies, Serpulina and Brachyspira were unified into one genus Brachyspira, as this genus 
name  was  published  and  accepted  before  Serpulina  (Ochiai  et  al.,  1997).  The 
Brachyspira  genus  currently  contains  the  species  B.  hyodysenteriae,  B.  innocens,  B. 
intermedia, B. murdochii, B. alvinipulli, B. pilosicoli, B. aalborgi, and the provisionally 
named “B. canis” and “B. pulli” (Hampson and La, 2006). With the exception of B. 
hyodysenteriae, they are all weakly β-haemolytic. Therefore, β-haemolytic activity has 
been one of the major phenotypic characteristics used to distinguish B. hyodysenteriae   - 19 - 
from other species of Brachyspira. Phenotypic features of these species are shown in 
Table 1.3. 
       
1.3.3. Swine dysentery 1.3.3. Swine dysentery 1.3.3. Swine dysentery 1.3.3. Swine dysentery       
               
1.3.3.1. Introduction 1.3.3.1. Introduction 1.3.3.1. Introduction 1.3.3.1. Introduction       
 
Swine dysentery (SD) is an infectious disease of pigs, arising from colonisation of the 
large intestine with virulent strains of the intestinal spirochaete B. hyodysenteriae. SD is 
characterised  by  inflammation,  excess  mucus  production,  and  necrosis  of  the  large 
intestine. The disease was first described in Indiana in the USA by Whiting et al (1921), 
and since then it has been reported from different countries worldwide. SD has a major 
economic impact in infected herds by causing mortality, decreased growth rate, poor 
feed conversion and the expense of in-feed medication (Harris and Lysons, 1992). As a 
consequence,  in  regions  where  it  occurs,  SD  is  considered  to  be  one  of  the  most 
significant production-limiting porcine infections.  
 
1.3.3.2. Clinical signs 1.3.3.2. Clinical signs 1.3.3.2. Clinical signs 1.3.3.2. Clinical signs       
       
SD occurs most commonly in pigs in the grower-finisher period (bodyweights 25-100kg). 
The clinical signs of SD vary in both duration and severity, and the spread of disease 
through a herd is varied and may be gradual. The first signs in most animals are reduced 
appetite and the passage of the semi-solid yellow to grey faeces, but the most consistent 
manifestation  is  a  bloody,  mucoid  diarrhoea  (Hampson  et  al.,  1997).  The  rectal 20 
Table 1.3. Biochemical reaction scheme for Brachyspira species 
 
Spirochaete characteristics in the table are based on results from previous studies (Fossi et al., 2004; Stanton et al., 1998). +/− 
indicates that some strains possess and other strains lack a particular activity.       
Species Species Species Species       
(MLEE group) (MLEE group) (MLEE group) (MLEE group)        Haemolysis Haemolysis Haemolysis Haemolysis        Indole Indole Indole Indole       
production production production production       
Hippurate Hippurate Hippurate Hippurate       
Hydrolysis Hydrolysis Hydrolysis Hydrolysis       
Flagella Flagella Flagella Flagella       
per cell per cell per cell per cell       
α- - - -Galactosidase Galactosidase Galactosidase Galactosidase       
activity activity activity activity       
β- - - -Glucosidase Glucosidase Glucosidase Glucosidase       
activity activity activity activity       
Demonstrated pathogenicity Demonstrated pathogenicity Demonstrated pathogenicity Demonstrated pathogenicity       
(animal) (animal) (animal) (animal)       
B. hyodysenteriae 
          (Ⅰ)  Strong  +/−  −  22-28  −  +  Yes (swine) 
B. intermedia 
          (Ⅱ)  Weak  +  −  24-28  −  +  Yes (chicken) 
B. murdochii 
         (Ⅴ)  Weak  −  −  22-26  −  +  No 
B. innocens 
        ( Ⅲ )  Weak  −  −  20-26  −  +  No 
B. pilosicoli 
        (Ⅵ)  Weak  −  +/−  8-12  +/−  −  Yes (swine; chicken) 
B. alvinipulli 
        (Ⅳ)  Weak  −  +  22-30  −  +  Yes (chicken) 
B. aalborgi 
        (Ⅶ)  Weak  ?  ?  8  −  −  No   21 
temperature of affected pigs may be elevated to 40-45˚C. As the disease progresses, 
quantities of undigested food, mucus and increasing amounts of blood appear in the 
faeces, and the colour of the faeces darkens with excess blood to a deep chocolate red 
(Alexander  and  Taylor,  1969).  Most  affected  pigs  remain  alert  and  are  only  mildly 
depressed, although in severe cases the animals may be very depressed and anorexic 
(Harris and Lysons, 1992). Due to marked weight loss and dehydration, sick pigs often 
become  gaunt  and  pinched  at  the  flanks.  The  death  rate  varies  markedly  between 
outbreaks, and sometimes can be very high (Alexander and Taylor, 1969). Death in 
most  animals  is  associated  with  dehydration,  acidosis,  toxaemia  and  hyperkalaemia 
(Harris and Lysons, 1992). 
  
1.3.3.3. Prevalence 1.3.3.3. Prevalence 1.3.3.3. Prevalence 1.3.3.3. Prevalence of swine d  of swine d  of swine d  of swine dysentery ysentery ysentery ysentery       
       
Swine dysentery has been reported in all major pig rearing countries in the world. In 
recent years SD has become uncommon in the USA, but remains a significant problem in 
Europe (Herbst et al., 2004; Plawinska et al., 2004; Stege et al., 2000), Brazil (Barcellos 
et al., 2000b) and Thailand (Kramomtong et al., 1996). In Germany, from 2002 to 
2003,  faecal  specimens  from  1445  healthy  pigs  and  2002  diarrhoeic  pigs  were 
investigated  using  polymerase  chain  reaction  (PCR)  for  the  presence  of  B. 
hyodysenteriae. The detection rate was 6.7% in the healthy group and 17.9% in the 
diarrhoeic group (Herbst et al., 2004). A similar survey was recently conducted in Korea 
on faecal samples of pigs with diarrhoea or a history of diarrhoea. The overall herd 
prevalence were 37.2%, and was 10.8% among all sampled pigs (Suh and Song, 2005).  
   22 
The variation in prevalence in different countries in part is related to differences in 
housing, management and feeding regimen (Jacobson et al., 2004). Moreover, the use 
of in-feed medication is known to suppress the occurrence of the disease. In Sweden, 
for example, all routine use of antimicrobials in pig diets as growth promoters was 
banned in 1986 and there was a subsequent rapid increase in the occurrence of SD 
(Fellström et al., 1996; Harris and Lysons, 1992). 
       
1.3.3.4. Pathogenesis 1.3.3.4. Pathogenesis 1.3.3.4. Pathogenesis 1.3.3.4. Pathogenesis       
       
SD  primarily  results  from  the  proliferation  of  B.  hyodysenteriae  and  perhaps  other 
synergistic supporting bacteria within the colon of pigs, although the exact nature of the 
interaction is unknown (Harris and Lysons, 1992; Whipp et al., 1978). In infected pigs, B. 
hyodysenteriae can be detected  in the  mucus layer over the  epithelium,  and  in  the 
crypts. The spirochaetes can invade goblet cells and are frequently seen in intercellular 
gaps, in the cytoplasm of degenerative epithelial cells, and sometimes in the lamina 
propria, particularly in cavities around blood vessels (Glock and Harris, 1972; Glock et 
al., 1974). As the disease progresses, necrosis and shedding of epithelial cells develop, 
exposing  small  blood  vessels  and  resulting  in  variable  haemorrhage.  The  damaged 
mucosa  also  becomes  susceptible  to  invasion  by  other  components  of  the  intestinal 
microbiota, and exposure to antigenic material from the lumen potentially can induce 
further immunologically-mediate damage (Hampson et al., 1997). 
 
Production of gross, microscopic and ultrastructure lesions have been observed in the 
colons of pigs with SD (Glock et al., 1974; Harris and Lysons, 1992). Most animals in the 
acute stage of disease have colonic lesions including the accumulation of fluid (oedema)   23 
and congestion of blood flow (hyperaemia) of the large intestinal walls and mesentery. 
There is also swelling of the mucosa with loss of the normal folding architecture. The 
submucosal glands appear white and are usually raised and pronounced on the serosal 
surface. The contents of the colon are composed of fresh blood, mucus and fibrin and 
are soft to watery in consistency. As the disease moves to a chronic stage, mucosal 
lesions appear to be more severe with increased fibrin exudation that eventually leads 
to a mucofibrinous pseudomembrane containing blood. Microscopically, lesions consist 
of goblet cell hyperplasia, and elongation of epithelial cells at the base of the crypts. 
The lamina propria consists of infiltrating leukocytes of the neutrophil lineage in and 
around capillaries near the lumen. Portions of epithelial cells lining the mucosa often 
separate from the surface, exposing capillaries to the surface. Haemorrhage results from 
this dissociation, and blood becomes mixed in the overlying mucus. Thickening of the 
mucosa and submucosa is also present due to vascular congestion and extravasations of 
fluids and leukocytes. In the later stages of dysentery, superficial necrosis develops but 
the deep ulceration seen in some other intestinal diseases such as salmonellosis is absent 
(Joens, 1997). 
 
To  date  the  mechanisms  by  which  the  lesions  occur  are  still  poorly  understood, 
although a number of virulence determinants have been described and characterised 
(outlined  in  section  1.3.4.3).  A  major  characteristic  of  SD  is  that  lesions  are  only 
produced in the large intestine (Glock and Harris, 1972; Harris and Lysons, 1992), but 
either the entire large intestine or segments may be affected.  
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Brachyspira hyodysenteriae (type strain B78T; ATCC 27168) is a Gram-negative, oxygen- 
tolerant, anaerobic, strongly β-haemolytic spirochaete, appearing as slender, loosely-
coiled rods ranging from around 9.8µm in length and 350nm in diameter (Harris et al., 
1972; Meyer et al., 1974). Cells have 14-26 periplasmic flagella, with 7-13 inserted at 
each cell end (ter Huurne and Gaastra, 1995). The ends of the cell typically are blunt 
(Fig 1.5).  
 
Figure  1.5.  Transmission  electron  micrograph  of  B.  hyodysenteriae  B78T  type  strain 
showing a blunt cell end and 12 periplasmic flagella (six originating at each cell end). 
Adapted from Sellwood and Bland (1997).   25 
The  bacteria  are  actively  motile,  having  a  serpentine  motility  in  semi-solid  or  solid 
media,  and  translational  or  rotational  type  motility  in  liquid  media.  They  produce 
visible surface growth after 48-96 h incubation at 38°C, and grow at 37°C and 42°C, 
but  not  at  30°C  (Hampson  et  al.,  1997).  In  Brain  Heart  infusion  broth,  B. 
hyodysenteriae cells have a population doubling time of 3-4 h and reach densities of 109 
cells/ml-1 culture (Stanton and Lebo, 1988). After 72 h incubation on blood agar plates, 
colonies are flat and translucent, and are 5-8 mm in diameter (Hudson et al., 1976). 
Strong  beta-haemolysis  is  produced  on  these  plates  (Stanton  et  al.,  1991).  B. 
hyodysenteriae strains typically (but not invariably) produce indole, fail to hydrolyse 
hippurate, have alpha-glucosidase and β-glucosidase activity, and lack alph-galactosidase 
activity (Trott et al., 1996).  
 
A distinctive feature of B. hyodysenteriae is that it causes strong β-haemolysis on blood 
agar plates. It has been isolated from pigs throughout the world, and is recognised as 
the  aetiologic  agent  of  SD.  However,  it  also  has  been  isolated  from  rheas  with 
typhlocolitis in the USA (Jensen et al., 1996), from wild mice and rats on piggeries 
(Hampson et al., 1991; Joens and Kinyon, 1982), and from wild mallards (Jansson et al., 
2004). 
                       
B.  hyodysenteriae  preferentially  colonises  the  mucus-filled  crypts  of  Lieberkuhn  and 
mucus layer covering the epithelial cells of the large intestine (Kennedy et al., 1988). 
Unlike B. pilosicoli, B. hyodysenteriae does not associate with the colonic epithelium by 
end-on attachment. It can invade into epithelial cells and intercellular gaps, and cause 
necrosis of those cells. The epithelial cell layer may be completely eroded, so exposing 
the lamina propria in which neutrophil numbers can increase remarkably (Glock and   26 
Harris, 1972; Neef et al., 1994). B. hyodysenteriae is observed to have strong motility in 
mucus  (Kennedy  et  al.,  1988;  Kennedy  and  Yancey,  1996),  as  well  as  positive 
chemotaxis towards porcine mucus both in vitro and in vivo, and this appears to be an 
important pathogenic characteristic (Kennedy et al., 1988; Kennedy and Yancey, 1996; 
Milner and Sellwood, 1994).  
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Combined physical and genetic maps of the B. hyodysenteriae B78T genome (Figure 1.6) 
have been constructed using pulsed field electrophoresis and DNA blot hybridization 
(Zuerner and Stanton, 1994; Zuerner et al., 2004). The B. hyodysenteriae genome is a 
single  circular  chromosome  of  approximately  3.2  Mb  (Zuerner  and  Stanton,  1994; 
Zuerner et al., 2004). It has a similar size to genomes of free-living bacteria and is of an 
intermediate size compared with those of other spirochaetes. B. burgdorferi (Casjens 
and  Huang,  1993)  and  T.  palladium  (Walker  et  al.,  1995)  have  genomes  of 
approximately 1 Mb, while L. interrogans has a genome of 4.6 Mb (Nascimento et al., 
2004). In contrast to both Borrelia and Leptospira, physical maps of the genomes of 
different strains of B. hyodysenteriae appear to be conserved (Humphrey et al., 1997). 
 
The codon usage by B. hyodysenteriae has been determined from the flaB1, flaB2, flaA, 
tlyA, tlyB, tlyC, nox and bhlp16 genes. The results show that A- and T-rich codons are 
predominant, as would be expected in view of the low G+C content of the genome   27 
(25.7%-25.9%) determined using the thermal denaturation technique (Zeijst and ter 
Huurne, 1997).  
                                      
Figure 1.6. Genetic map of B. hyodysenteriae, adapted from Zuerner et al (2004). 
       
Ter Huurne et al (1992) demonstrated that DNA containing a cloned haemolysin gene 
could  be  transferred  by  electroporation  to  the  spirochaetal  cells  and  undergo 
homologous recombination with chromosomal genes. This methodology subsequently 
has  allowed  genes  to  be  mapped  with  greater  precision,  and  gene  function  to  be 
studied in vivo. The known genes and their potential function are described below. 
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The  ribosomal  RNA  (rRNA)  gene  organization  in  B.  hyodysenteriae  is  unusual.  In 
B. hyodysenteriae 
3.2 Mb 
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contrast to multiple copies presented in most bacterial genera, B. hyodysenteriae has 
one gene each for 5S, 16S and 23S rRNAs (rrf, rrs and rrl gene respectively), with rrl and 
rrf closely linked, yet separated from rrs by several hundred thousand bases (Zuerner 
and Stanton, 1994; Zuerner et al., 2004).  This pattern of rRNA gene organization is 
identical to B. pilosicoli and can be used to distinguish Brachyspira species from other 
spirochaetes (Zuerner et al., 2004). 
 
The 16S and 23S rRNA  gene sequences are highly conserved in Brachyspira species 
strains (98-99.6% and 96.85%-99.84%, respectively) (Leser et al., 1997; Stanton et al., 
1996). Consequently, analysis of 16S or 23S rRNA gene sequences is a powerful and 
accurate method for studying spirochaetal phylogeny (Johansson et al., 2004; Mikosza 
et  al.,  2004;  Paster  et  al.,  1991),  and  is  a  relatively  simple  genotypic  method  for 
differentiation  of  uncharacterised  intestinal  spirochaetes  (Barcellos  et  al.,  2000a; 
Pettersson et al., 1996). Unfortunately, these sequences cannot be used to determine the 
identity of genetically closely related species, and their identity must be confirmed using 
phenotypic traits and DNA-DNA hybridization.  
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B. hyodysenteriae flagellar filaments are different from the simple external flagella in 
most  rod-shaped  enteric  bacteria,  and  are  referred  to  as  periplasmic  flagella  or 
endoflagella  (Rosey et al., 1995). The periplasmic flagellar filaments wrap around the 
protoplasmic cylinder. They consist of a core of three proteins (FlaB1, FlaB2, and FlaB3) 
with masses of 37, 34 and 32 kDa, and one to two sheath proteins (FlaA1 and FlaA2) 
with masses of 44 and 35 kDa. These proteins are encoded by separate genes, with   29 
extensive immunological and N-terminal sequence homology with each other and with 
other spirochaete flagellar core proteins (Koopman et al., 1992a; Koopman et al., 1993; 
Li et al., 2000). Together, the flagellins account for 5-10% of the total protein content 
of  B. hyodysenteriae  (Zeijst and ter Huurne, 1997). 
 
Transcription of the core proteins is suggested to be from σ-28 like promoters and the 
sheath  polypeptides  from  σ-70  like  promoters  (Koopman  et  al.,  1992b).  The  19  N-
terminal amino acid residues of FlaA1 act as a signal peptide and the remaining 20 to 38 
residues  are  the  mature  protein.  DNA  motifs  upstream  have  homology  with  the 
consensus  E.  coli  -35  and  -10  promoter  sequences  and  a  ribosome  binding  site. 
Downstream  from  the  gene,  two  inverted  repeat  sequences  may  serve  as  a  rho-
independent  transcription  termination  signal  (Koopman  et  al.,  1992b).  Nucleotide 
sequence data and N-terminal amino acid sequence information indicate that FlaA1 is 
likely to be secreted into the periplasmic space via the general secretory pathway. In 
contrast,  FlaB  is  not  cleaved  at  the  N-terminus  and  is  most  likely  secreted  into  the 
periplasmic space by a type-III secretion system (Li et al., 2000).  
 
Various lines of evidence indicate that the flaA and flaB genes of B. hyodysenteriae play 
an essential role in motility and intestinal colonisation, since mutations in both of these 
genes rendered B. hyodysenteriae  impaired for in vivo-like motility and significantly 
reduced its ability to colonise and infect mice (Gabe et al., 1995; Kennedy et al., 1997; 
Li et al., 2000). However, inactivation of one of the flab genes still resulted in the 
retention of motility and filament syntheses, even with altered motility observed in 
each mutant species (Li et al., 2000; Rosey et al., 1995; Rosey et al., 1996). Given the 
distinctive similarity in the deduced amino acid sequences of the three FlaB proteins, it   30 
has then been proposed that FlaB proteins are at least somewhat redundant in terms of 
function. Also, based on a mutational study, Li et al (2000) suggested that FlaA was 
associated  with  the  FlaB  core,  helping  stabilize  the  FlaB  helical  core  into  desired 
configurations  for  optimal  performance  as  it  rotates  between  the  outer  membrane 
sheath and the cell cylinder. 
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Initially, three separate genes from B. hyodysenteriae were identified and associated 
with beta-haemolysis based on their ability to induce a haemolytic phenotype in E. coli 
(Muir et al., 1992; ter Huurne et al., 1994). These three genes, referred to as tlyA, tlyB 
and tlyC, are presented as a single copy on the chromosome of all B. hyodysenteriae 
strains tested (Zeijst and ter Huurne, 1997).  Sequence comparison demonstrated that 
the tlyB gene product had homology to Clp proteins with proteolytic activities and 
being regulators of proteolysis. By protein sequencing, however, none of Tly products 
are identical with the haemolysins isolated and purified from culture supernatants of B. 
hyodysenteriae.  A  further  search  for  haemolysin-associated  genes  resulted  in 
identification of the hlyA beta-haemolysin gene (Hsu et al., 2001). The hlyA gene is 
much smaller than the previously reported tly genes, and it has no link with these genes. 
Biochemical analysis confirmed that there was a direct correlation between the hlyA 
product and the native beta-haemolysin (Hsu et al., 2001). 
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The  gyrA  gene  can  be  used  as  an  indicator  of  the  bacterial  chromosome  origin  of   31 
replication. A clone of the partial gyrA gene in B. hyodysenteriae was prepared by 
Huang et al (1986) and used for constructing the genome map described by Zuerner 
and Stanton  (1994).  
 
The B. hyodysenteriae gyrB gene sequence was identified from a גZAPII library of strain 
B204 genomic DNA by Stanton et al (2001). The GyrB protein of B. hyodysenteriae 
with an estimated molecular mass of 71 kDa is smaller than the E. coli GyrB protein. 
Based on sequence alignment, four regions of the B. hyodysenteriae protein exhibit high 
similarities  (48  to  60%)  with  E.  coli  GyrB,  three  of  which  appear  conserved.  The 
conserved  domains  can  be  used  to  differentiate  bacterial  GyrB  proteins  from 
homologous ParE proteins, which are subunits of DNA topoisomerase IV (Stanton et al., 
2001). 
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A 16 kDa membrane-associated and hydrophobic lipoprotein was identified and named 
smpA  by  Thomas  and  Sellwood  (1993)  and  then  renamed  bmpA  (Brachyspira 
membrane protein A) to be  consistent with the new genus name Brachyspira (Lee et al., 
2000).  Recently it was redesignated bhlp16 based on the novel nomenclature system 
for Brachyspira membrane proteins and lipoproteins (Hampson et al., 2006). In full 
length, it encodes a prolipoprotein of 16.8 kDa. After cleavage of the signal peptide, the 
mature protein corresponds to 15.1 kDa peptides.  
 
This  gene  was  only  presented  in  half  the  B.  hyodysenteriae  strains  investigated  as 
demonstrated  by  PCR  and  Southern  hybridization.  Across  Brachyspira  species,   32 
hybridization  was  weak  and  no  PCR  products  were  obtained  in  seven  strains of  B. 
innocens, B. intermedia and B. murdochii (Turner et al., 1995). Taken together, these 
results  indicated  that  the  bhlp16  gene  is  quite  divergent  both  in  strains  of  B. 
hyodysenteriae and in other Brachyspira species. 
 
Bhlp16 is expressed in vivo since antibodies to this antigen are detectable in sera from 
pigs convalescent from SD. Sellwood et al (1995) monitored expression of the antigen 
in different stages of development of experimental SD using an immunoabsorbent assay 
(ELISA) with a monoclonal antibody to the Bhlp16 antigen. The ELISA titre appeared to 
correlate with the numbers of viable B. hyodysenteriae spirochaetes excreted in the 
faeces. However, about the time of onset of clinical signs, expression of the lipoprotein 
was  not  detected  by  ELISA  or  by  Western  blotting.  Subsequently,  Bhlp16  was  re-
expressed when the in vivo grown spirochaetes were transferred to in vitro culture 
conditions.  Lack  of    expression  of  Bhlp16  was  also  observed  in  B.  hyodysenteriae 
obtained  from  a  mouse  model  of  SD  (Sellwood  et  al.,  1995).  Therefore,  it  was 
concluded that expression of the Bhlp16 gene had been affected in vivo, and may have 
been regulated environmentally, which may be a mechanism of evasion of the immune 
response and contribute to the persistent nature of the infection (Sellwood et al., 1995).  
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A  novel  outer  membrane  protein-encoding  gene  was  recently  identified  in  B. 
hyodysenteriae. The predicted protein, provisionally designated SmpB (Holden et al., 
2005), shares an identical leader sequence and the first 10 amino acids of the mature 
protein  with  the  previously  identified  lipoprotein  SmpA  (currently  Bhlp16).  The   33 
remainder  of  the  predicted  protein  sequence showed  no  similarity  to  Bhlp16.  smpB 
encodes  for  a  slight  larger  protein  than  bhlp16,  17.6  compared  to  16.8  kDa.  A 
distribution study indicated that either the bhlp16 or the smpB gene was contained in B. 
hyodysenteriae strains investigated, but not both. It was therefore hypothesized that 
bhlp16 and smpB are localised on the same region of the chromosome. Nevertheless, in 
terms of antigenicity, the proteins are unique, as no cross-reactivity was found with 
both antisera.  
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An outer membrane lipoprotein of B. hyodysenteriae of approximately 30 kDa was 
identified using a specific monoclonal antibody designated BJL/SH1 (Lee and Hampson, 
1996; Lee et al., 2000). This gene was present as a single copy in all B. hyodysenteriae 
strains investigated, but was absent from other Brachyspira species, except B. innocens 
strain B256T. It shared 97.9-100% nucleotide sequence similarity with the gene of B. 
innocens strain B256T (La et al., 2005). Further analysis of the amino acid usage of this 
lipoprotein, initially designated BmpB, showed its possible outer membrane localization. 
Comparison  of the  gene  encoding the  lipoprotein,  bmpB,  with  GenBank  nucleotide 
sequences showed that it has homology with the gene (plp3) encoding Plp3, an outer 
membrane lipoprotein of Pasteurella haemolytica (54% identity in 735 bp) (Lee et al., 
2000). Comparison of the deduced amino acid sequence with the SWISS-PROT amino 
acid  database  revealed  greatest  homology  with  the  D-methionine  binding  protein 
(MetQ) of a number of pathogenic bacterial species (La et al., 2005). Unfortunately, 
due to confusion in nomenclature, the gene is the same as the later described blpA, 
identified  as  a  component  of  a  locus  designated  blpGFEA,  encoding  four  tandem   34 
paralogous proteins of 30 kDa in B. hyodysenteriae  (Cullen et al., 2003; La et al., 
2005).        
 
It has been confirmed that this gene is expressed in vivo, because pigs immunised with 
an E. coli clone expressing recombinant BmpB generated antibodies that recognised the 
native  B.  hyodysenteriae  BmpB  lipoprotein.  Also,  pigs  naturally  infected  with  B. 
hyodysenteriae develop serum antibodies that recognised the native BmpB (La et al., 
2004; Lee et al., 2000).  
 
As a result of the confusion in the nomenclature of bmpB and blpA, it has recently been 
proposed that the nomenclature for membrane proteins and lipoproteins of Brachyspira 
be revised (Hampson et al., 2006). In this system, bmpB is redesignated bhlp29.7. 
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The blpGFEA locus (Cullen et al., 2003) comprises four genes linked tandemly on the 
chromosome, with intergenic regions of 31, 20 and 78 bp, respectively. Among these, 
blpA is the same as bhlp29.7, as indicated previously. Although these genes share great 
identity in coding regions, the products contain unique epitopes. It has been shown that 
antisera against recombinant BlpF and BlpG had no cross-reactivity with BlpA and BlpE, 
while antisera against BlpA and BlpE were slightly cross-reactive. In the blpGFEA locus 
genes, only blpA was expressed under in vitro culture conditions, and only the epitope 
of BlpA reacted with convalescent swine serum. 
 
         35 
1.3.4.2.10.  1.3.4.2.10.  1.3.4.2.10.  1.3.4.2.10. bhmp39 bhmp39 bhmp39 bhmp39 genes (formerly   genes (formerly   genes (formerly   genes (formerly vsp vsp vsp vsp genes): encoding variable surface proteins  genes): encoding variable surface proteins  genes): encoding variable surface proteins  genes): encoding variable surface proteins       
       
Initially, a tandem pair of closely related genes (bhmp39a and bhmp39b) was identified 
by  performing  enzymatic  iodination  of  surface  proteins of    B.  hyodysenteriae  strain 
B204 (Gabe et al., 1998). In order to retrieve the remainder of the bhmp39 gene, an 
additional attempt was made to screen the genomic library using oligonuleotide probes 
based upon the cloned gene sequence (McCaman et al., 1999). This gave rise to the 
discovery of two more adjacent and related genes (bhmp39c and bhmp39d).  All these 
genes are in a parallel orientation with 83% to 90% homology in their deduced amino 
acid sequence, and they appear to be expressed separately under a set of similar but 
distinct  regulatory  elements.  Thus,  four  contiguous  bhmp39  genes  are  predicted  to 
encode  a  cluster  of  structurally  conserved  proteins  (McCaman  et  al.,  1999). 
Subsequently  four  more  novel  bhmp39  genes  (identified  as  bhmp39e-h)  have  been 
identified with extensive sequence similarity to the previously reported four tandemly 
linked alleles (McCaman et al., 2003). This new gene cluster of 7481 nucleotides is not 
adjacent to the bhmp39a-d gene cluster, but is arranged in the same homology pattern 
and orientation as identified for bhmp39a-d.  
 
All eight bhmp39 ORFs have several conserved hydrophobic and variable hydrophilic 
regions. It has been proposed that this pattern may allow these polypeptides to be 
anchored in or span the outer membrane of B. hyodysenteriae and to present a variable 
surface epitope to its environment. Sequential expression of the different variants of  
such surface exposed antigens has been suggested to contribute to antigenic variation 
and perhaps successful evasion of the host immune system, similar to the case of bhlp16 
expression under environmental regulation (McCaman et al., 2003). A recent study of   36 
transcriptional organization of the bhmp39 genes revealed that the genes of the second 
locus  resulted  in  monocistronic  transcripts,  and  bhmp39f  and  bhmp39h  were  the 
transcripts most abundantly expressed by B. hyodysenteriae strain B204 under in vitro 
growth conditions (Witchell et al., 2006). 
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The nox ORF (1.3 kb) encodes a NADH oxidase protein which consumes oxygen to 
enable anaerobic B. hyodysenteriae cells to contend with or consume oxygen in their 
natural microhabitat, the oxygen-respiring mucosal tissues of the swine gut (Stanton and 
Jensen, 1993; Stanton and Sellwood, 1999). Based on an analysis of GenBank sequences, 
the  B.  hyodysenteriae  NOX  protein  shares  significant  amino  acid  sequence  identity 
(46%)  and  common  functional  domains  with  the  NADH  oxidases  of  Enterococcus 
faecalis and Streptococcus mutans, suggesting a common evolutionary origin for these 
proteins (Stanton and Sellwood, 1999).  
 
The  coding  regions  of  the  nox  gene  were  found  to  be  highly  conserved  in  B. 
hyodysenteriae strains B204, A-1 and R-1, which originated from different animal hosts 
(swine  and  a  rhea)  and  different  geographical  locations  (the  U.S.A,  and  the  U.K.) 
(Stanton and Sellwood, 1999). On the contrary, there has been obvious diversity of nox  
gene sequences between B. hyodysenteriae and other Brachyspira species. As a result, 
the nox gene has been a good target for designing gene probes or PCR reactions to be 
used in the clinical identification of  B. hyodysenteriae and other Brachyspira species  
(Atyeo et al., 1999; Mikosza et al., 2004; Rohde et al., 2002). 
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VSH-1 is known as a  mitomycin C-inducible, non-lytic, phage-like agent that contains 
random 7.5-kb fragments from the B. hyodysenteriae genome (Humphrey et al., 1997). 
It  is the first clarified mechanism for gene transfer between B. hyodysenteriae cells 
(Stanton et al., 2003). To analyse the distribution of VSH-1 among spirochaetes, a 344-
bp fragment of gene svp38, encoding the VSH-1 major head protein, was amplified by 
polymerase chain reaction and used as a probe in Southern hybridizations with genomic 
DNA from various spirochaete genera. In B. hyodysenteriae strain B78T, only a 40-kb 
SaII-Smal fragment hybridized with the svp38 probe, indicating that VSH-1 DNA inserts 
into the chromosome at a unique site. Twenty seven strains from six Brachyspira species 
(B.  hyodysenteriae,  B.  innocens,  B.  pilosicoli,  B.  murdochii,  B.  intermedia  and  B. 
alvinipulli) were investigated, and each contained a single hybridization fragment. The 
probe did not hybridize to genomic DNAs from the other genera such as Treponema, 
Spirochaeta, Borrelia, and Leptospira. These results suggested that VSH-1-like agents are 
widely distributed among Brachyspira species and may also serve as useful gene transfer 
agents for Brachyspira species other than B. hyodysenteriae (Stanton et al., 2003). 
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Dugourd  et  al  (1999)  determined  the  nucleotide  sequence  from  the  pathogenic 
spirochaete  B.  hyodysenteriae  bit  (for  “Brachyspira  iron  transport”)  genomic region. 
Due to some homology with sequences encountered in Gram-negative bacteria, the bit 
region is considered to encode an iron ATP-binding cassette transport system. In this 
region, six coding genes oriented in the same direction and physically linked have been   38 
identified.  This  system  contains  a  protein  with  ATP-binding  motifs  (BitD),  two 
hydrophobic  cytoplasmic  membrane  permeases  (BitE  and  BitF),  and  at  least  three 
lipoproteins (BitA, BitB, and BitC) with identity to iron periplasmic binding proteins. 
BitA-C exhibit lipoprotein features and have signal peptides typical for substrates of the 
type II secretory peptidase. BitB and BitC are involved in iron binding, as shown by 
using the FURTA system (Fur titration assay) and a Congo red assay. The Bit system was 
not detected in B. innocens or B. pilosicoli (Dugourd et al., 1999). 
 
Recently, a gene designated ftnA (Davis et al., 2005) has been cloned and sequenced in 
B. hyodysenteriae. The full-length gene is 543 bp and predicted to code for a putative 
ferritin protein of 180 amino acids. The predicted translation of B. hyodysenteriae ftnA 
(FtnA) shares sequence similarity with the putative iron-storage protein, FTN2, from 
Haemophilus influenzae. The staining of cell extracts of E. coli overexpressing FtnA for 
the presence of iron-containing proteins also validated the belief that FtnA is an iron-
storage  protein,  and  RT-PCR  and  Western  blot  demonstrated  that  the  gene  was 
expressed in vivo.  
       
1.3.4.2.14.  1.3.4.2.14.  1.3.4.2.14.  1.3.4.2.14. gap gap gap gap gene  gene  gene  gene       
       
The gap gene product, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is a key 
enzyme in glycolysis and the Calvin cycle that catalyzes the reversible interconversion 
between  glyceraldehyde-3-phosphate  and  1,  3-diphosphoglycerate.  The  novel  partial 
gap  sequences  from  nine  spirochaetes  including  B.  hyodysenteriae  and  B.  murdochii 
have been determined (Figge and Cerff, 2001). Sequencing results indicate that each 
spirochaete probably harbours only one copy of the gap gene. Comparisons of Gap   39 
sequences in a number of spirochaetes and phylogenetic analysis of the spirochaetal Gap 
sequences with other gap genes in the database demonstrated that gap sequences were 
highly divergent. This is probably due to several lateral gene transfer events between 
spirochaetes and other eubacterial phyla, and early gene duplications in the eubacterial 
ancestor. 
 
1.3.4.3. Virulence factors/traits associated with  1.3.4.3. Virulence factors/traits associated with  1.3.4.3. Virulence factors/traits associated with  1.3.4.3. Virulence factors/traits associated with B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae       
 
B. hyodysenteriae  is a rather large spirochaete which originally was thought to reside 
only in the colon of its natural host, the pig (Jensen et al., 1996). Its discovery as the 
primary  agent  of  swine  dysentery  (SD)  in  the  early  1970s  was  followed  by  a 
considerable search for virulence factors responsible for lesion development during the 
disease  process  (Joens,  1997).  Virulence  determinants  in  an  enteric  disease  typically 
include colonisation factors (motility, adhesion, and invasion), and toxins (endotoxins, 
enterotoxins, haemolysins, and cytotoxins), or hydrolytic enzymes like proteases and 
hyaluronidase  (ter  Huurne  and  Gaastra,  1995).  Due  to  similar  infectious  routes  and 
colonisation  conditions  for  enteric  pathogens,  the  potential  roles  of  these  putative 
virulence factors in B. hyodysenteriae pathogenicity have been investigated. 
       
1.3.4.3.1. Motility 1.3.4.3.1. Motility 1.3.4.3.1. Motility 1.3.4.3.1. Motility       
       
Under the influence of chemotaxis spirochaetes demonstrate a corkscrew motility which 
maintains  their  maximum  performance  in  viscous  material  (Kennedy  et  al.,  1988). 
Motility  itself  can  be  an  important  virulence  factor  for  spirochaetes  (Joens,  1997). 
Motility varies for B. hyodysenteriae depending on the sampling matrix. For example, B.   40 
hyodysenteriae  cells grown on agar are almost non-motile under phase microscopy, 
whereas cells in faecal material of pigs with SD are extremely motile (Joens, 1997). 
Their motility has been attributed to the presence of two bundles of seven to thirteen 
periplasmic  flagella  (FP)  which  are  attached  subterminally  to  the  ends  of  the 
protoplasmic cylinder and overlap at the middle of the cell (ter Huurne and Gaastra, 
1995). It has been noted that flagella genes in B. hyodysenteriae account for 5-10% of 
its genomic content, and the abundance of genetic material relating to production of 
periplasmic  flagella  supports  the  essential  role  of  motility  in  the  survival  of  these 
bacteria in the host environments and in some cases, in causing disease. 
 
Wild-type strains of B. hyodysenteriae colonise the mucous lining of the intestinal lumen 
and the crypts, and also are present in degenerative epithelial cells and in goblet cells of 
pigs with SD (Joens, 1997). Mutant strains deprived of either the flaA1 or flaB1 gene 
were constructed and reported to be significantly less motile and less able to colonise 
mice and pigs than wild-type B. hyodysenteriae (Kennedy et al., 1997; Rosey et al., 
1995).  These  results  provided  further  evidence  that  motility  plays  a  key  role  in  the 
colonisation of B. hyodysenteriae, and hence contributes to the pathogenesis of SD.  
       
1.3.4.3.2. Chemotaxis  1.3.4.3.2. Chemotaxis  1.3.4.3.2. Chemotaxis  1.3.4.3.2. Chemotaxis        
       
Chemotaxis  is  the  behaviour  of  most  motile  bacteria  whereby  they  are  capable  of 
orientating  their  movement  to  chemical  gradients  (Bren  and  Eisenbach,  2000; 
Djordjevic  and  Stock,  1998),  and  it  appears  to  be  the  predominant  mechanism  of 
mucosal association during colonisation by B. hyodysenteriae (Kennedy and Yancey, 
1996).  The  importance  of  chemotaxis  in  bacterial  virulence  has  been  explored  in  a   41 
number of bacteria.  For instance, the chemotactic response of Campyobacter concisus 
towards formate is associated with gingival colonisation (Paster and Gibbons, 1986), 
whilst non-chemotactic Campyobacter jejuni mutants fail to colonise in animal models 
(Takata et al., 1992).  
 
Early studies with animals experimentally infected with B. hyodysenteriae have also 
indicated  that  the  initial  stage  of  the  disease  development  appears  to  involve  an 
association of B. hyodysenteriae with the porcine gut mucosal surface (Kennedy et al., 
1988). Later, the same group found that B. hyodysenteriae was strongly chemotactic to 
porcine gastric and colonic mucin, L-serine and L-fucose (Kennedy and Yancey, 1996). In 
the colonisation of the mucus layer of the porcine large intestine by B. hyodysenteriae it 
was  proposed  that  a  chemotactic-related  response  was  used  by  the  spirochaete  to 
obtain  nutrients  trapped  in  the  mucus  layer  or  constituents  of  the  mucus  itself. 
Interestingly,  virulent  strains  of  B.  hyodysenteriae  showed  more  chemotaxis  than 
avirulent  strains  (Milner  and  Sellwood,  1994).  Thus,  the  pathogenicity  of  B. 
hyodysenteriae  may  partially  be  attributed  to  attraction  of  the  spirochaete  cells  to 
porcine intestinal mucus.  
       
1.3.4.3.3. Haemolysin / cytotoxin 1.3.4.3.3. Haemolysin / cytotoxin 1.3.4.3.3. Haemolysin / cytotoxin 1.3.4.3.3. Haemolysin / cytotoxin       
       
A haemolysin from B. hyodysenteriae was extracted and injected into ligated ileal and 
colonic loops in germ-free pigs (Lysons et al., 1991). It caused severe epithelial damage, 
characterised  by  swelling  and  shedding  of  cells  with  disrupted  organelles.  These 
pathological changes were similar to those observed in natural cases of SD. A further 
study was carried out to compare morphological changes of the caecal mucosa in mice   42 
challenged with B. hyodysenteriae or exposed to the beta-haemolysin purified from B. 
hyodysenteriae. The haemolysin extract induced some of the same colonic epithelial cell 
damage as seen during infection with B. hyodysenteriae (Hutto and Wannemuehler, 
1999).  Therefore,  the  β-haemolytic  activity  of  the  bacteria  is  believed  to  be  closely 
correlated with the pathogenicity of SD, and has been considered a major virulence 
attribute of B. hyodysenteriae. 
 
As  stated  earlier,  four  possible  haemolysin  genes  (tlyA-C  and  hlyA)  have  been 
characterised. Only the hlyA gene product is directly linked to purified native beta-
haemolytic toxin (Hsu et al., 2001). However, tlyA mutants have a reduced haemolysis 
(ter Huurne et al., 1993) and  the recombinant proteins of tlyB and tlyC expressed in E. 
coli exhibit both haemolytic and cytotoxic activity in vitro (ter Huurne et al., 1994). 
When  infected  with  the  tlyA-minus  mutants,  mice  and  pigs  developed  less  severe 
colonic or caecal lesions respectively than with wild-type strains (Hyatt et al., 1994; ter 
Huurne et al., 1993).  
 
1.3.4.3.4. Oxygen metabolism 1.3.4.3.4. Oxygen metabolism 1.3.4.3.4. Oxygen metabolism 1.3.4.3.4. Oxygen metabolism       
       
B. hyodysenteriae is an aerotolerant anaerobe that has optimal growth under a 1%O2-
99% N2 atmosphere. Growing cells of the spirochaete utilize considerable amounts of 
oxygen to survive in the oxygen-respiring epithelial surface of the swine large bowel 
(Stanton and Lebo, 1988). Based on the high specific activities and versatility of NADH 
oxidase (NOX) in soluble cell fractions of the spirochaetes, it has been viewed as a 
major mechanism for oxygen metabolism by B. hyodysenteriae  and other Brachyspira 
species (Stanton, 1989; Stanton and Jensen, 1993; Stanton et al., 1997). The importance   43 
of the enzyme is reflected in early stages of the disease when spirochaetes first colonise 
mucosal tissues or in later stages when oxygen is released from erythrocytes that enter 
the spirochaete habitat and are lysed by the B. hyodysenteriae haemolysin (Stanton et 
al.,  1999).  Additionally,  NADH  oxidase  may  serve  to  protect  cells  from  oxygen 
exposure during transmission (faecal-oral passage) between hosts (Stanton et al., 1999). 
All of these roles played by NADH oxidase suggest its involvement in the virulence of B. 
hyodysenteriae. 
 
To determine the virulence of NADH oxidase in vitro and in vivo, Stanton et al (1999) 
constructed two nox mutant strains (Nox-Cm and Nox-Km) using inactivated nox genes 
containing cat or kan. The mutants had a 92 to 96% reduction in the activity of soluble 
NADH  oxidase,  and  both  mutants  were  at  least  100-fold  more  sensitive  to  oxygen 
exposure than the wild-type parent strain B204 (Stanton et al., 1999). Studies in pigs 
demonstrated that the overall incidence, onset and severity of dysentery were reduced 
for both nox mutants compared to the wild-type strain. Furthermore, it appeared that 
the ability to colonise the gut was reduced for the mutant strains when compared to 
wild-type strains. These results indicate that the nox mutant cells were less virulent than 
wild-type cells and had a reduced capacity for establishing and maintaining populations 
in the porcine intestinal tract (Stanton et al., 1999). 
 
1.3.4.3.5. Invasion 1.3.4.3.5. Invasion 1.3.4.3.5. Invasion 1.3.4.3.5. Invasion       
 
Pohlenz et al (1983) believed that B. hyodysenteriae actively invaded the goblet cells of 
the colonic mucosa, and subsequently spread further into the enteroabsorptive cells as 
cell numbers increased. It was proposed that the penetration into the basal membrane   44 
of epithelial cells arose from the loss of tight junctions due to either enzymatic activity 
of B. hyodysenteriae or due to the activity of cytokines produced by affected epithelial 
cells  (ter  Huurne  and  Gaastra,  1995).  Although  some  researchers  have  observed  B. 
hyodysenteriae in epithelial cells and in the lamina propria of tissues from pigs with 
lesions of SD, the association between invasion and lesion production remains unclear. 
       
1.3.4.3.6. Lipopolysaccharide (LPS) 1.3.4.3.6. Lipopolysaccharide (LPS) 1.3.4.3.6. Lipopolysaccharide (LPS) 1.3.4.3.6. Lipopolysaccharide (LPS)       
       
The lipopolysaccharide of B. hyodysenteriae reacts strongly with hyperimmune sera, 
and therefore it has been regarded as a prime target for the host immune response 
(Wannemuehler  et  al.,  1988).  In  addition,  LPS  has  been  used  as  the  basis  for  the 
serological typing scheme for differentiating B. hyodysenteriae strains (Hampson et al., 
1990).  A  number  of  in  vitro  and  in  vivo  studies  have  indicated  that  LPS  possesses 
endotoxic  properties  and  can  induce  inflammatory  lesions  by  stimulating  cytokine 
secretion (Nibbelink et al., 1997; Sacco et al., 1996). The potential role of LPS in the 
pathogenesis of SD has been examined both in experimental mice and pigs. Nuessen et 
al  (1983)  infected  LPS-responsive  and  hyporesponsive  mice  strains  with  B. 
hyodysenteriae. The LPS-hyporesponsive C3H/HeJ strain mice failed to develop typical 
caecal lesions. Later,  Nibbelink et al (1990) showed that this strain of mice actually can 
develop lesions, but the infectious dose required is 100-fold higher for the C3H/HeJ 
mice (8.3 x 107 organisms) when compared to the LPS responsive C3H/HeN mice (5.0 x 
105 organisms). Clinical signs of endotoxemia (depression and diarrhoea) were observed 
in  pigs  receiving  B.  hyodysenteriae  endotoxin  (Nibbelink  et  al.,  1997),  and  these 
findings support a link between LPS and the pathogenicity of B. hyodysenteriae. 
         45 
1.3.4.3.7. Enterotoxin 1.3.4.3.7. Enterotoxin 1.3.4.3.7. Enterotoxin 1.3.4.3.7. Enterotoxin       
       
It is not clear whether the fluid accumulation in the colon of infected pigs results from 
enterotoxin  products,  as  observed  with  toxigenic  strains  of  E.  coli  (Argenzio  et  al., 
1980).  However, genes encoding known enterotoxins in E. coli have not been detected 
in B. hyodysenteriae strains (ter Huurne and Gaastra, 1995). 
       
1.3.5. Immunity 1.3.5. Immunity 1.3.5. Immunity 1.3.5. Immunity       
       
1.3.5.1. Humoral immunity 1.3.5.1. Humoral immunity 1.3.5.1. Humoral immunity 1.3.5.1. Humoral immunity       
       
Some  convalescent  pigs  are  resistant  to  subsequent  infection  with  B.  hyodysenteriae 
(Joens et al., 1979), and to investigate this further swine ligated colonic loops have been 
used for studying passive protection against SD (Joens et al., 1985).  At necropsy colonic 
loops inoculated with B. hyodysenteriae and homologous immune serum were normal, 
whereas heterologous immune serum only reduced the severity of lesions, and naive 
sera provided no protection (Joens et al., 1985). When loops were inoculated with 
heat-inactivated  immune  serum,  only  partial  protection  was  obtained.  These  results 
suggest that complement and serum antibody produced during infection are involved in 
immune  mediated  protection  (Joens  et  al.,  1985).  Nuessen  and  Joens  (1982)  also 
demonstrated  the  importance  of  antibody  in  opsonization  of  phagocytes,  a  known 
protective  mechanism,  although  the  opsonization  mediated  by  convalescent  serum 
seemed to be LPS-serotype specific. 
 
Many investigators have detected circulating lgG, lgA and lgM antibodies and secretory   46 
lgA  (slgA)  after  experimental  or  natural  SD  (Fernie  et  al.,  1983;  Rees  et  al.,  1989), 
particularly against LPS and outer membrane proteins such as bhlp16 and bhlp29.7 (Lee 
et al., 2000; Rees et al., 1989; Sellwood et al., 1995). The B-cell-mediated humoral 
response has been widely accepted as being associated with the development of SD, but 
the definitive role of these antibodies in protection is not fully understood. However, 
the appearance of serum lgG and slgA has not been related to recovery from the disease 
(Rees et al., 1989). In general, a high level of lgG is considered to correlate with the 
duration  of  clinical  signs,  while  colonic  lgA  is  indicative  of  recent  exposure  to  the 
organism (Rees et al., 1989). 
 
1.3.5.2. Cellular immunity 1.3.5.2. Cellular immunity 1.3.5.2. Cellular immunity 1.3.5.2. Cellular immunity       
       
Most  early  studies  on  host  defence  responses  in  SD  were  concentrated  on  humoral 
immunity, but the humoral response is unlikely to be fully responsible for protective 
immunity.    As  a  consequence,  efforts  have  been  made  to  investigate  cell  mediated 
immunity. Cell-mediated immunity may be important in SD, as degraded spirochaetes 
have  been  observed  in  colonic  phagocytes of  pigs  with  SD  (Albassam  et  al.,  1985). 
Jenkins  (1980)  also  demonstrated  cell-mediated  immunity  in  pigs  with  SD  with  a 
leukocyte  migration  inhibition  agarose  test  (LMAT),  using  soluble  antigens  of  B. 
hyodysenteriae.  Sensitized  leucocytes  from  the  blood  of  infected  pigs  showed  a 
significant in vitro lymphocyte stimulation response, and migration of leukocytes from 
SD-affected pigs was inhibited by the soluble antigen. Migration was not noticeable in 
leucocytes from non-infected pigs. Cell-mediated immunity occurred after the onset of 
clinical  signs  of  SD  (Jenkins,  1980).  A  subsequent  study  showed  that  inhibition  of 
peripheral blood leukocyte migration was related to a delayed hypersensitive response   47 
in the majority of pigs recovered from SD (Jenkins et al., 1982). A T-cell proliferative 
response  also  was  observed  in  peripheral  blood  of  affected  pigs  when  exposed  to 
several protein antigens of B. hyodysenteriae (Kennedy et al., 1992). In an examination 
of the biological activity of B. hyodysenteriae LPS on host cells, the LPS was shown to 
induce secretion of tumor necrosis factor (TNF) and interleukin (IL)-6 (Nibbelink et al., 
1997) and to contribute to leukocyte migration (Nuessen et al., 1982). At the onset of 
SD,  there  is  an  increase  in  monocytes  and  neutrophils  (Jonasson  et  al.,  2004),  in 
agreement with the fact that large numbers of leucocytes are observed in lesions of SD 
(Glock and Harris, 1972).  
 
There are a large proportion of systemic CD4+CD8+ and γδ T cells presented in the 
swine T cell repertoire (Jonasson et al., 2004), but their roles remain controversial. 
Intramuscular vaccination of pigs with a B. hyodysenteriae protein-enriched bacterin 
resulted  in  an  increase  in  both  mucosal  and  peripheral  blood  CD8+  cells,  with 
concurrent decreases in CD4+ cells (Waters et al., 1999b). T cell (CD3+) proliferation 
from  vaccinated animals  was predominant after  in  vitro stimulation with  whole-cell 
antigens of B. hyodysenteriae, particularly CD8+ (single positive and CD4/CD8 double 
positive) and γδ+ T cells (Waters et al., 1999a). A subsequent study by the same group 
further demonstrated that pigs convalescent from a colitis resulting from experimental 
infection  with  B.  hyodysenteriae  had  a  significantly  higher  percentage  of  peripheral 
blood  CD4-CD8+  (Waters  et  al.,  2000).  High  levels  of  CD4+CD8+  cells  during 
experimental inoculation with B. hyodysenteriae were also reported by another group 
who analysed lymphocyte subpopulations before and after induced SD (Jonasson et al., 
2004). According to their results, susceptibility to infection is attributed to high levels of 
γδ T cells and low levels of CD8+ and CD4+CD8- - - -, , , , whilst monocytes and CD4+CD8+   48 
seem to be the major responding lymphocytes (Jonasson et al., 2004). Jonasson et al 
(2006)  further  investigated  the  systemic  immune  response  in  different  stages  of  SD. 
Increasing levels of circulating monocytes, neutrophils and CD8α
+ cells (not γδ T cells, 
CD8α+CD8β+ T cells or CD4+CD8α+ T cells) were observed, and correlated with the 
clinical  signs  of  SD.  During  the  recovery  period,  increased  numbers  of  circulating 
neutrophils  and  γδ  T  cells  were  noted.  In  experimental  pigs  developing  dysentery, 
CD21+ cells decreased in the blood during disease and recovery (Jonasson et al., 2006).  
Recently,  in  order  to  determine  the  role  of  mucosal  CD4+  and  γδ  T  cells  in  SD, 
Hontecillas et al (2005) compared differences in the CD4+ and γδ T-cell composition 
and  population  in  different  compartments  of  the  colonic  mucosa  of  pigs  with 
experimentally induced SD. In these pigs, γδ T cells were significantly dispersed in the 
epithelial layer, but there was no difference in the lamina propria. CD4+ T-cells formed 
large  aggregated  clusters  located  in  the  lamina  propria  and  submucosa,  which  was 
correlated with ex vivo analyses of the CD4+ T-cell response to B. hyodysenteriae in 
infected pigs; CD4+ T cell from peripheral blood and colonic lymph nodes of infected 
pigs proliferated on stimulation with B. hyodysenteriae antigens, whereas no obvious 
difference  was  noted  in  the  γδ  T  responses  between  infected  and  control  groups. 
Phenotypic analysis showed that most of the colonic lymph node CD4+ T cells were 
CD45RC
￿ (memory/activated) following stimulation with B. hyodysenteriae antigens. 
Collectively, these results indicate that B. hyodysenteriae infection stimulates a mucosal 
CD4+ T-cell proliferation, and highlight CD4+ T cells as important contributors to the 
immunopathogenesis of SD (Hontecillas et al., 2005). 
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1.3.6. Detection of serum antibody 1.3.6. Detection of serum antibody 1.3.6. Detection of serum antibody 1.3.6. Detection of serum antibody       
       
A  number  of  techniques  have  been  developed  to  demonstrate  the  presence  of 
circulating  antibodies  directed  against  B.  hyodysenteriae.  These  included  indirect 
fluorescent antibody tests (Lee and Olson, 1976), passive haemolysis tests (Jenkins et al., 
1976), microtitration agglutination tests (Joens et al., 1978; Joens and Harris, 1980), 
complement  fixation  tests  (Adachi  et  al.,  1984)  and  enzyme-linked  immunosorbent 
assays using as antigen either LPS (Joens et al., 1982), whole sonicated spirochaetes, or 
outer membrane proteins (Smith et al., 1991; Wright et al., 1989). Since LPS is serotype 
specific and common cell surface antigens are often present in different spirochaetes, 
these assays suffer from uncertainties about their sensitivity and specificity. Generally 
these methods are useful for detecting infected herds, but not individual pigs with SD 
(La and Hampson, 2001).  
 
Outer membrane proteins of bacteria have been used as antigens for diagnostic studies 
in many infectious diseases. Their importance for serological tests also has been noted 
by  many  investigators  working  with  B.  hyodysenteriae.  To  date,  the  potential  of 
published surface molecules of B. hyodysenteriae as diagnostic reagents is limited by the 
fact  that  these  antigens  show  much  cross-reactivity  between  B.  hyodysenteriae  and 
other  related  spirochaetes.  Nevertheless,  considerable  progress  can  be  expected  if  a 
species-specific, highly immunogenic and membrane-associated antigen can be identified 
from B. hyodysenteriae for use in a serological assay.  
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1.3.7. Vaccine development 1.3.7. Vaccine development 1.3.7. Vaccine development 1.3.7. Vaccine development       
       
Control of SD currently involves the use of antimicrobial treatments and eradication 
programmes.  However,  emerging  antimicrobial  resistance  is  an  increasing  problem 
(Hampson, 2004), and concerns are growing about the presence of antimicrobial drug 
residues in meat (Hampson et al., 1997). Dietary modifications have been investigated 
to reduce colonisation with B. hyodysenteriae, but, unfortunately, it has proved difficult 
to  produce  commercial  diets  that  are  practical  and  cost  effective  for  controlling  SD 
(Hampson, 2004). 
 
Vaccination  against  SD  seems  feasible  since  in  some  cases  convalescent  animals  are 
protected against the disease (Rees et al., 1989). To date, attempts to develop vaccines 
to control SD have met with very limited success, either because they have provided 
inadequate protection on a herd basis, or they have been too costly and difficult to 
produce to make them commercially viable (Galvin et al., 1997). 
 
1.3.7.1. Bacterin vaccines 1.3.7.1. Bacterin vaccines 1.3.7.1. Bacterin vaccines 1.3.7.1. Bacterin vaccines       
 
Attempts to induce immunity to SD by using whole-cell bacterins have not been very 
successful, as these preparations typically lead to only partial protection in pigs (Waters 
et al., 1999a). Bacterin vaccines also tend to be lipopolysaccharide serogroup-specific, 
which then requires the use of multivalent bacterins; furthermore, they are difficult and 
costly  to  produce  on  a  large  scale  because  of  the  fastidious  anaerobic  growth 
requirements of the spirochaete. In contrast, and as a note of warning, Olson et al 
(1994) reported that pigs vaccinated intramuscularly with a B. hyodysenteriae bacterin   51 
developed  more  severe  SD,  and  more  vaccinated  animals  were  affected  than 
unvaccinated control pigs. This suggests that the vaccine induced some form of immune-
mediated damage in the infected pigs. 
       
1.3.7.2. Attenuated live 1.3.7.2. Attenuated live 1.3.7.2. Attenuated live 1.3.7.2. Attenuated live vaccines  vaccines  vaccines  vaccines       
       
An alternative approach for vaccine development is the use of attenuated or genetically 
modified live avirulent vaccines for SD (Hyatt et al., 1994; Kennedy et al., 1997; Rosey 
et al., 1996; Stanton et al., 1999). Several mutant strains have been constructed with 
deletions introduced in different virulence factors such as tlyA (haemolysin) (Hyatt et al., 
1994),  nox  (NADH  oxidase)  (Stanton  et  al.,  1999),  and  flaA1  and  flaB1  (motility) 
(Kennedy et al., 1997; Rosey et al., 1996), and their virulence has been characterised in 
mice or pigs. One protection study was conducted in pigs using the tlyA mutant strain. 
The  results  indicate  that  previous  colonisation  by  the  B.  hyodysenteriae  tlyA-minus 
mutant provided partial protection to challenge with a virulent B. hyodysenteriae strain. 
Not only were the clinical signs and lesions of SD less in the previously inoculated pigs, 
but these pigs also shed B. hyodysenteriae for a much shorter period than the control 
pigs (Hyatt et al., 1994). Follow-up studies with these strains to confirm this protection, 
and to test whether this is dose and/or serotype dependent do not appear to have been 
undertaken.  Mutant  stains  deficient  in  nox,  flaA1  and  flaB1  have  similarly  displayed 
attenuated virulence in swine and mouse models of experimental infections (Rosey et 
al.,  1996;  Stanton  et  al.,  1999),  however,  no  further  protection  study  have  been 
published for these strains. 
 
A disadvantage of this approach is that attenuated strains show reduced colonisation,   52 
and hence cause less immune stimulation.  Due to the lack of information available on 
genetic regulation and organization in the organism, there also is a concern of reversion 
to virulence when using live vaccines. 
 
1.3.7.3. Protein 1.3.7.3. Protein 1.3.7.3. Protein 1.3.7.3. Protein- - - -based vaccines based vaccines based vaccines based vaccines       
 
The use of recombinant subunit vaccines for the control of SD is an attractive alternative 
to other methods, since the products would be well-defined (desirable for registration 
purpose), and relatively easy to produce on a large scale. 
 
Significant  efforts  have  been  made  to  identify  outer  envelope  proteins  from  B. 
hyodysenteriae that could be used as recombinant vaccine components (Chatfield et al., 
1988; Joens et al., 1993; Lee et al., 2000), but no successful vaccine has yet been made. 
The first reported use of a recombinant protein (FlaB1) from B. hyodysenteriae as a 
candidate vaccine showed that it failed to protect pigs from an experimental challenge 
(Gabe  et  al.,  1995).  In  a  recent  study,  Bhlp29.7,  the  29.7  kDa  outer-membrane 
lipoprotein of B. hyodysenteriae, was expressed in E. coli as a histidine-tagged protein 
(His-Bhlp29.7)  or  as  an  8  kDa  carboxyl-terminal  portion  fused  to  maltose-binding 
protein (MBP-Bhlp29.7-F604). These recombinant proteins were used to immunise pigs 
by two different vaccine regimes in pen trials. After inoculation with B. hyodysenteriae, 
50-70% of controls and 17-40% of His-Bhlp29.7-vaccinated pigs developed disease. 
The incidence of disease for the all His6-Bhlp29.7-vaccinated groups was significantly 
less (P=0.047) than for the control groups, with approximately a 50% reduction in 
disease (La et al., 2004). However, in this study MBP-Bhlp29.7-F604 did not induce   53 
obvious seroconversion against Bhlp29.7, and offered no protection against SD  (La et 
al., 2004). 
 
The results with His6-Bhlp29.7 are encouraging, as they support the contention that 
outer membrane lipoproteins used as subunits can confer a degree of protection against 
SD. 
 
1.3.7.4. DNA vaccine 1.3.7.4. DNA vaccine 1.3.7.4. DNA vaccine 1.3.7.4. DNA vaccine       
       
Recently,  the  ftnA  gene  was  delivered  as  a  DNA  vaccine  in  a  mouse  model  of  B. 
hyodysenteriae infection (Davis et al., 2005). Vaccine efficacy was monitored by caecal 
pathology and/or quantification of B. hyodysenteriae numbers in the caecal samples by 
real-time PCR. Unfortunately, this approach failed to induce protective immunity in the 
vaccinated mice. 
       
1.3.7.5. Summary 1.3.7.5. Summary 1.3.7.5. Summary 1.3.7.5. Summary       
 
Overall, most vaccines developed against SD have not provided suitable protection. 
Nevertheless,  the  recombinant  vaccine  approach  appears  promising  as  a  means  to 
prevent  the  disease.  Hence,  a  much  more  global  approach  is  needed  for  the 
identification  of  potentially  useful  immunogenic  recombinant  proteins  from  B. 
hyodysenteriae, particularly outer-membrane proteins involved in the pathogenesis of 
the  disease.  These  target  proteins  may  have  to  be  combined  in  order  to  produce 
efficacious vaccines.  
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1.4.  1.4.  1.4.  1.4. AIMS AND OBJECTIVES  AIMS AND OBJECTIVES  AIMS AND OBJECTIVES  AIMS AND OBJECTIVES OF THIS PROJECT OF THIS PROJECT OF THIS PROJECT OF THIS PROJECT       
       
Natural  immunity  against  SD  has  been  demonstrated  in  convalescent  animals,  and 
currently  available  commercial  bacterin  vaccines,  while  partially  protective,  do  not 
provide resistance comparable to that seen in animals that have recovered from infection. 
Recent advances in DNA sequencing and bioinformatics have facilitated animal vaccine 
discovery,  and  enabled  systematic  identification  of  all  the  potential  antigens  of  a 
pathogen in conjunction with other molecular biology technologies. This new concept of 
taking  “a  genomic-based  approach”  to  identify  potential  targets  for  novel  vaccine 
development in SD forms the basis of this thesis.       
       
As a result, the main aim of the work presented in this thesis is to apply the reverse 
vaccinology strategy to identify potentially effective subunit vaccine components for use 
in the control of SD. Since the surface-associated proteins identified from the genomic 
approach are also considered to be good targets for developing diagnostic reagents, a 
secondary aim is to subject these recombinant proteins to serological testing to identify 
specific immunological reagents that could be used for the diagnosis of SD. 
 
Consequently, to achieve these two aims, the specific objectives of this study are as 
follows: 
 
1)  To conduct comprehensive bioinformatics analysis on genomic sequence data of 
B.  hyodysenteriae  to  identify  a  set  of  genes  encoding  surface-exposed  outer 
membrane proteins and/or secreted proteins.   55 
2)  To discover the distribution of the identified genes in different B. hyodysenteriae 
strains. 
 
3)  To  clone  appropriate  genes  and  produce  recombinant  proteins  in  an  E.  coli 
expression system. 
 
4)  To  further  screen  these  recombinant  proteins  in  vitro  and  in  vivo  in  an 
immunologic assay, and select highly immunodominant antigens.  
 
5)  To evaluate selected recombinant proteins for vaccine efficacy in the target animal 
species (swine), and determine their suitability as vaccine components for ultimate 
use in commercial vaccines for the control of SD. 
 
6)  To select suitable immunological reagents from refined outer-membrane proteins 
and to test these proteins for their usefulness in the serological diagnosis of SD. 
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2.1. INTRODUCTION 2.1. INTRODUCTION 2.1. INTRODUCTION 2.1. INTRODUCTION       
       
Brachyspira hyodysenteriae is a common and widespread endemic pathogen of pigs in 
many  countries  around  the  world.  The  spirochaete  causes  swine  dysentery  (SD),  a 
disease  which  has  a  significant  influence  on  efficient  pig  production.  Losses  occur 
through  development  of  diarrhoea,  reduced  growth  rates,  cost  of  medication,  and 
occasional deaths (Harris and Lysons, 1992). Although the incidence of the disease can 
be  reduced  by  using  antibiotics,  the  increasing  frequency  of  antibiotic-resistant  B. 
hyodysenteriae strains provides an impetus for vaccine development as an alternative 
or supplement to the use of antimicrobials.  
 
Currently  available  SD  vaccines  are  based  on  inactivated  whole  cells  of  B. 
hyodysenteriae,  and  this  form  of  vaccine  apparently  induces  protective  responses 
mainly  through  production  of  antibodies  against  the  lipopolysaccharide  of  B. 
hyodysenteriae (Waters et al., 1999a). However, it fails to confer a satisfactory degree 
of  protection  against  infection,  and  does  not  provide  adequate  cross-protective 
immunity  against  B.  hyodysenteriae  strains  of  different  serogroups  (Hampson  et  al., 
1997).  These  problems  have  led  to  an  examination  of  B.  hyodysenteriae  outer 
membrane proteins (OMPs) because of their potential for use as effective, safe and well-
defined subunit vaccines. The challenge is to reveal which components in the pathogen 
should  be  included  in  the  vaccine,  particularly  with  bacterial  pathogens  potentially 
carrying several thousands of encoded proteins (Stemke-Hale et al., 2005). Numerous   57 
investigators  have  used  a  variety  of  methods  to  isolate  and  characterise  complex 
mixtures of antigens from B. hyodysenteriae which may be involved in the colonisation 
of  the  swine  colon,  the  pathogenicity  of  the  spirochaete  or  in  the  generation  of  a 
protective immune response by the host. These include the flagellin genes (Koopman et 
al., 1992a; Koopman et al., 1993; Li et al., 2000); the bhlpA gene encoding an outer 
membrane lipoprotein (Thomas and Sellwood, 1993); haemolysin genes (Muir et al., 
1992; ter Huurne et al., 1994); the nox gene (Stanton et al., 1999), and the bhlp29.7 
gene (Lee et al., 2000), encoding a 29.7 kDa surface lipoprotein. These approaches for 
identifying vaccine candidates are a biased way to search for target components. More 
importantly, to date none of the proteins identified has generated a fully protective 
immune response in vaccinated and experimentally infected mice used as a model for 
swine dysentery, or in the natural host, the pig. 
 
The availability of the complete genomic sequence of Neisseria meningitidis serogroup 
B offered a new strategy for the identification of vaccine candidates (Pizza et al., 2000). 
This landmark approach, now called reverse vaccinology (Rappuoli, 2000; Rappuoli, 
2001), has been applied to several bacteria in the last few years, revolutionizing the 
vaccine  research  area.  The  design  of  vaccines  is  based  on  a  systematic  approach 
combining recent advances in bioinformatics and genetic technologies. In addition, this 
approach has the advantage of revealing proteins independently of their abundance 
and without the need for growing the microorganism in vitro. 
 
In the current study reverse vaccinology was applied to vaccine development for B. 
hyodysenteriae. The aim was to identify new OMPs from the genome sequence of B. 
hyodysenteriae using a variety of bioinformatics tools. The candidate targets from in   58 
silico  selection  were  then  to  be  driven  into  an  experimental  screening  pipeline  to 
produce a small number of novel, high potential vaccine candidates. 
 
2.2. MATERIALS AND METHODS 2.2. MATERIALS AND METHODS 2.2. MATERIALS AND METHODS 2.2. MATERIALS AND METHODS       
       
The source of commercial reagents and kits used in these studies are listed in Appendices 
B.1 and B.2. The formulation of all buffers and solution are listed in Appendix B.3.  
 
2.2.1. Spirochaete strains 2.2.1. Spirochaete strains 2.2.1. Spirochaete strains 2.2.1. Spirochaete strains       
       
The B. hyodysenteriae strains used in this section of the study were obtained from the 
collection held at the Australian Reference Centre for Intestinal Spirochaetes, School of 
Veterinary and Biomedical Science, Murdoch University. The details of the strains are 
given in Table 2.1, including working identity (ID), strain name, origin and serotype. All 
strains  were  in  pure  culture  and  had  been  routinely  identified  in  the  Reference 
Laboratory on the basis of phenotypic and genotypic tests. 
 
2.2.2. Animals 2.2.2. Animals 2.2.2. Animals 2.2.2. Animals       
 
The experimental work in mice was conducted with the approval of the Murdoch 
University Animals Ethics Committee. All procedures were carried out under Australian  
National Health and Medical Research Council guidelines. 
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Table 2.1. Strains of B. hyodysenteriae used for the genomic study. All originated from pigs.       
Working ID Working ID Working ID Working ID        Str Str Str Strain ID ain ID ain ID ain ID        Origin Origin Origin Origin        Serogroup Serogroup Serogroup Serogroup       
HD1  D90.8506  USA  A 
HD3  N91.1589.2  NSW  ND 
HD4  V3821  VIC  F 
HD6  D94.00498  USA  ND 
HD7  Q4662.4  QLD  D 
HD8  V2809/87  VIC  H 
HD9  155.9  WA  B 
HD10  ACK 300/8  USA  B 
HD11  N5503/92  NSW  ND 
HD12  B8044  USA  B 
HD13  Q9374  QLD  D 
HD14  155.18  WA  B 
HD26  N884  NSW  B 
HD36  FM88-90  CANADA  J 
HD37  B234  USA  B 
HD44  3391.90B  VIC  B 
HD46  155.11  WA  E 
HD49  155.8  WA  E 
HD51  FMV89-3323  CANADA  K 
HD52  SA2206  SA  A 
HD54  SA43.3  SA  D 
HD55  Q95.0715.1  QLD  B/I 
HD80  B204  USA  B 
*NSW, New South Wales; VIC, Victoria; QLD, Queensland; WA, Western Australia; SA, Southern 
Australia. ID identity. ND, not determined. 
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2.2.3.  2.2.3.  2.2.3.  2.2.3. In silico In silico In silico In silico analysis  analysis  analysis  analysis       
       
The genome of Australian B. hyodysenteriae strain WA1 (ATCC 49526, 155-6, from a 
pig in Bullsbrook, WA, serogroup B based on LPS, strong β-haemolysis, indole positive, 
API-ZYM profile-14.1.4.10.1) was sequenced using a shotgun sequencing approach under 
a commercial agreement at the Australian Genome Research Facility (AGRF), University 
of  Queensland,  Australia.  The  sequencing  procedure  involved  chromosomal  DNA 
extraction  from  a  culture  of  the  B.  hyodysenteriae  strain  by  the 
cetyltrimethylammonium bromide method, followed by establishment of plasmid clone 
libraries of sheared genomic DNA. Sufficient DNA sequencing was performed so that 
each base pair was covered > 6 times, in fragments of about 500 bp. After sequencing, 
working  with  team  colleagues  at  the  Centre  for  Comparative  Genomics  (CCG)  at 
Murdoch University, the program Phred was used for fragment assembly (Ewing et al., 
1998),  Consed  for  viewing  (Gordon  et  al.,  1998),  and  Glimmer  and  GeneMark  for 
identification of open reading frames (ORFs) (Lukashin and Borodovsky, 1998; Salzberg 
et al., 1999). Due to the large number of ORFs predicted from the B. hyodysenteriae 
genome, this work only analysed partial sequences in the context of the genomic study. 
Therefore,  candidate  genes  identified  in  silico  from  this  work  represented  partial 
candidate antigens of the whole project. 
       
For selected ORFs, searches for functional assignments were conducted by using BlastP 
(ftp.ncbi.nlm.nih.gov) performed with the non-redundant protein database (Altschul et 
al., 1997). Protein domains were assigned by searching against Pfam (Bateman et al., 
2002) and the Conserved Domain Database (CDD) (Wheeler et al., 2001). The cut-off   61 
E-value was set to 10-7 as a default, and proteins with lower E-values were considered 
hits. 
 
Cellular localization predictions for each ORF were carried out as follows: prediction of 
the presence and location of signal peptides in the N-terminal 70 amino acids of        
an  ORF,  using  the  program  SignalP  (Version  3.0,  http:// 
www.Cbs.dtu.dk/services/SignalP/)  (Bendtsen  et  al.,  2004);  prediction  of  protein 
localization sites in Gram-negative bacteria using the software PSORTb (version 2.0, 
http://www.psort.org/psortb/)  (Gardy  et  al.,  2005;  Nakai,  2000);  identification  of 
lipoprotein signatures by the Lipop program of the PSORT package (Nakai, 2000), and 
SpLip (Setubal et al., 2006) for specifically predicting spirochaetal lipoproteins (obtained 
from  Setubal  and  Haake,  Virginia  Bioinformatics  Institute,  USA);  and  recognition  of 
membrane-spanning  regions,  using  the  program  TMpred 
(http://www.ch.embnet.org/software/TMPRED_form.html) (Hofmann et al., 1999). 
 
The %G +C content of an ORF was calculated as the (G +C) content of the third 
nucleotide  position  of  all  the  codons.  Theoretical  molecular  weight  and  isoelectric 
points were calculated using the Pepstats program (Emboss). 
 
All  the  computer  programs  used  were  downloaded  into  the  CCG  server,  and  the 
analyses  were  conducted  in  a  local  network.  Throughout  this  work,  the  predicted 
coding sequences are referred to as the NAV-H number.  
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2.2.4. Gene distribution study by PCR 2.2.4. Gene distribution study by PCR 2.2.4. Gene distribution study by PCR 2.2.4. Gene distribution study by PCR       
 
PCR  amplification  was  conducted  to  screen  all  selected  genes  in  23  strains  of  B. 
hyodysenteriae  belonging  to  different  genetic  types,  serogroups  and  from  different 
geographical origins (Table 2.1). In this study, if a gene could be amplified from more 
than 90% of the strains examined, it was considered to have a good distribution and 
was taken into further screening. For genes detected in only a few strains by one PCR, 
another PCR was conducted aiming to amplifying different regions of the gene. 
       
2.2.4.1. Primer design 2.2.4.1. Primer design 2.2.4.1. Primer design 2.2.4.1. Primer design       
       
Initially,  one  pair  of  primers  was  designed  to  cover  a  large  coding  region  of  each 
putative  ORF.  Since  oligonucleotide  regions  were  randomly  selected,  there  was  a 
likelihood of there being accidental variation at the binding sites of the ORFs, which 
would lead to PCR-negative results in some strains. A second pair of primers was then 
developed  specifically  for  genes  recorded  as  poorly  distributed  in  the  first  run.  The 
primers used in the gene distribution study are listed in Table 2.2. 
       
Table 2.2. Primers used for gene distribution studies in B. hyodysenteriae 
Gene Gene Gene Gene        Primer Primer Primer Primer        Sequence Sequence Sequence Sequence        Size (bp) Size (bp) Size (bp) Size (bp)       
NAV-H7  F94&R948  5’-GGTGATGCAACAACATTGAAAGTGGC-3’  1038 
    5’-GTCAGCTGTTATTCTTACAGAATCACC-3’   
       
NAV-H8  F85&R1450  5’-AGGAATACAGGCTGGAATTGGACTA-3’  1452 
    5’-CATAATCTATGGCAAGCAAAGCTCTGT-3’   
       
NAV-H12  F7&R792  5’-GTTTTTATTAGTGCGGATATTGAAGG-3’  804 
    5’-CAAGGCTCTTAGTATTTCATAATAG-3’   
       
NAV-H14  F343&R1151  5’-GGATTAGGACCTGCTGATTTTCATAAACC-3’  1350 
    5’-AGCCTTTGCCACTATATAAGCCTCATCTCC-3’     63 
Gene Gene Gene Gene        Primer Primer Primer Primer        Sequence Sequence Sequence Sequence        Size (bp) Size (bp) Size (bp) Size (bp)       
       
NAV-H16  F301&R915  5’-CCTAGCTTCATGAGTGCTGATGATATTC-3’  1203 
    5’-CATACTGCTGTAGCACAGGCAGTAATTG-3’   
       
NAV-H17  F451&R2937  5’-GTTACAGTAAACGATTACCTCGCTA-3’  2940 
    5’-AGGATTATCCTTCCCATGGCAATGC-3’   
  F972&R2039  5’-CACCATGTTAATCAGGCATTGAAAGCTC-3’   
    5’-CTCTCGCCGCCGAATAAACGCATTAAATC-3’   
       
NAV-H18  F381&R1027  5’-ACAATCTGCAGCTATGGCTAGCTGGATTC-3’  1338 
    5’-AAGATTCTCTGCTATATCATCAGGGTTG-3’   
       
NAV-H20  F274&R792  5’-CAGGAACTTGAAGGTGCTGATAATGT-3’  921 
    5’-ATAGCAAGTGCAGCAAGTAGGGTAGA-3’   
       
NAV-H26  F13&R526  5’-GCTTCTATACCTGTTGCTATAGTAGGC-3’  537 
    5’-GAAGAAAACTGCCATTCCGGCTA-3’   
       
NAV-H27  F4&R660  5’-GAGAAAAGTGCTTTTTATATCGATATAC-3’  672 
    5’-GCTATATAAAAACCAATAATGGCA-3’   
       
NAV-H28  F551&R1794  5’-CTATGGAAGCGATGTTTTATTCTGCTG-3’  2412 
    5’-CTCACCGCTTGCTAATAAAACAGCC-3’   
  F46&R2261  5’-AACTCGAGGTATTTACAGACGGTATAAAGCTTAGTG-3’   
    5’-GAGAATTCATCATAGCCTATATACTCAGTATACATTCC-3’   
       
NAV-H29  F4&R729  5’-GCAAATCCTGTTTTATCAAATAAAGC-3’  732 
    5’-TCTGCTTCTTATTTTAGATAAAAGTTTTA-3’   
       
  F58&R686  5’-GATAACACAATGACTCTTAATGGAGCA-3’   
    5’-GCCATACCAAAGTAACAAGAAGTCCG-3’   
       
NAV-H34  F84&R1146  5’-AGAGTACAATTAACAGATGTAAAAGCACC-3’  1149 
    5’-TCCCCATACATCGGGTTCAAACTCT-3’   
       
NAV-H38  F4&R573  5’-GAACTTTTAGCACCTGCTGGAAAT-3’  585 
    5’-CTGAGAGCATTCTCCGCCGTTAGCATC-3’   
       
NAV-H39  F499&R1574  5’-AGTAGAAGTTGTAAGCGATGATTCAG-3’  2199 
    5’-GTTTCAAGTCCGTCTCTAATATCTCTGG-3’   
       
NAV-H42  F47&R708  5’-CTGTTGCATTCTTGTTGTTTGCCCA-3’  708 
    5’-CCAAGTATCTAATGGGTCATCTTCTTC-3’   
       
NAV-H46  F13&R926  5’-AATAGAGTTTTAATATCAGATGATGGTC-3’  930 
    5’-ATGAGCATTAAGCCAAGCAATTATCTC-3’   
       
NAV-H49  F319&R1124  5’-GGAGTTGGCGGAGATACTAATGAATTG-3’  1464 
    CCCTGTCTTGTTTCACCTTTAAGACT-3’   
       
NAV-H53  F446&R1380  5’-ATAACGCATTAGCTTCTGCTAATACAG-3’  1809 
        5’-TCTCCAGGTCTCTTAGGTCCCATTTCA-3’     
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2.2.4.2. PCR amplification 2.2.4.2. PCR amplification 2.2.4.2. PCR amplification 2.2.4.2. PCR amplification       
 
PCR cycling conditions involved an initial template denaturation step of 5 min at 95°C, 
followed by 33 cycles of denaturation at 95°C for 30s, annealing at 55°C for 45s, and 
primer extension at  72°C for 1-2 min (1min/1kb). 1 µl of template chromosomal DNA 
was mixed in a total volume of 25 µl, consisting of 10 × PCR buffer, 1.5 mM MgCl2, 0.2 
mM each of dATP, dTTP, dGTP and dCTP, 0.5 µM of each primer (listed in Table 2.2), 
and 0.25U Taq DNA polymerase in MIQ water. The PCR products were subjected to 
electrophoresis in 1.5% (w/v) agarose gels in 1 × TAE buffer (40 mM Tris-acetate, 1 mM  
EDTA), stained with a 1 µg/ml ethidium bromide and viewed over UV light. 
       
2.2.5. Recombinant DNA te 2.2.5. Recombinant DNA te 2.2.5. Recombinant DNA te 2.2.5. Recombinant DNA techniques chniques chniques chniques       
 
2.2.5.1. Molecular cloning 2.2.5.1. Molecular cloning 2.2.5.1. Molecular cloning 2.2.5.1. Molecular cloning       
       
All  putative  genes  were  cloned  into  the  pTrcHisA  expression  system  (Invitrogen, 
Carlsbad, CA, USA), and expressed as an N-terminal histidine-tagged fusion proteins in E. 
coli strain JM109. 
       
2.2.5.1.1. Preparation of  2.2.5.1.1. Preparation of  2.2.5.1.1. Preparation of  2.2.5.1.1. Preparation of E. E. E. E. coli  coli  coli  coli plasmid DNA  plasmid DNA  plasmid DNA  plasmid DNA       
       
Using a minprep kit (QIAGEN GmbH, Germany), plasmid DNA was prepared from E. 
coli  grown  overnight  in  3  ml  of  Luria  Broth  (LB)  medium,  according  to  the 
manufacturer’s  specification.  The  culture  was  transferred  into  a  microcentrifuge  tube 
and centrifuged in an “Eppendorf 5417C” microfuge for 15 min at 14,000 rpm. The   65 
supernatant was removed and the cell pellet resuspended in 250 µl Buffer P1.  To lyse 
cells and denature chromosomal DNA and proteins, 250 µl Buffer P2 was added and 
mixed by gently inverting the tube. This was followed by addition of 350 µl Buffer N3 
and mixing by inverting the tube several times. The tube was centrifuged for 10 min at 
13,000 rpm at room temperature. The clear lysate was transferred to a QIAprep spin 
column,  and  centrifuged  for  60s.  The  spin  column  was  washed  by  adding  0.75  ml 
Buffer PE and centrifuging for 60s. The column was centrifuged for an additional 1 min 
to remove residual wash buffer. Finally, 50 µl Buffer EB (10mM Tris·Cl, pH 8.5) was 
added to the QIAprep column in a clean tube, and the column was centrifuged for 60s 
at 13,000 rpm to elute DNA. 
       
2.2.5.1.2. Preparation of competent cells ( 2.2.5.1.2. Preparation of competent cells ( 2.2.5.1.2. Preparation of competent cells ( 2.2.5.1.2. Preparation of competent cells (E. coli E. coli E. coli E. coli strain JM109)  strain JM109)  strain JM109)  strain JM109)       
 
Competent cells were prepared using the method of Hanahan (1983). The bacterial 
strain  was  streaked  onto  an  LB  agar  plate  and  incubated  overnight  at  37°C.  The 
following day, a single colony was inoculated into 20 ml of LB broth and incubated 
overnight at 37°C. 2.5 ml of the overnight culture was used for further inoculation into 
250 ml of pre-warmed LB and incubated at 37°C with shaking (220 rpm) until the 
OD600 reached 0.5-0.6, as determined in a UV-Vis spectrophotometer (Shimadzu). The 
cells were transferred to a polypropylene tube and cooled on ice for 2 hours, then 
centrifuged at 2500 g for 20 min at 4°C in a Sorvall GS3 rotor. The supernatant was 
discarded, the pellet resuspended in 10 ml of ice-cold trituration buffer (100 mM CaCl2, 
70 mM MgCl2 and 40 mM sodium acetate, pH 5.5), and then diluted to 250 ml with 
the  same  solution.  The  cells  were  incubated  on  ice  for  another  45  min  and  then 
centrifuged  at  1800  ×  g  for  10  min  and  gently  resuspended  in  25  ml  of  ice-cold   66 
trituration buffer. The cells were added to glycerol to a final concentration of 15%, 
divided into 200 µl aliquots, frozen in liquid nitrogen, and stored at -80°C. 
       
2.2.5.1.3. PCR for preparing inserts 2.2.5.1.3. PCR for preparing inserts 2.2.5.1.3. PCR for preparing inserts 2.2.5.1.3. PCR for preparing inserts       
       
The primers (listed in Table 2.3) were designed in frame with the putative genes, with 
restriction enzyme cutting sites on both ends. The gene sequences were amplified from 
B. hyodysenteriae strain WA1 chromosomal DNA. If an N-terminal signal peptide for 
secretion was predicted, the corresponding nucleotide sequence was excluded. Among 
17 selected coding sequences, NAV-H17, encoding a large protein with a predicted size 
of 111.05 kDa was amplified and cloned in two smaller subfragments (NAV-H17 N-
terminus and NAV-H17 C-terminus) to facilitate subsequent expression and purification. 
The PCR was conducted in a 50 µl total volume using 0.2U Taq DNA polymerase 
(Promega, Madison, WI, USA) and 0.02U pfu DNA polymerase (Promega). The other 
components were the same as described in section 2.2.4.              
       
Table 2.3. Primers and cloning sites used in gene cloning 
Primer Primer Primer Primer        Sequence Sequence Sequence Sequence        Cloning site Cloning site Cloning site Cloning site       
NAV-H7-FPC58   5’-TACTCGAGTGTGCTAATAAGGGATCATCATCT-3’ 
NAV-H7-RPC1036  5’-CACTGCAGTGCTTTACCTAATAATTCAGTATC-3’ 
XhoI + PStI 
     
NAV-H8-FPC62  5’-AACTCGAGACTTTGACTTATGCTGCTTATATGG-3’ 
NAV-H8-RPC1454  5’-TTGAATTCATAATCTATGGCAAGCAAAGCTCTG-3’ 
Xhol + EcoRI 
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Primer Primer Primer Primer        Sequence Sequence Sequence Sequence        Cloning site Cloning site Cloning site Cloning site       
NAV-H12-FPC7  5’-AACTCGAGGTTTTTATTAGTGCGGATATTGAAGG-3’ 
NAV-H12-RPC792  5’-ATGAATTCCAAGGCTCTTAGTATTTCATAATAG-3’ 
Xhol + EcoRI 
     
NAV-H14-FPC10  5’-TGCTCGAGGTTTCAAATTCTGAAAGTGTTTTAAGCAG-3’ 
NAV-H14-RPC1347  5’-TCGAATTCAAGAAAGAAATATGCAAAAGGCACAGCGA-3’ 
Xhol + EcoRI 
     
NAV-H16-FPC19  5’-AGCTCGAGCTAGGTCTAGTTCCAAGACTGATTA-3’ 
NAV-H16-RPC1161  5’-TCGAATTCTATAACACCCAAAGCATTATCACCAG-3’ 
Xhol + EcoRI 
     
NAV-H17-FPC451  5’-AGCTCGAGGTTACAGTAAACGATTACCTCGCTA-3’ 
NAV-H17-RPC2937  5’-CAGAATTCAGGATTATCCTTCCCATGGCAATGC-3’ 
Xhol + EcoRI 
     
NAV-H17-FPC451  5’-AGCTCGAGGTTACAGTAAACGATTACCTCGCTA-3’ 
NAV-H17-RPC1572  5’-ATGAATTCTGCCATGTTTGTAGCAAGTGTAACAGC-3’ 
Xhol + EcoRI 
     
NAV-H17-FPC1545  5’-AGCTCGAGGCTGTTACACTTGCTACAAACATGGCA-3’ 
NAV-H17-RPC2937  5’-CAGAATTCAGGATTATCCTTCCCATGGCAATGC-3’ 
Xhol + EcoRI 
     
NAV-H18-FPC10  5’-CCGGATCCTCGTTTGCTAATATATTTAGAGTACAAG-3’ 
NAV-H18-RPC1335  5’-GCAAGCTTTCTCACCTTAGATTTCTTTAATATGCCG-3’ 
BamHI + HindIII 
     
NAV-H20-FPC53  5’-GACTCGAGCCGTTTGTTAAAATTATGCCTATAGCTGC-3’ 
NAV-H20-RPC905  5’-TCGAATTCCATAAATAGTATTAAAAGTCCGCTTGC-3’ 
Xhol + EcoRI 
     
NAV-H26-FPC4  5’-GACTCGAGGTGATAATAGCTTCTATACCTGTTGC-3’ 
NAV-H26-RPC534  5’-TCGAATTCCTGCAAAAAGTAGAAGAAAACTGCC-3’ 
Xhol + EcoRI 
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Primer Primer Primer Primer        Sequence Sequence Sequence Sequence        Cloning site Cloning site Cloning site Cloning site       
NAV-H27-FPC4  5’-CGCTCGAGGAGAAAAGTGCTTTTTATATCGATATAC-3’ 
NAV-H27-RPC660  5’-ATGAATTCGCTATATAAAAACCAATAATGGCA-3’ 
Xhol + EcoRI 
     
NAV-H34-FPC84  5’-GACTCGAGAGAGTACAATTAACAGATGTAAAAGCACC-3’ 
NAV-H34-RPC1146  5’-TCGAATTCTCCCCATACATCGGGTTCAAACTCT-3’ 
Xhol + EcoRI 
     
NAV-H38-FPC4  5’-CGCTCGAGGAACTTTTAGCACCTGCTGGAAAT-3’ 
NAV-H38-RPC573  5’-CAGAATTCCTGAGAGCATTCTCCGCCGTTAGCATC-3’ 
Xhol + EcoRI 
     
NAV-H39-FPC4  5’-GACTCGAGGCAACAAGTGAAGCTTTTCTTGATGA-3’ 
NAV-H39-RPC2196  5’-TCGAATTCACCGCCATTATTCTGATTAAGTGAAGAC-3’ 
Xhol + EcoRI 
     
NAV-H42-FPC76  5’-GACTCGAGGCGGCTCAAACAGGTGAGCAA-3’ 
NAV-H42-RPC705  5’-GCCTGCAGAGTATCTAATGGGTCATCTTCTTCTC-3’ 
XhoI + PStI 
     
NAV-H46-FPC13  5’-CGCTCGAGAATAGAGTTTTAATATCAGATGATGGTC-3’ 
NAV-H46-RPC926  5’-CAGAATTCATGAGCATTAAGCCAAGCAATTATCTC-3’ 
Xhol + EcoRI 
     
NAV-H49-FPC64  5’-CACTCGAGACAAATGAGTTAGTTTTACCTCCTGAA-3’ 
NAV-H49-RPC1458  5’-TCGAATTCTCCTTCTTCTGCTGCTGTCTCATCAGTAAC-3’ 
Xhol + EcoRI 
     
NAV-H53-FPC82  5’-CTCTCGAGGATGCTGCTAGAATAACTCAGGAAGCT-3’ 
NAV-H53-RPC1806  5’-TCGAATTCATTTGCAGTGTTAGCCTCTTCTTGAGCAT-3’ 
Xhol + EcoRI 
 
Note. Number indicates sequence position. The primers’ designated restriction enzyme 
recognition sites are underlined. 
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2.2.5.1.4. PCR produc 2.2.5.1.4. PCR produc 2.2.5.1.4. PCR produc 2.2.5.1.4. PCR product purification  t purification  t purification  t purification        
       
50 µl PCR reaction from the last step was purified using an UltraCleanTM PCR CleanTM  
Kit (MO BIO, Laboratories, Inc). 250 µl SpinBind buffer was added to the PCR reaction 
and  then  centrifuged  in  a  microfuge  for  30s  at  13,000  rpm.  After  the  liquid  flow 
through was discarded, 300 µl SpinClean buffer was added to the spin filter, followed 
by centrifuging for 30s at 13,000 rpm. The liquid flow through was discarded and the 
spin filter basket was centrifuged for 60s at 13,000 rpm. The spin filter was transferred 
to a clean collection tube, 50 µl of elution buffer solution (10 mM Tris) was added and 
the tube was centrifuged for 60s at 13,000 rpm to elute pure DNA. 
       
2.2.5.1.5. DNA quantification 2.2.5.1.5. DNA quantification 2.2.5.1.5. DNA quantification 2.2.5.1.5. DNA quantification       
       
DNA  concentration  was  determined  by  measuring  the  OD260  on  a  UV-Vis 
spectrophotometer. For calculating DNA concentration, an OD260 of 1 was considered 
to correspond to a concentration of 50 µg/ml for double stranded DNA and 20 µg/ml 
for oligonucleotides. The quality of DNA was considered satisfactory when the 260/280 
spectral ratio was 1.6-2.0. Alternatively, the samples and standard DNA solutions were 
electrophoresed  in  an  agarose  gel  and  then  stained  with  ethidium  bromide.  DNA 
concentration was estimated by comparing the intensity of fluorescence emitted under 
UV light by ethidium bromide stained DNA with samples containing known quantities 
of predefined DNA. 
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2.2.5.1.6. Restriction digestion 2.2.5.1.6. Restriction digestion 2.2.5.1.6. Restriction digestion 2.2.5.1.6. Restriction digestion       
       
Restriction digestion of DNA and the vectors (pTrcHisA) was routinely carried out in 
20-50  µl  reactions  containing  10  ×  restriction  enzyme  buffer  and  5-25U  of  the 
appropriate  restriction  enzyme.  The  reactions  were  incubated  overnight  at  37°C, 
stopped  by  heating  for  15  min  at  60°C  and  the  DNA  was  cleaned  up  using  the 
UltraClean PCR Clean-up Kit. The DNA pellet was dissolved in double distilled water 
(ddH2O) to give a final concentration of 100 ng/µl. 
       
2.2.5.1.7. Ligation of DNA fragments 2.2.5.1.7. Ligation of DNA fragments 2.2.5.1.7. Ligation of DNA fragments 2.2.5.1.7. Ligation of DNA fragments       
 
All ligation reactions were undertaken using a 1:1 or 1:3 molar ratio of plasmid vector to 
insert. The reactions were set up using 200 ng of vector, a corresponding ratio of insert 
and 1 Weiss unit of T4 DNA ligase (Promega) in a 10 µl reaction containing 1 × ligation 
buffer. The reactions were incubated overnight at 16°C and then stored at -20°C until 
required. 
       
2.2.5.1.8. Transformation of competent cells 2.2.5.1.8. Transformation of competent cells 2.2.5.1.8. Transformation of competent cells 2.2.5.1.8. Transformation of competent cells       
       
Competent  cells  of  E.  coli  JM109  were  thawed  on  ice  and  50  µl  aliquots  were 
transferred to chilled 1.5 ml microcentrifuge tubes containing 5 µl of ligation mix. The 
cells were gently mixed with the ligation mix and incubated on ice for 30 min. The cells 
were heated at 42°C for 30 sec, cooled on ice for 2 min, resuspended in 1 ml LB broth 
and incubated for 1h at 37°C with shaking (225 rpm). After incubation, 200 µl aliquots   71 
were spread on LB plates containing 100 µg/ml ampicillin and incubated overnight at 
37°C. 
 
2.2.5.1.9. Screening of recombinant clones by PCR 2.2.5.1.9. Screening of recombinant clones by PCR 2.2.5.1.9. Screening of recombinant clones by PCR 2.2.5.1.9. Screening of recombinant clones by PCR       
       
Eight to 14 colonies were picked, and each was resuspended in 50 µl distilled water. 
Subsequently, a 1 µl sample was taken for PCR testing using vector (pTrcHisA)-specific 
primers. The forward primer was 5’-GAGGTATATATTAATGTATCG-3’ and the reverse 
primer  was  5’-TCTTCTCTCATCCGCCAAAAC-3’.  PCR  was  carried  out  using  the 
protocol described in section 2.2.4. 
       
2.2.5.1.10. Sequencing of the insert 2.2.5.1.10. Sequencing of the insert 2.2.5.1.10. Sequencing of the insert 2.2.5.1.10. Sequencing of the insert       
       
Once positive colonies were selected, the plasmid was purified from the E. coli cells 
using  the  QIAprep  Spin  Miniprep  Kit  (QIAGEN)  according  to  the  manufacturer’s 
instructions (described in section 2.2.5.1.4). DNA sequencing was conducted to verify 
that there were no PCR errors and to confirm the correct orientation of the insert. 
Using the vector-specific primers, the PCR products containing inserts were amplified 
and  were  subsequently  subjected  to  sequencing.  The  details  of  the  procedure  are 
described later in section 2.2.7.  
 
2.2.5.2. Recombinant protein expression 2.2.5.2. Recombinant protein expression 2.2.5.2. Recombinant protein expression 2.2.5.2. Recombinant protein expression       
 
The production of recombinant proteins was achieved by the addition of isopropyl β-D-   72 
thiogalactoside  (IPTG)  to  the  culture  medium.  After  6-8  hours  induction  with  1mM 
IPTG the transformants were screened for protein production and a protein band of the 
expected size was detected by Western blot using total protein extracts from each clone. 
For each fragment several positive colonies were used in Western blot to choose highly 
expressing clones for large-scale expression and subsequent purification.  
       
2.2.5.2.1. Growth of standard  2.2.5.2.1. Growth of standard  2.2.5.2.1. Growth of standard  2.2.5.2.1. Growth of standard E. coli E. coli E. coli E. coli expression cultures  expression cultures  expression cultures  expression cultures       
       
10 ml of LB medium containing ampicillin (100 µg/ml) was inoculated with E. coli strain 
JM109 transformed with a recombinant plasmid in a 50 ml flask and grown at 37°C 
overnight. Next day 100 ml of pre-warmed medium (with ampicillin) with 5 ml of the 
overnight cultures was incubated at 37°C with vigorous shaking until an OD600 was 
reached. Cultures were induced by adding IPTG to a final concentration of 1 mM and 
grown for an additional 6-8h. 1 ml of culture was used to check expression by Western 
blot analysis, and the rest of the cells were harvested by centrifugation at 4000 × g for 
20 min and stored at -20°C for subsequent protein purification.  
       
2.2.5.2.2. Sodium dodecyl sulphate  2.2.5.2.2. Sodium dodecyl sulphate  2.2.5.2.2. Sodium dodecyl sulphate  2.2.5.2.2. Sodium dodecyl sulphate – – – – polyacrylamide gel electrophoresis (SDS  polyacrylamide gel electrophoresis (SDS  polyacrylamide gel electrophoresis (SDS  polyacrylamide gel electrophoresis (SDS- - - -PAGE) PAGE) PAGE) PAGE)       
       
Proteins  were  separated  using  10%  (w/v)  discontinuous  sodium  dodecyl  sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), as described in the manual of Hoefer 
Scientific Instrument (San Francisco, USA, 1994). The frozen cell pellet was resuspended 
in  50  µl  ddH2O  and  then  mixed  with  an  equal  volume  of  sample-reducing  buffer 
containing  0.125  M  Tris-HCl  (pH  6.8),  4%  SDS,  10%  3ß-mercaptoethanol,  20% 
glycerol  and  0.001%  bromophenol  blue  (w/v).  Samples  were  boiled  for  five  min   73 
immediately prior to being added (10 µl) into wells in the gel. The gel included a 4% 
stacking  gel  consisting  of  0.125M  Tris-HCI  pH  6.8,  4%  acrylamide,  0.15%  bis-
acrylamide, and 0.1% SDS, and a 12% separating gel comprising 0.375M Tris-HCI pH 
8.8, 12% acrylamide, 0.13% bis-acrylamide, and 0.1% SDS. These were polymerised by 
the addition of 0.1% TEMED and 0.05% freshly prepared ammonium sulphate solution. 
Samples were electrophoresed in Tris-glycine buffer (14.4g glycine, 3.0g Tris base, 1.0g 
SDS and ddH2O to make 1L total volume) at a constant 150V until the bromophenol 
blue tracking dye reached the bottom of the gel. The apparatus used for SDS-PAGE was 
a mini-Protein dual slab cell (Bio-Rad Laboratories, USA). Prestained marker proteins 
(Bio-Rad Laboratories) were electrophoresed in parallel to obtain an estimation of the 
molecular weights of the separated proteins.  
 
2.2.5.2.3. Western blot analysis 2.2.5.2.3. Western blot analysis 2.2.5.2.3. Western blot analysis 2.2.5.2.3. Western blot analysis       
       
After electrophoresis, the SDS-PAGE gel was equilibrated in Tris buffered saline (TBS, 
14.4g glycine, 3.0g Tris base, 40% methanol, and ddH2O to make a 1L total volume) 
for 5 min, and then transferred to nitrocellulose paper (Hybond-C extra, 0.45 µm pore 
size; Amersham, Sydney). Following the manufacturer’s instructions, the elecro-transfer 
plates were assembled with the nitrocellulose membrane facing the anode and the cell 
chamber was filled with transfer buffer. Electrophoretic transfer was performed at 30V 
at 4°C overnight. After transfer, the membrane was removed and blocked in TBS-skim 
milk powder (5% w/v) at room temperature for 1h. The membrane was rinsed briefly 
with 1 × TBS-T buffer and the primary antibody (mouse anti-His lgG, diluted 1:3000, 
Sigma) was added to the membrane and incubated for one hour. The membrane was 
washed three times with 1 × TBS-T to remove non-specifically bound antibodies. The   74 
diluted  secondary  antibody  (goat  anti-mouse  lgG-AP,  diluted  1:3000,  Sigma)  was 
subsequently  added  to  the  membrane  and  incubated  for  one  hour.  Following 
incubation,  the  membrane  was  washed  as  above.  Antigen-bound  antibodies  were 
visualized by incubating the membrane in a freshly prepared alkaline phosphatase (AP) 
staining solution. Upon development of the desired colour intensity, the colour reaction 
was stopped by rinsing the membrane with distilled water. Finally the membrane was 
dried, photographed, and stored in the dark. 
       
2.2.5.3. Protein purification 2.2.5.3. Protein purification 2.2.5.3. Protein purification 2.2.5.3. Protein purification       
       
2.2.5.3 2.2.5.3 2.2.5.3 2.2.5.3.1. Determination of target protein solubility .1. Determination of target protein solubility .1. Determination of target protein solubility .1. Determination of target protein solubility       
 
For  each  protein  of  interest,  50  ml  from  the  standard  E.  coli  expression  cultures 
(described in 2.2.5.2.1) was used to examine solubility. The cells were harvested by 
centrifugation at 4000 g for 20 min and the cell supernatant was collected for later 
analysis. The cell pellet was resuspended in 5 ml of lysis buffer. The sample underwent 
three  cycles  of  being  frozen  in  liquid  nitrogen  and  thawed  at  42°C,  followed  by 
sonicating at 200-300 W for 6 × 10 s with 10 s pauses. The lysate was centrifuged at 
10,000 g at 4°C for 25 min. The supernatant (crude extract A, soluble protein) was 
saved  on  ice  for  detection.  The  pellet  (crude  extract  B,  insoluble  protein)  was 
resuspended in 5 ml lysis buffer. The samples were subjected to SDS-PAGE analysis to 
determine the solubility of the target protein.  
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2.2.5.3.2. Purification methods 2.2.5.3.2. Purification methods 2.2.5.3.2. Purification methods 2.2.5.3.2. Purification methods       
 
The  purification  strategy  used  depended  on  the  protein  solubility  and  intracellular 
location, and was performed using immobilized-metal affinity chromatography (IMAC, 
QIAexpress  kit)  according  to  the  QIAGEN  handbook,  with  minor  modification.  For 
fusion  proteins  located  in  cytoplasmic  inclusion  bodies,  purification  was  conducted 
under denaturing conditions; for soluble forms, a native method was employed.  
       
2.2.5.3.2.1. Protein purification under denaturing conditions 2.2.5.3.2.1. Protein purification under denaturing conditions 2.2.5.3.2.1. Protein purification under denaturing conditions 2.2.5.3.2.1. Protein purification under denaturing conditions       
 
Most recombinant proteins accumulated as denatured aggregates, known as inclusion 
bodies (Sassenfeld, 1990). Inclusion bodies can be dissolved with highly concentrated 
dissociating  agents  such  as  guanidine  or  urea,  and  purified  by  Ni-NTA  agarose 
chromatography  under  denaturing  conditions  (Hochuli,  1990).  To  obtain  highly 
purified proteins, high stringency washing buffer (3-5 fold volume of lysis buffer, pH 
6.3) was used to remove contaminating E. coli proteins from the absorbed recombinant 
protein. Tagged proteins were eluted from the column by reducing the pH to cause the 
histidine  residues  to  become  protonated  and  to  dissociate  from  the  Ni-NTA.  The 
desired quantity of high purity proteins was eluted at around pH 5.0. 
 
The cell pellet was thawed for 15 min on ice, resuspended in buffer B at 20 ml per gram 
wet weight and stirred for three hours at room temperature. The lysate was centrifuged 
at  10,000  ×  g  for  25  min  at  room  temperature  to  pellet  the  cellular  debris.  The 
supernatant was carefully removed for lysis. 1 ml of the 50% Ni-NTA slurry was added 
to 4 ml lysate and mixed gently by shaking (200 rpm on a rotary shaker) for 1-2 h at   76 
room temperature. The lysate-resin mixture was carefully loaded into an empty Ni-NTA 
Superflow column with the bottom cap still attached. The bottom cap was removed 
and the column was washed three times with 10 ml buffer C (pH 6.3). Recombinant 
protein was eluted three times with 4 ml buffer D (pH 5.0). 
 
2.2.5.3.2.2. Protein purification under native conditions 2.2.5.3.2.2. Protein purification under native conditions 2.2.5.3.2.2. Protein purification under native conditions 2.2.5.3.2.2. Protein purification under native conditions       
       
The cell pellet was thawed for 15 min on ice and resuspended in lysis buffer at 4-10 ml 
per  gram  wet  weight.  The  suspension  was  subjected  to  3  cycles  of  freeze/thawing 
(frozen in liquid nitrogen and thawed at 42°C). Freshly prepared lysozyme (20 mg/ml) 
was added to the tubes to a final concentration of 1mg/ml and incubated on ice for 30 
min, and then sonicated on ice using a sonicator equipped with a microtip (six 10 s 
bursts at 200-300 W with a 10 s cooling period between each burst). The lysate was 
centrifuged  at  10,000  ×  g  for  25  min  at  4°C  to  pellet  the  cellular  debris,  and  the 
supernatant was saved. 1 ml of the 50% Ni-NTA slurry was added to 10 ml lysate and 
mixed gently (200 rpm on a rotary shaker) for 60 min at 4°C. The lysate-resin mixture 
was  carefully  loaded  into  an  empty  column  with  the  bottom  outlet  capped.  The 
bottom cap was removed and column was washed three times with 10 ml wash buffer. 
Recombinant protein was eluted four times with 5 ml elution buffer. 
       
2.2.5.3.3. Coomassie Brilliant Blue Staining 2.2.5.3.3. Coomassie Brilliant Blue Staining 2.2.5.3.3. Coomassie Brilliant Blue Staining 2.2.5.3.3. Coomassie Brilliant Blue Staining       
 
The recombinant proteins were separated by SDS-PAGE (section 2.2.5.2.2). After the 
electrophoretic run was completed, the gel was immediately subjected to Coomassie 
Brilliant Blue staining by immersion in Coomassie staining Buffer (45% methanol, 10%   77 
acetic acid, 35% ddH2O, and 0.1% Coomassie Brilliant Blue) overnight. Destaining was 
undertaken by immersion in Coomassie destaining Buffer (5% methanol, 7% acetic acid, 
and 88% ddH2O) overnight. The gel was put into distilled water overnight to remove 
methanol, and then dried using a Gel Drying kit (Gel Drying Frames 17.5 × 20 cm, Gel 
Drying Film 25.0 × 28cm and Clamps, Promega).  
 
2.2.5.3.4. Protein quantification 2.2.5.3.4. Protein quantification 2.2.5.3.4. Protein quantification 2.2.5.3.4. Protein quantification       
       
Bovine serum albumin (BSA, 1mg/ml, Promega) was used as a protein standard. It was 
diluted with distilled water (200 ng/µl and 100 ng/µl) to make 200 µl total volumes. An 
equal volume (5-10 µl) of BSA and recombinant proteins was loaded and separated by 
SDS-PAGE. After Coomassie Blue staining, the band intensity of the test solution was 
compared to the intensity of the control, and the approximate concentration of the 
recombinant proteins was calculated. 
       
2.2.5.3.5. Calculation of the recombinant proteins expression level 2.2.5.3.5. Calculation of the recombinant proteins expression level 2.2.5.3.5. Calculation of the recombinant proteins expression level 2.2.5.3.5. Calculation of the recombinant proteins expression level       
 
After calculating the concentration of each recombinant protein in the standard culture 
size,  the  expression  level  was  determined  with  reference  to  the  standard  table  of 
relationships  between  concentration  of  6  ×  His-tagged  protein  and  expression  level 
(QIAGEN,  a  handbook  for  high-level  expression  and  purification  of  6  ×  His-tagged 
proteins, Fifth Edition, p65). 
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2.2.6. Immunogenicity analysis by Western blot analysis 2.2.6. Immunogenicity analysis by Western blot analysis 2.2.6. Immunogenicity analysis by Western blot analysis 2.2.6. Immunogenicity analysis by Western blot analysis       
       
2.2.6.1. Preparation of sera 2.2.6.1. Preparation of sera 2.2.6.1. Preparation of sera 2.2.6.1. Preparation of sera       
       
A  total  of  16  sera  from  healthy  swine  or  swine  that  had  either  undergone  natural 
infections  with  SD  or  been  vaccinated  or  experimentally  challenged  with  B. 
hyodysenteriae or related Brachyspira species were obtained from the Reference Centre 
for  Intestinal  Spirochaetes  at  Murdoch  University,  and  were  used  to  detect  the 
expression and antigenicity of recombinant proteins by Western blot. The sera included: 
N1-N3: sera from healthy grower pigs; M1-M3: sera from pigs immunised with whole 
cell bacterins of B. hyodysenteriae, B. pilosicoli and B. innocens respectively; S1-S5: sera 
from  individual  pigs  experimentally  infected  with  B.  hyodysenteriae  that  developed 
clinical SD, and had lesions of SD at post-mortem; S6-S9: sera from individual infected 
pig with a serological conversion to B. hyodysenteriae using a whole cell ELISA assay; 
S10-S13: convalescent-phase sera from 4 pigs recovering from SD. All sera were used at a 
1:100 dilution. 
       
2.2.6.2. Western blot analysis of serum 2.2.6.2. Western blot analysis of serum 2.2.6.2. Western blot analysis of serum 2.2.6.2. Western blot analysis of serum       
 
Western  blot  analysis  was  performed  as  described  by  La  et  al  (2005).  100  ng  of 
recombinant protein were loaded into the well of a 7 cm preparative gel and subjected 
to  electrophoresis  through  a  10%  (w/v)  SDS-PAGE  gel  (details  of  SDS-PAGE  are 
described in 2.2.5.2.2). The separated proteins then were electro-transferred to a 0.2 
µm nitrocellulose membrane using a Mini Trans-Blot® apparatus (BioRad), according to 
the manufacturer’s instructions. After electro-transfer, the membrane was removed from   79 
the transfer apparatus and blocked with TBS containing 5% (w/v) skim milk powder. 
The membrane was washed with TBS-T (Tween 20, 0.1%, v/v) for 5 min and then 
assembled  into  a  multi-probe  apparatus  (BioRad).  The  wells  of  the  multi-probe 
apparatus were loaded with 100 µl of pig serum diluted 100-fold in TBS-T (Tween 20, 
0.1%, v/v) and incubated for 2h at room temperature with shaking. The membrane 
was removed and washed three times with TBS-T, followed by incubation for 1h at 
room temperature with 10 ml of goat anti-swine lgG-AP (BioRad), diluted 5000-fold. 
The membrane was again washed three times with TBS-T and once with distilled water. 
Colour development occurred in 10 ml of nitro-blue-tetrazolium chloride and 5-bromo-
4  chloro-3indolyl  phosphate  (Sigma)  solution,  and  the  membrane  was  washed  with 
distilled water when sufficient development had occurred. 
       
2.2.7. Sequencing and analysis 2.2.7. Sequencing and analysis 2.2.7. Sequencing and analysis 2.2.7. Sequencing and analysis       
       
DNA sequence analysis was undertaken to investigate sequence variation of selected 
candidate genes, aimed at assuring that only conserved genes were taken into the next 
experimental phase.  
       
2.2.7.1. Primer design and PCR 2.2.7.1. Primer design and PCR 2.2.7.1. Primer design and PCR 2.2.7.1. Primer design and PCR       
 
ORFs were firstly amplified by PCR using a pair of flanking primers (Table 2.4) that 
annealed  to  regions  external  to  the  coding  sequence  of  the  putative  genes. 
Chromosomal DNA from eight       strains of B. hyodysenteriae was randomly adopted as 
amplification  template  based  on  the  results  of  the  distribution  study,  and  then 
sequencing  of  the  PCR  products  was  conducted  on  PCR-positive  strains.  For  ORFs   80 
greater than 1600 bp, one or more internal primers (derived from the distribution study 
in Table 2.2) were used to cover the missing regions. Therefore, whole ORFs were 
amplified for sequencing with the flanking primers and/or internal primer(s). The PCR 
products were purified using the UltraClean up Kit (described in section 2.2.5.1.4). 
 
Table 2.4. Flanking primers used for sequencing in B. hyodysenteriae 
Gene Gene Gene Gene        Primer Primer Primer Primer        Sequence Sequence Sequence Sequence       
F+70  5’-TGAACAGAAGATATGCTAGTTGGTAATTC-3’  NAV-H7 
  R-35  5’-CTATATTCTCTTCCATATACATAGTCC-3’ 
F+28  5’-CTATGATTTGATGCGATAAGGAGAG-3’  NAV-H8 
  R-225  5’-CTTAGGTTAAAGTAGTAGTAGCCTCC-3’ 
F+208  5’-TTTGCAACTTTGGCGAAGCCCAAAAAAAG-3’  NAV-H12 
  R-132  5’-ATCCCAAATCTCTGCCATAAACTTTACCC-3’ 
F+70  5’-TGAACAGAAGATATGCTAGTTGGTAATTC-3’  NAV-H17 
  R-35  5’-CTATATTCTCTTCCATATACATAGTCC-3’ 
F+129  5’-GGAAAAAATTTGAAATGGACTGGAATAC-3’  NAV-H34 
  R-152  5’-GAAATTGATACCAGATATCCGCCTTATG-3’ 
F+105  5’-CAGAAGGCGGAGCTAAAGTAGTAGG-3’  NAV-H42 
  R-155  5’-TAGACATAATAACTCTCTTCAAATTGT-3’ 
Note. The primer number indicates upstream or downstream position of the gene. 
       
2.2.7.2. Sequencing reaction 2.2.7.2. Sequencing reaction 2.2.7.2. Sequencing reaction 2.2.7.2. Sequencing reaction       
 
Cycle sequencing of the PCR products was carried out using the Dye Terminator Cycle 
Sequencing Reaction Mix (PE Applied Biosystems, Foster City, CA, USA), using the same 
sets of primers as shown in Table 2.4, and an ABI 3730 capillary machine (PE Applied   81 
Biosystems). Each 10 µl of the half reaction contained 3.2 pmol of the primer, 4 µl of 
Dye terminator mix and 4 µl (~100 ng) of DNA template. The amplification involved a 
96°C denaturing step for 2 min and 20 seconds, followed by 25 cycles of denaturation 
of 96°C for 10s, annealing at 55°C for 5s and a final polymerization step at 60°C for 4 
min. The reaction was held at 10°C once completed.  
 
2.2.7.3. Post 2.2.7.3. Post 2.2.7.3. Post 2.2.7.3. Post- - - -reaction purification reaction purification reaction purification reaction purification       
       
After thermal cycling, the reaction was purified to remove salts and unincorporated dye 
terminators  that  would  otherwise  have  obscured  the  first  100  or  so  bases  of  the 
sequence. Excess terminator was removed by ethanol precipitation for Big Dye version 
3.1 dye terminators.  For each half reaction, 25 µl of 100% ethanol, 1 µl of 3 M sodium 
acetate  (pH  5.2)  and  1  µl  of  125  mM  EDTA  were  added  to  the  10  µl  reactions  in 
microcentrifuge tubes, vortexed and then incubated on ice for 30 min. The tubes were 
centrifuged at 14,000 rpm for 20 min and then the total supernatant was removed 
carefully.  The  pellet  was  washed  by  adding  200  µl  of  80%  ethanol  and  the 
supernatants were discarded. The pellet was vacuum dried using the vacuum of a micro-
ultra  centrifuge  (Du  Pont)  for  15  min.  Purified  samples  were  electrophoresed  on  a 
3073A automatic DNA sequencer. 
       
2.2.7.4. 2.2.7.4. 2.2.7.4. 2.2.7.4. Alignment of sequences Alignment of sequences Alignment of sequences Alignment of sequences       
 
The raw sequence results were edited and compiled using SeqED v1.0.3 (PE Applied 
Biosystems) before being translated into amino acids and compiled using the BioEdit 
Sequence  Alignment  Editor  (North  Carolina  State  University).  The  nucleotide  and   82 
translated protein sequences for all the genes detected were compared to generate a 
multiple alignment matrix using Clustal W (Thompson et al., 1994).  
       
2.2.8. 2.2.8. 2.2.8. 2.2.8. In vivo In vivo In vivo In vivo immunogenicity test  immunogenicity test  immunogenicity test  immunogenicity test       
 
2.2.8.1. Treatment of recombinant prot 2.2.8.1. Treatment of recombinant prot 2.2.8.1. Treatment of recombinant prot 2.2.8.1. Treatment of recombinant proteins: Dialysis and freeze drying eins: Dialysis and freeze drying eins: Dialysis and freeze drying eins: Dialysis and freeze drying       
       
The recombinant protein elution was dialyzed for use in immunisations. The elution 
was carefully transferred to the dialysis tube, leaving enough space for expansion. The 
dialysis tube was then closed with a knot at the top and placed into a 2 liter flask with 
distilled water. The flask was held at 4°C, and the solution was stirred with a magnetic 
stirrer and changed twice every 24 h for 4 days. The sample was transferred to a 50 ml 
tube,  frozen  at  -80°C  and  freeze  dried  for  72  h.  Finally  the  protein  powder  was 
obtained and stored at -20°C until used. 
 
2.2.8.2. Immunisation of mice 2.2.8.2. Immunisation of mice 2.2.8.2. Immunisation of mice 2.2.8.2. Immunisation of mice       
 
Thirty-five  female  5-6  week-old  C3A/HeJ  mice  were  purchased  from  the  Animal 
Resources Center and were maintained in the Animal House at Murdoch University. 
They were divided into seven groups of five, one group for each recombinant protein, 
with each group in a separate cage. All mice were placed on a balanced mouse food 
containing 63% (w/w) dextrose (Glen Forrest Stockfeeds). 
       
Each recombinant protein powder was resuspended in phosphate buffered saline (PBS), 
emulsified with a 50% volume of VSA3 adjuvant (Novartis Animal Health), and 100 µg   83 
of recombinant protein in a total volume of 100 µl was injected intramuscularly into the 
quadriceps muscles of each mouse. Two weeks after the vaccination, the mice were 
administrated with a second vaccination of the same dose and by the same route. The 
mice  were  killed  two  weeks  after  the  second  vaccination.  They  were  gassed  with 
methoxyfluorane  then  subjected  to  cervical  dislocation.  Serum  was  immediately 
obtained  by  heart  puncture  at  necropsy.  The  sera  were  tested  in  Western  blot  for 
antibodies to the vaccine antigen, and against cell extracts of B. hyodysenteriae. 
       
2.2.8.3.  2.2.8.3.  2.2.8.3.  2.2.8.3.  Western  blotting  of  recombinant  pro Western  blotting  of  recombinant  pro Western  blotting  of  recombinant  pro Western  blotting  of  recombinant  proteins  and  cell  envelopes  of  teins  and  cell  envelopes  of  teins  and  cell  envelopes  of  teins  and  cell  envelopes  of  B.  B.  B.  B. 
hyodysenteriae hyodysenteriae hyodysenteriae hyodysenteriae using sera from immunised mice   using sera from immunised mice   using sera from immunised mice   using sera from immunised mice        
       
Whole cells of B. hyodysenteriae WA1 (108/ml in PBS) were sonicated (XL2015 sonicator) 
at 200 W on ice using three cycles of 30s with 2 min between cycles. The sonicate was 
centrifuged at 10,000g for 10 min and the supernatant was used as antigen stock. Total 
protein content was determined using a commercial dye-binding       assay Kit (Appendix 
B.2).  
 
Fifteen mg of the protein from the B. hyodysenteriae whole cell preparation and one 
hundred ng of each of the recombinant proteins were loaded into the wells of a 7cm 
preparative gel and subjected to Western blot analysis as described in section 2.2.6.2, 
except  that  the  secondary  antibody  was  anti-mouse  lgG-AP  for  mouse  sera  (Sigma; 
diluted 1: 5000). All the serum samples (diluted 1:100) raised against the recombinant 
proteins were tested against the cell extracts of B. hyodysenteriae and the recombinant 
proteins. 
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2.2.9. Bacterial agglutination assay 2.2.9. Bacterial agglutination assay 2.2.9. Bacterial agglutination assay 2.2.9. Bacterial agglutination assay       
 
The  mouse  sera  raised  against  each  antigen  were  examined  for  their  capacities  to 
agglutinate  B.  hyodysenteriae.  Naïve  mouse  serum  and  serum  from  a  pig 
hyperimmunised with B. hyodysenteriae B78T bacterin were used as the negative and 
positive  controls  respectively.  The  agglutination  test  was  performed  in  96  well  U-
bottom plates with 5 × 109 cells of B. hyodysenteriae strain WA1 resuspended in 50 µl 
PBS, carried out as described by Diarra et al (1994), with minor modification. Antiserum 
was serially diluted in 50 µl PBS (1:100 to 1: 6800) and added to each well containing 
spirochaetes. The last column was left without serum as a control. The plates were 
covered  and  incubated  overnight  at  37°C.  The  antibody  titer  was  expressed  as  the 
reciprocal  of  the  highest  dilution  of  serum  showing  a  definite  positive  pattern  (flat 
sediment) as compared with the pattern of the negative control (smooth dot) in the 
center of the well. 
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2.3. RESULTS 2.3. RESULTS 2.3. RESULTS 2.3. RESULTS       
       
2.3.1. Functional annotation of ORF products 2.3.1. Functional annotation of ORF products 2.3.1. Functional annotation of ORF products 2.3.1. Functional annotation of ORF products 
 
From the initial study on partial sequences of the B. hyodysenteriae genome, 19 ORFs 
were  identified  as  encoding  potential  outer-membrane  proteins  or  virulence  factors. 
Among  these,  15  proteins  were  annotated  as  having  cell  envelope  function,  being 
transporter proteins, or having pathogenesis- or toxin-involved functions. Due to the 
lack of striking sequence homologies to the other well-characterised bacterial proteins, 
the other 4 genes (NAV-H14, and NAV-H29, NAV-H49, NAV-H53) were annotated as 
hypothetical proteins. Of the 19 ORF products, 13 contained either a secretion signal 
sequence  (cleavable  or  uncleavable)  and/or  a  transmembrane  segment(s)  (typical 
examples shown in Figures 2.1 and 2.2). The PSORT program could not give the precise 
bacterial localization prediction for 8 ORFs, because these either did not produce a 
significant  “Certainty  Score”  in  the  classified  location  category  or  had  multiple 
localization sites. Since 4 hypothetical genes had a predicted signal sequence required 
for  export  and/or  had  a  trans-membrane  domain  typical  for  membrane  associated 
proteins,  or  were  predicted  to  be  in  the  outer-membrane  region,  they  also  were 
selected for further analysis. NAV-H7 and NAV-H49 were predicted to be lipoproteins 
by SpLip (Setubal et al., 2006) for lipoprotein computational predicting in spirochaetal 
genomes, while neither of these genes was identified as lipoprotein using Lipop (Nakai, 
2000). The candidate genes identified from in silico analysis are summarized in Table 
2.5, and were subjected to further screening in the laboratory. 
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>Sequence              length = 70   
# Measure  Position  Value  Cutoff  signal peptide? 
  max. C    27    0.213   0.52   NO     max. Y    27       0.407   0.33   YES 
  max. S    15    0.993   0.92   YES    mean S     1-26    0.840   0.49   YES  D  1-26    0.624   0.44 YES 
# Most likely cleavage site between pos. 26 and 27: ANK-GS 
Fig 2.1. The SignalP output for NAV-H7 as an example of a secretion signal sequence. The graphical output 
comprises three different scores, C, S, and Y. The C-score is the “cleavage site” score. Y-max is a derivative 
of the C-score combined with the S-score resulting in a better cleavage site prediction than the raw C-score 
alone. The S-mean is the average of the S-score, ranging from the N-terminal amino acid to the amino acid 
assigned with the highest Y-max score, thus the S-mean score is calculated for the length of the predicted 
signal peptide. The D-score is a simple average of the S-mean and Y-max score, reported as numerical 
values. The scores produced in the output indicate that NAV-H7 has a cleavage site between amino acids 
26-27.         87 
               
 
 
 
 
 
Figure 2.2. NAV-H26 shown as an example of transmembrane regions predicted by 
TMpred. Six strong transmembrane helices were found at amino acid positions from 4 
to 22, 26 to 43, 63 to 83, 90 to 110, 117 to 137 and 144 to 164. 
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Table 2.5. Characterisation of products of selected candidate genes identified by bioinformatics analysis                              
Locus ID Locus ID Locus ID Locus ID        Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E- - - -value value value value        Signalp Signalp Signalp Signalp       
TMpred TMpred TMpred TMpred       
(helix) (helix) (helix) (helix)       
SpLip SpLip SpLip SpLip        PSORT PSORT PSORT PSORT        Pfam Pfam Pfam Pfam        GC GC GC GC       
NAV-H7 
Solute-binding protein of ABC transport (44%) 
NZ_AABG00000000, 2e-92 
0.995 
(26-27) 
1  Yes  Unknown 
SBP_bac_3, 
 Bacterial extracellular solute-
binding protein 
0.33 
NAV-H8 
Outer membrane protein , TolC precursor (22%) 
NZ_AAAS02000014, 1e-07 
0.011  1  No  Unknown 
OEP, 
 outer membrane efflux 
protein 
0.32 
NAV-H12 
Dipeptide ABC transporter associated protein (40%) 
NP_107125, 1e-48 
0  0  No  Unknown 
Peptidase_M55,  
D-aminopeptidase 
0.32 
NAV-H14 
Hypothetical membrane-spanning protein (45%) 
NP_603245, e-113 
0  13  No  Cytoplasmic Membrane 
DUF1437,  
Protein of unknown function 
0.28 
NAV-H16 
Serine/threonine sodium symporter (50%) 
NP_602838, e-100 
0.001  10  No  Cytoplasmic Membrane 
SDF,  
Sodium: dicarboxylate 
symporter family 
0.34 
NAV-H17 
Preprotein translocase SecA subunit (48%) 
AE011368, 0.0 
0  0  No 
Unknown 
 (multiple localization sites) 
SecA_DEAD,  
SecA DEAD-like domain 
0.35 
NAV-H18  Preprotein translocase, SecY subunit (44%)  0  10  No  Cytoplasmic Membrane  SecY,    0.35   89 
Locus ID Locus ID Locus ID Locus ID        Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E- - - -value value value value        Signalp Signalp Signalp Signalp       
TMpred TMpred TMpred TMpred       
(helix) (helix) (helix) (helix)       
SpLip SpLip SpLip SpLip        PSORT PSORT PSORT PSORT        Pfam Pfam Pfam Pfam        GC GC GC GC       
NP_953880, e-106  eubacterial secY protein 
NAV-H20 
Related to protein-export membrane protein (32%) 
YP_064542, 2e-38 
0.016  6  No  Cytoplasmic Membrane 
SecD_SecF,  
Protein export membrane 
protein 
0.29 
NAV-H26 
Bacitracin resistance protein (44%) 
NP_276544, 1e-22 
0  6  No  Cytoplasmic Membrane 
BacA,  
Bacitracin resistance protein 
BacA 
0.3 
NAV-H27 
Haemolysin III(yplQ) (43%) 
AAC66515, 3e-37 
0  6  No  Cytoplasmic Membrane 
UPF0073,  
Uncharacterised protein 
family (Hly-III / UPF0073) 
0.28 
NAV-H28 
Hypothetical protein (52%) 
AAP76647, 2e-68 
0  0  No  Unknown 
DUF285,  
Mycoplasma 
protein of unknown function 
0.26 
NAV-H29 
Hypothetical protein (41%) 
NP_987964, 4e-46 
0.371  7  No 
Cytoplasmic Membrane 
(multiple localization sites) 
DUF1112,  
Protein of unknown function 
0.28 
NAV-H34 
Sporulation protein and related proteins(36%) 
ZP_00301071, 1e-42 
0.996 
(23-24) 
2  No  Unknown 
DiS_P_DiS,  
Bacterial Peptidase A24 N-
terminal domain 
0.31   90 
Locus ID Locus ID Locus ID Locus ID        Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E Possible identity, Accession No, E- - - -value value value value        Signalp Signalp Signalp Signalp       
TMpred TMpred TMpred TMpred       
(helix) (helix) (helix) (helix)       
SpLip SpLip SpLip SpLip        PSORT PSORT PSORT PSORT        Pfam Pfam Pfam Pfam        GC GC GC GC       
NAV-H38 
Collagenase and related proteases (56%) 
NP_622877, 2e-53 
0  0  No  Unknown 
Peptidase_U32,  
Peptidase family U32 
0.28 
NAV-H39 
Flagellar hook-associated protein 2 (19%) 
NP_92078, 2e-27 
0  0  No  Extracellular 
FliD_C, 
 Flagellar hook-associated 
protein 2 C 
0.34 
NAV-H42 
Flagellar filament outer layer protein (36%) 
NP_219101, 4e-27 
1.000 
(23-24) 
1  No  Unknown 
FlaA,  
Flagellar filament outer layer 
protein FlaA 
0.36 
NAV-H46 
Lysophospholipase (38%) 
NP_622099, 1e-61 
0  0  No  Cytoplasmic  
Abhydrolase_1,  
alpha/beta hydrolase fold 
0.32 
NAV-H49 
Treponemal membrane protein, putative (28%) 
NP_973032, 2e-14 
0.998 
(19-20) 
1  Yes 
OuterMembrane 
( multiple localization sites) 
LysM,  
LysM domain 
0.31 
NAV-H53 
Treponemal membrane protein, putative (37%) 
NP_973032, 1e-13 
0.939 
(25-26) 
1  No 
Cytoplasmic Membrane 
(multiple localization sites) 
TolA,  
TolA protein 
0.35 
 
This table includes database homology matches (Blastp), signal peptide predictions, transmembrane region predictions, spirochaetal 
lipoprotein predictions, PSORT outer membrane probability, Pram family protein domain and GC content.  91 
2.3.2.  Preliminary  analysis  of  conservation  of  vaccine  candidates  among  2.3.2.  Preliminary  analysis  of  conservation  of  vaccine  candidates  among  2.3.2.  Preliminary  analysis  of  conservation  of  vaccine  candidates  among  2.3.2.  Preliminary  analysis  of  conservation  of  vaccine  candidates  among  B.  B.  B.  B. 
hyodysenteriae hyodysenteriae hyodysenteriae hyodysenteriae strains  strains  strains  strains       
 
Seventeen  of  the  investigated  genes  were  identified  in  more  than  90%  of  the  B. 
hyodysenteriae strains tested (Figure 2.3). Two genes, NAV-H28 and NAV-H29, only 
demonstrated 34.9% and 73.9% distribution, and consequently were discarded. Results 
of the distribution study by PCR are summarized in Table 2.6. 
 
2.3.3. Antigen cl 2.3.3. Antigen cl 2.3.3. Antigen cl 2.3.3. Antigen cloning  oning  oning  oning        
 
A total of 19 molecules (17 full ORFs and NAV-H17 also in 2 parts) were successfully 
cloned  into  the  pTrcHisA  expression  vector.  Recombinant  clones  were  screened  by 
colony PCR and DNA sequencing. Between 8-14 colonies per gene reaction were picked 
for screening to increase the chances of obtaining recombinant clones. A typical agarose 
gel of the PCR screening is shown in Figure 2.4. The cloning efficiency was about 85% 
for  the  pTrcHisA  system  used.  Negative  clones  occurred  where  no  colonies  were 
produced or were associated with internal deletions and/or no recombination. DNA 
sequencing from both 5’- and 3’-junctions was successful for all master clones, validating 
the identities of the cloned ORFs.  
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  Table 2.6. B. hyodysenteriae gene distribution by PCR.  + indicates positive product presented with expected size. ￿ indicates negative.        
Gene Gene Gene Gene        Primers Primers Primers Primers        HD1 HD1 HD1 HD1        HD3 HD3 HD3 HD3        HD4 HD4 HD4 HD4        HD6 HD6 HD6 HD6        HD7 HD7 HD7 HD7        HD8 HD8 HD8 HD8        HD9 HD9 HD9 HD9        HD10 HD10 HD10 HD10        HD11 HD11 HD11 HD11        HD12 HD12 HD12 HD12        HD13 HD13 HD13 HD13        HD14 HD14 HD14 HD14        HD26 HD26 HD26 HD26        HD36 HD36 HD36 HD36        HD37 HD37 HD37 HD37        HD44 HD44 HD44 HD44        HD46 HD46 HD46 HD46        HD49 HD49 HD49 HD49        HD51 HD51 HD51 HD51        HD52 HD52 HD52 HD52        HD54 HD54 HD54 HD54        HD55 HD55 HD55 HD55        HD80 HD80 HD80 HD80        PCR PCR PCR PCR       
NAV-H7  F94&R948  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  95.7%(22/23) 
NAV-H8  F85&R1450  +  ￿  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  91.3%(21/23) 
NAV-H12  F7&R794  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H14  F343&R1151  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H16  F301&R915  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%23/23) 
NAV-H17  F451&R2937  +  ￿  ￿  +  +  +  +  ￿  ￿  +  +  +  ￿  +  +  +  +  +  ￿  +  ￿  ￿  ￿  60.9%(14/23) 
  F972&R2039  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  +  ￿  91.3%(21/23) 
  OVERALL  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  +  ￿  91.3%(21/23) 
NAV-H18  F381&R1027  +  ￿  ￿  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  91.3%(21/23) 
NAV-H20  F274&R792  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H26  F13&R526  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H27  F4&R660  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%923/23) 
NAV-H28  F46&R2261  ￿  ￿  +  ￿  ￿  +  +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  +  +  ￿  ￿  ￿  ￿  21.7%(5/23) 
  F551&R1794  ￿  ￿  ￿  ￿  ￿  +  ￿  ￿  ￿  ￿  ￿  ￿  +  +  ￿  +  ￿  ￿  +  ￿  ￿  ￿  ￿  21.7%(5/23) 
  OVERALL  ￿  ￿  +  ￿  ￿  +  +  ￿  ￿  ￿  ￿  ￿  +  +  ￿  +  ￿  +  +  ￿  ￿  ￿  ￿  34.8%(8/23) 
NAV-H29  F4&R729  +  ￿  ￿  ￿  +  ￿  +  +  ￿  ￿  ￿  ￿  +  +  +  ￿  +  +  +  +  +  ￿  ￿  52.2%(12/23) 
  F58&R686  +  ￿  ￿  +  +  +  +  +  ￿  ￿  ￿  +  +  +  +  +  +  +  +  +  +  +  ￿  73.9%(17/23) 
  OVERALL  +  ￿  ￿  +  +  +  +  +  ￿  ￿  ￿  +  +  +  +  +  +  +  +  +  +  +  ￿  73.9%(17/23) 
NAV-H34  F84&R1146  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H38  F4&R573  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H39  F499&R1574  +  +  ￿  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  91.3%(21/23) 
NAV-H42  F47&R708  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  ￿  95.7%(22/23) 
NAV-H46  F13&R926  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H49  F319&R1124  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
NAV-H53  F440&R1380  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  100%(23/23) 
B. hyodysenteriae strains   93 
 
 
 
 
 
 
          
 
Figure 2.3. Distribution study by PCR on NAV-H46. Lane 1-23: DNA amplified from B. 
hyodysenteriae strains corresponding to those listed in Table 2.6. Lane 24, no DNA 
template control. Lane 25, Standard DNA marker. 
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Figure 2.4.  Example of agarose gel electrophoresis of PCR products obtained whilst 
selecting  positive  colonies  containing  NAV-49.  Lane  1,  negative.  Lane  2,  4-8,  10-12, 
positive colonies. Lane 3, not amplified. Lane 9, non-specific product. Lane 13, no DNA 
template control. Lane 14, standard DNA marker. 
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2.3.4. Expression and purification of recombinant proteins in  2.3.4. Expression and purification of recombinant proteins in  2.3.4. Expression and purification of recombinant proteins in  2.3.4. Expression and purification of recombinant proteins in E. coli E. coli E. coli E. coli       
 
Of the 19 molecules cloned, 14 (74%) were successfully expressed as determined by 
detection with an anti-6x His tag antibody by Western blot (Figure 2.5). Five molecules 
(NAV-H14, NAV-H16, NAV-H20, NAV-H27 and NAV-H28) failed to express even after 
optimisation  of  the  time-course,  alteration  of  IPTG  concentration  and  expression 
temperature,  and  using  another  expression  system  (pET19b  and  pQE30)  (data  not 
shown).  Highly  expressing  colonies  were  used  for  protein  purification,  as  shown  in 
Figure 2.6. 
 
Most of the expressed proteins were found in the cytoplasm as an insoluble form, as 
evaluated  by  SDS-PAGE  (Figure  2.7)  and  were  therefore  purified  under  denaturing 
conditions  (Figure  2.8).  Two  recombinant  proteins  (NAV-H8  and  NAV-H12)  were 
determined  to  be  soluble  in  the  cytoplasm  and  therefore  were  purified  in  native 
conditions. Compared with denaturing purification, there were more contaminants in 
native conditions, reflected in the large number of proteins that appeared in the first 
wash (Figure 2.9), in agreement with the report of the QIAGEN handbook. 
 
All expressed proteins are shown in the SDS-PAGE gel in Figure 2.10. Expression level 
and a comparison between predicted molecular weight and actual recombinant protein 
size are summarized in Table 2.7. 
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Figure  2.5.  Recombinant  protein  expression  detected  by  Western  blot  using  anti-
Histidine-tagged mouse serum. Lane 1, Molecular mass marker (kDa). Lane 2, NAV-H7. 
Lane 3, NAV-H8. Lane 4, NAV-H12. Lane 5, NAV-H17. Lane 6, NAV-H17 N-terminal. 
Lane 7, NAV-H17 C-terminal. Lane 8, NAV-H18. Lane 9, NAV-H34. Lane 10, NAV-H38. 
Lane 11, NAV-H39. Lane 12, NAV-H42. Lane 13, NAV-H46. Lane 14, NAV-H49. Lane 15, 
NAV-H53. 
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Figure 2.6. Western blot analysis of NAV-H42 expression using anti-Histidine-tagged 
mouse serum. Lane 1, Molecular mass marker. Lanes 2-11, individual positive clones, 
induced by 1 mM IPTG for six hours. 
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Figure 2.7. Three recombinant proteins (NAV-H7, NAV-H8 and NAV-H17 C-terminal) 
shown in a SDS-PAGE gel for determination of target solubility. Lane 1, Molecular mass 
marker (kDa). Lane 2, cell supernatant. Lane 3, soluble protein (crude extract A). Lane 4, 
insoluble  protein  (crude  extract  B).  The  arrows  indicate  the  position  of  the  target 
proteins. 
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Figure  2.8.  Denaturing  purification  of  heterologously  expressed  NAV-H18.  Lane  1, 
Molecular mass marker (kDa). Lane 2, cleared lysate. Lane 3, flow-through. Lanes 4-6, 
wash. Lane 7, elute at pH 5.9. Lanes 8-9, elute at pH 5.0. Lane 10, elute at pH 4.5. The 
arrow indicates the position of the recombinant NAV-H18. 
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Figure 2.9. Purification of NAV-H8 under native conditions. NAV-H8 was expressed in 
E. coli and purified using Ni-NTA Agarose with the indicated imidazole concentrations 
in the wash and elution steps. Proteins were visualized by Coomassie staining. Lane 1, 
Molecular mass marker. Lane 2, cell lysate. Lane 3, flow-through. Lanes 4-5, 10 mM 
wash. Lanes 6-7, 100 mM elution. Lanes 8-9, 200 mM elution. The arrow shows the 
position of the recombinant NAV-H8. 
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Figure 2.10. SDS-PAGE analysis of recombinant proteins purified from E. coli, resolved 
in a 10% PAGE gel and stained with Commassie blue. Lane 1, Molecular mass marker 
(kDa). Lane 2, NAV-H7. Lane 3, NAV-H8. Lane 4, NAV-H12. Lane 5, NAV-H17. Lane 6, 
NAV-H17 N-terminal. Lane 7, NAV-H17 C-terminal. Lane 8, NAV-H18. Lane 9, NAV-
H34. Lane 10, NAV-H38. Lane 11, NAV-H39. Lane 12, NAV-H42. Lane 13, NAV-H46. 
Lane 14, NAV-H49. Lane 15, NAV-H53. 
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Table  2.7.  Molecular  weights  of  native  and  recombinant  proteins  and  expression  level  in  the 
pTrcHisA E. coli expression vectors of 14 B. hyodysenteriae genes and gene fragments. The histidine-
fusion of the recombinant protein adds approximately 4 kDa to the native protein. Seven molecules 
were  used  to  immunise  mice,  and  then  the  actual  sizes  of  native  proteins  were  determined  by 
examining the reactivity of B. hyodysenteriae whole-cell extracts with post-immunisation mouse sera. 
The apparent molecular weight was determined from SDS-PAGE.  
Gene Gene Gene Gene       
Predicted MW of  Predicted MW of  Predicted MW of  Predicted MW of 
native protein native protein native protein native protein       
(kDa) (kDa) (kDa) (kDa)       
MW of recombinant  MW of recombinant  MW of recombinant  MW of recombinant 
protein protein protein protein       
(kDa) (kDa) (kDa) (kDa)       
Apparent MW of   Apparent MW of   Apparent MW of   Apparent MW of  
the reactive native  the reactive native  the reactive native  the reactive native 
protein protein protein protein       
(kDa) (kDa) (kDa) (kDa)       
Expression  Expression  Expression  Expression 
level level level level       
       
NAV-H7  37.36  41.36  37.36  5% 
NAV-H8  54.50  60  61  1% 
NAV-H12  30.19  37.10  30.19  0.4% 
NAV-H17  111.05  115.05  125  1% 
NAV-H17 
(N-terminal) 
41.62  46.62  __  8% 
NAV-H17 
(C-terminal) 
52.37  56.37  125  4% 
NAV-H18  49.23  53.23  __  5% 
NAV-H34  43.06  47.06  43.06  6% 
NAV-H38  21.68  28  __  4% 
NAV-H39  82.02  86.02    2% 
NAV-H42  27.05  31.05  30.00  5% 
NAV-H46  35.15  39.15  __  2% 
NAV-H49  54.67  59.64  __  4.6% 
NAV-H53  65.96  75  __  3.5%   103 
2.3.5. Antigenicity of the selected  2.3.5. Antigenicity of the selected  2.3.5. Antigenicity of the selected  2.3.5. Antigenicity of the selected in vitro in vitro in vitro in vitro recombinant proteins  recombinant proteins  recombinant proteins  recombinant proteins       
       
The 14 purified proteins were screened for reactivity by immunoblotting with a range of 
porcine  sera.  Seven  proteins  (NAV-H7,  NAV-H8,  NAV-H12,  NAV-H17,  NAV-H17  C-
terminal,  NAV-H34  and  NAV-H42),  derived  from  six  genes,  were  found  to  be 
immunoreactive (Figure 2.11 and Table 2.8). These protein products also reacted with 
the hyperimmune pig anti-B. pilosicoli and B. innocens sera, and showed weak cross-
reactivity with normal pig serum.  NAV-H12 and NAV-H42 are shown in Figures 2.12 
and 2.13 as typical examples. The seven proteins were then used to immunise mice. 
       
All seven molecules produced antibody responses in mice and the sera were specific, in 
that  they  recognised  whole-protein  extracts  of  B.  hyodysenteriae  preparations  with 
native proteins of the correct size (Figures 2.14 and 2.15). On the other hand, sera taken 
from the non-immunised mice did not recognise any of the components tested (data 
not shown). The apparent molecular weight of these native proteins is incorporated 
into  Table  2.7  for  comparison  with  predicted  sizes  of  the  native  proteins  and  the 
observed sizes of the recombinant counterparts. 
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Figure 2.11. Western blot showing reactivity of all 14 selected candidate proteins with 
convalescent serum from a pig recovered from SD. Lane M, Molecular mass marker 
(kDa); Lane 1, NAV-H7. Lane 2, NAV-H8. Lane 3, NAV-H12. Lane 4, NAV-H17. Lane 5, 
NAV-H17 N-terminal. Lane 6, NAV-H17 C-terminal. Lane 7, NAV-H18. Lane 8, NAV-
H34. Lane 9, NAV-H38. Lane 10, NAV-H39. Lane 11, NAV-H42. Lane 12, NAV-H46. 
Lane 13, NAV-H49. Lane 14, NAV-H53. 
       
       
       
M   1     2       3        4     5    6       7     8       9    10    11      12     13   14       
250 
kDa 
150 
100 
75 
50 
37 
25   105 
       
       
       
       
                                                                                                                   
                                      
       
Figure 2.12. Western blot analysis of NAV-H12 recombinant protein, performed using 
sera  from  pigs  naturally  or  experimentally  infected  with  SD,  or  immunised  with 
Brachyspira  spp.  bacterins.  Lane  M,  molecular  mass  markers  (kDa);  Lanes  N1-N3, 
normal pig sera. Lanes M1-M3, sera from pigs hyperimmunised with B. hyodysenteriae, 
B.  pilosicoli  and  B.  innocens,  respectively.  Lanes  S1-S5,  serum  from  individual 
experimentally infected pigs. Lanes S6-S9, sera from pigs showing seroconversion to B. 
hyodysenteriae in a whole cell–ELISA. Lanes S10-S13, individual sera from pigs in the 
convalescent phase of SD. The arrow shows the position of the recombinant NAV-H12. 
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Figure 2.13. Western blot analysis of NAV-H42 recombinant protein performed using 
sera  from  pigs  naturally  or  experimentally  infected  with  SD,  or  immunised  with 
Brachyspira  spp.  bacterins.  Lane  M,  molecular  mass  markers  (kDa);  Lanes  N1-N3, 
normal pig sera. Lanes M1-M3, sera from pigs hyperimmunised with B. hyodysenteriae, 
B.  pilosicoli  and  B.  innocens,  respectively.  Lanes  S1-S5,  serum  from  individual 
experimentally infected pigs. Lanes S6-S9, sera from pigs showing seroconversion to B. 
hyodysenteriae in a whole cell–ELISA. Lanes S10-S13, individual sera from pigs in the 
convalescent phase of SD. The arrow shows the position of the recombinant NAV-H42. 
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Table 2.8. Results of the reactivity of purified candidate antigens with a range of sera from healthy or naturally and experimentally infected pigs. Details of serum 
samples used are shown in section 2.2.6.1. ￿ and ±  ±  ±  ± indicates either not or weakly reactive, while  + indicates reactive with a specific band. All positive antigens are 
highlighted in bold in the table.
Gene Gene Gene Gene        N1 N1 N1 N1        N2 N2 N2 N2        N3 N3 N3 N3        M1 M1 M1 M1        M2 M2 M2 M2        M3 M3 M3 M3        S1 S1 S1 S1        S2 S2 S2 S2        S3 S3 S3 S3        S4 S4 S4 S4        S5 S5 S5 S5        S6 S6 S6 S6        S7 S7 S7 S7        S8 S8 S8 S8        S9 S9 S9 S9        S10 S10 S10 S10        S11 S11 S11 S11        S12 S12 S12 S12        S13 S13 S13 S13       
NAV NAV NAV NAV- - - -H7 H7 H7 H7        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV NAV NAV NAV- - - -H8 H8 H8 H8        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV NAV NAV NAV- - - -H12 H12 H12 H12        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV NAV NAV NAV- - - -H17 H17 H17 H17        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
(N-terminal)  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
(C (C (C (C- - - -terminal) terminal) terminal) terminal)        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-H18  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
NAV NAV NAV NAV- - - -H34 H34 H34 H34        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-H38  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
NAV-H39  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
NAV NAV NAV NAV- - - -H42 H42 H42 H42        ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-H46  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
NAV-H49  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
NAV-H53  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
Serum number Serum number Serum number Serum number         - 108 - 
       
       
       
       
       
                          
                                                                                                                               
       
Figure 2.14. Western blot reactivity of mouse serum raised against recombinant His6-
NAV-H7  with  a  whole  cell  preparation  of  B.  hyodysenteriae  WA1  and  NAV-H7 
recombinant protein. Lane 1, Molecular mass markers (Promega). Lanes 2-6, individual 
mouse sera raised against NAV-H7 protein. Lane 7, mouse anti-His-tag serum against 
NAV-H7  protein,  as  the  positive  control.  Lanes  8-12,  individual  mouse  sera  raised 
against a B. hyodysenteriae whole cell extract. The size of the native protein is indicated 
with an arrow. 
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Figure 2.15.       Western blot reactivity of mouse serum raised against recombinant His6-
NAV-H17  C-terminal  with  a  whole  cell  preparation  of  B.  hyodysenteriae  WA1  and 
NAV-H17 C-terminal fusion protein. Lane 1, Molecular mass markers (Promega). Lanes 
2-6, individual mouse sera against NAV-H17 C-terminal truncated proteins. Lanes 7-11, 
individual mouse sera against B. hyodysenteriae whole cell extract. The expected size of 
the proteins is indicated by an arrow. The full-length NAV-H17 product was recognised 
by serum raised against the C-terminal truncated protein. The size of the native protein 
is indicated with an arrow. 
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2.3.6. Analysis of antigenic co 2.3.6. Analysis of antigenic co 2.3.6. Analysis of antigenic co 2.3.6. Analysis of antigenic conservation among  nservation among  nservation among  nservation among B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae strains   strains   strains   strains        
       
The entire ORFs of six genes from which seven immunoreactive molecules originated 
were examined using DNA sequencing. The sequence data from the final six vaccine 
candidate  genes  demonstrated  that  they  were  highly  conserved  over  the  B. 
hyodysenteriae strains with 98-100% homology in selected strains (Table 2.9). The full 
details of sequence comparison are shown in Appendix A. 
 
    Table 2.9.  Selected ORF candidates used in the sequencing study  
Gene Gene Gene Gene        Number of st Number of st Number of st Number of strain rain rain rains s s s        Identity of nucleotide Identity of nucleotide Identity of nucleotide Identity of nucleotide        Identity of amino acid Identity of amino acid Identity of amino acid Identity of amino acid       
NAV-H7  6  100%  100% 
NAV-H8  6  99%-100%  100% 
NAV-H12  6  98%-100%  99%-100% 
NAV-H17  7  99%-100%  100% 
NAV-H34  7  100%  100% 
NAV-H42  7  100%  100% 
 
         
2.3.7. Bacterial agglutination 2.3.7. Bacterial agglutination 2.3.7. Bacterial agglutination 2.3.7. Bacterial agglutination       
       
The  mouse  antisera  produced  following  vaccination  with  the  candidate  proteins 
agglutinated B. hyodysenteriae in a dose-dependent manner. Sera raised against NAV-
34, NAV-H17 and its truncated form had more agglutinating activity than sera raised 
against the other proteins, whereas with the naïve sera, agglutination was not observed 
(Table 2.10).   - 111 - 
       
 
 
Table  2.10.  The  highest  dilution  of  mouse  serum  raised  against  each  recombinant 
protein that agglutinated B. hyodysenteriae cells. Reactivity with positive (porcine) and 
negative (murine) sera is also shown. 
       
       
       
       
       
       
       
       
       
       
       
       
 
       
       
       
       
       
       
       
Sera  Dilution 
NAV-H7  1:400 
NAV-H8  1:800 
NAV-H12  1:400 
NAV-H17  1:1600 
NAV-H17 C-terminal  1:1600 
NAV-H34  1:1600 
NAV-H42  1:800 
Hyperimmune pig serum                                      
against B. hyodysenteriae B78T 
1:3200 
Normal mouse serum  0   - 112 - 
2.4. DISCUSSION 2.4. DISCUSSION 2.4. DISCUSSION 2.4. DISCUSSION       
 
In this study, bacterial genomic sequence information from B. hyodysenteriae was used 
to identify novel proteins with potential as vaccine antigens. The strategy followed was 
to use a bioinformatics selection process to identify likely candidates from the whole 
genome sequence, and then put this smaller group of candidates through a laboratory 
screening process. This process consisted of a distribution study, sequencing analysis, and 
in vitro and in vivo immunological assays. All of these approaches were designed to 
refine the candidate list produced in silico, and to identify novel antigens that could be 
taken  forward  for  validation  as  vaccine  subunits  in  B.  hyodysenteriae  pig  infection 
models. 
 
From a review of the literature, the starting assumption was that antibody mediated 
mechanisms can kill B. hyodysenteriae directly by complement activation, or indirectly 
by opsonizing it for phagocytosis. Accordingly, the bioinformatics strategy for candidate 
vaccine selection targeted outer membrane surface proteins accessible to the immune 
response  during  host  infection.  This  task  was  achieved  by  similarity  searching  and 
identifying  several  signature  sequence  motifs  commonly  found  in  known  secreted 
proteins from other bacteria. OMPs are known to have extensive interspecies variation 
in linear sequence so that homology searching alone could not be relied upon to extract 
all potential surface proteins. Searching was also performed by examining the intrinsic 
biochemistry of the protein including the presence of a signal peptide, transmembrane 
helix  and  lipoprotein  signature,  without  direct  reference  to  the  linear  sequence.  By 
combining  these  prediction  algorithms,  19  ORFs  encoding  putative  membrane-  - 113 - 
associated  targets  from  the  genome  of  B.  hyodysenteriae  were  initially  selected  for 
further evaluation. 
 
Ideally, a vaccine should be effective against all disease-causing strains of a pathogenic 
species. Many different strains of B. hyodysenteriae  have been recognised (Lee et al., 
1993),  and  they  have  been  classified  into  serotypes  (1  through  9)  or  serogroups  (A 
through I) based on the reactivity of LPS antigens with hyperimmune sera (Hampson, 
1990; Hampson et al., 1997). Due to diversity within natural populations of bacterial 
pathogens, a genomic program for vaccine design discovery undertaken on only on one 
representative strain of the species runs the risk of identifying candidate genes/epitopes 
that are absent in other genetically distinct pathogenic strains of the species (Moxon et 
al., 2002). The 19 putative ORFs identified as potential candidate components were 
therefore screened for distribution in different strains among diverse serotypes of the 
spirochaete. In total, 17 ORFs passed the distribution study criteria (present in more 
than 90% of investigated stains), and were considered suitable for further testing. 
   
Optimal utilization of this genomic information should involve the process of cloning, 
expression,  and  purification  prior  to  in  vivo  functional  screening.  The  recombinant 
cloning  technology  is  rapid  and  highly  efficient  and  has  been  used  as  a  standard 
platform for the discovery of new vaccine targets based on the reverse vaccinology 
approach  to  various  bacterial  genomes  (Ariel  et  al.,  2002;  Gamberini  et  al.,  2005; 
Montigiani et al., 2002; Pizza et al., 2000; Ross et al., 2001). For the expression of 
recombinant proteins, E. coli is the most widely used microorganism because it is easily 
manipulated genetically (Blight and Holland, 1994; Sorensen and Mortensen, 2005), 
and  it  has  high  growth  rates,  relatively  simple  nutritional  requirements  and   - 114 - 
fermentation scale-up can be straightforward (Baneyx and Georgiou, 1992; Sorensen 
and Mortensen, 2005). In spite of the lack of certain kinds of post-translation processing, 
this microorganism accumulates many proteins to at least 20% of total cellular protein 
and can translocate them from the cytoplasm to the periplasm or into the extracellular 
medium (Blight and Holland, 1994). In this study, all conserved ORFs were cloned into 
the pTrcHisA vector for expression in an E. coli mediated system. Each recombinant 
protein  was  incorporated  with  an  epitope  tag  at  the  N-terminal  end  to  allow  for 
expression detection and immunoaffinity purification. The 6 x His tag in pTrcHisA is 
small and therefore in most cases does not affect the folding of the attached protein. It 
also has very strong reversible binding attributes allowing for a very rapid and single-
step  purification.  More  importantly,  the  recombinant  proteins  can  be  used  for 
immunoreactive study without prior removal of the polyhistidine tag, as it is poorly 
immunogenic. 
 
Using this cloning and expression system, of 19 candidate molecules from 17 genes, 14 
(74%)  recombinant  proteins  were  produced  successfully.  Five  molecules  failed  to 
express in the E. coli system. This was not unexpected given the low G+C (25.7%-
25.9%) content of the B. hyodysenteriae genome (Zeijst and ter Huurne, 1997). Besides 
the possibility that toxic fragments interfered with growth, it is known that membrane 
permeation of certain protein domains is a challenge for expression due to the high 
selectivity of the outer membrane translocase (Braun et al., 1999). It has to be noted 
that  expression  of  a  recombinant  protein  in  native  conformation  in  E.  coli  can  be 
particularly difficult when attempting over-expression of hydrophobic proteins normally 
founded embedded in membranes. This problem can be solved by expressing truncated 
versions of the genes to remove hydrophobic regions of the protein (Ross et al., 2001),   - 115 - 
although this is difficult, time-consuming and imprecise. Most of the proteins in this 
study were detected in inclusion bodies, although some soluble material was present in 
the cytoplasm (Figure 2.6). Due to the low amount of target protein obtained and the 
presence of contaminant proteins which always co-purify in native configuration (Figure 
2.8),  the  recombinant  proteins  mostly  located  in  cytoplasmic  inclusion  bodies  were 
purified under denaturing conditions in this phase. 
 
To  evaluate  expression  and  antigenicity  of  these  novel  B.  hyodysenteriae  antigens 
during infection in the pig host, sera from healthy, and naturally and experimentally 
infected or vaccinated pigs was tested for reactivity with the 14 recombinant antigens in 
an immunoblot assay. Seven molecules, derived from six genes, reacted strongly with all 
the  sera  used  for  selection,  but  also  weakly  with  the  normal  sera  from  healthy 
individual  pigs.  Cross-reactivity  with  hyperimmune  sera  against  B.  pilosicoli  and  B. 
innocens also was found for these seven recombinant proteins. This was not unexpected, 
as structural proteins in related organisms are likely to share common epitopes which 
would produce cross-reacting antibodies when used as immunogens (Lee et al., 2000). 
In regards to vaccine development, this is not a problem, but an advantage, since cross-
species protection might be achieved. The presence of specific antibodies proves proof 
for the expression of the corresponding antigens in vivo during exposure, colonisation, 
or  disease.  All  seven  recombinant  antigens  identified  also  had  low  titers  of  the 
corresponding  antibodies  in  healthy  subjects,  consistent  with  the  finding  by 
Wannemuehler et al (1988) that antibodies in naïve swine serum were reactive with B. 
hyodysenteriae OMP antigens. The healthy pigs in this experiment came from a herd 
with no reported history of B. hyodysenteriae, but B. pilosicoli and B. innocens had 
been isolated on occasion (D.J. Hampson, personal communication).   - 116 - 
One  of  the  genes  which  encoded  a  protein with  a  predicted  mass of  110  kDa  was 
expressed as two fragments (NAV-H17 N-terminal and NAV-H17 C-terminal), but only 
the  C-terminal  showed  reactivity  with  convalescent  sera.  Interestingly,  a  gene 
orthologous  for  NAV-H17  has  been  found  in  the  B.  pilosicoli  genome  with  85.6% 
identity,  and  has  a  similar  pattern  of  serological  activity  (Murdoch  University, 
unpublished  data).  The  immunoreactivity  of  the  B.  hyodysenteriae  cell  extract  with 
serum raised against the NAV-H17 version truncated in the C-terminal appeared to be 
identical to that observed against the full length gene product (Fig 2.14). Thus, for the 
NAV-H17 gene product, the C-terminal segment contributes in a significant manner to 
its immunogenicity. This truncated segment was later selected for use in the vaccination 
and diagnostic studies rather than full-length NAV-H17 gene. 
 
The  sera  against  these  seven  molecules  had  the  capacity  to  agglutinate  B. 
hyodysenteriae cells, and also recognised the cognate proteins of B. hyodysenteriae in 
cell extracts, thus providing additional evidence that these proteins were expressed in 
vivo.  However,  the  size  of  the  reactive  native  proteins  of  NAV-H8,  NAV-H17  and 
NAV-H42 did not exactly correspond with the predicted molecular mass (Table 2.7). 
This  apparent  discrepancy  can  be  simply  explained  by  anomalies  in  the  SDS-PAGE 
separation. The difference in molecular mass between the recombinant proteins and 
native  proteins  (Table  2.7)  may  arise  from  the  fact  that  truncated  version  of  the 
proteins was used, and post-translational modifications were different between E. coli 
and B. hyodysenteriae. In addition, 6 x His recombinant proteins migrate at a slower 
rate in SDS-PAGE gel than would be expected from their molecular weights (QIAGEN). 
For example, it has been reported that the DHFR-6 x His marker which has a molecular 
weight of 19 kDa was found at 26 kDa (Tabar, 1998). Hence, the apparent molecular   - 117 - 
weights of the recombinant proteins in this study usually were greater than their actual 
size. 
 
There  has  been  concern  that  the  heterogeneity  of  some  proteins  among  bacterial 
isolates  can  cause  problems  with  cross-protection,  which  limits  their  usefulness  as 
vaccines (de Moraes et al., 1992; Tappero et al., 1999). Conserved antigenic fragments 
have received the greatest interest in vaccine studies because they have the potential to 
be sufficiently antigenically conserved among pathogenic isolates to be effective in a 
commercial vaccine. Preliminary study of the genetic distribution of the selected genes 
indicated that these six fragments were presented in most B. hyodysenteriae strains, but 
it did not provide any information on potential sequence variation. As a consequence, 
further DNA sequence analysis was undertaken. The amino acid sequence of selected 
antigens  from  the  5-6  strains  tested  was  ≥99%  identical  to  the  sequence  of  the 
corresponding protein from strain WA1 (Table 2.9). However, in order to obtain whole 
ORF product for analysis, DNA sequencing was only conducted on PCR-positive strains. 
Among the PCR-negative strains, some degree of sequence heterogeneity was likely to 
exist.   
 
In summary, of 19 genes, six (NAV-H7, NAV-H8, NAV-H12, NAV-17, NAV-H34 and 
NAV-H42) were selected as novel, outer membrane and highly conserved immunogens 
from the in silico study and laboratory testing. Among these, NAV-H7, NAV-H12 and 
NAV-H17  were  assigned  functions  as  transporter  or  translocase  associated  proteins. 
NAV-H8  was  annotated  as  an  outer  membrane  protein  Tolc  precursor,  which  is 
involved  in  haemolysin  secretion,  colicin  import,  and  antibiotic  efflux,  and  also  is 
exploited by a bacteriophage as a cell surface receptor (Werner et al., 2003). NAV-H34   - 118 - 
had homology with a sporulation related protein, while NAV-H42 was identified as a 
novel flagellar sheath protein. Considering the molecular mass and homology of NAV-
H42, it is likely to be a previously uncharacterised flaA2 gene, although the 30 kDa 
mass of the product was slightly less than the previously reported B. hyodysenteriae 
flaA2  product,  with  a  35  kDa  mass  (Koopman  et  al.,  1992a).  All  of  these  proteins 
appeared  to  be  membrane  associated  molecules  as  deduced  from  in  silico  selection 
criteria. More importantly, their immunogenicity in vivo in mice and their characteristics 
as assessed in in vitro assays made them attractive targets for a further protection study 
in the target animal species. Their use in this context is described in the next chapter. 
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IN A PROTECTION STUDY AGAINST SWINE DYSENTERY IN PIGS IN A PROTECTION STUDY AGAINST SWINE DYSENTERY IN PIGS IN A PROTECTION STUDY AGAINST SWINE DYSENTERY IN PIGS IN A PROTECTION STUDY AGAINST SWINE DYSENTERY IN PIGS 
       
3.1. INTRODUCTION 3.1. INTRODUCTION 3.1. INTRODUCTION 3.1. INTRODUCTION       
       
The humoral immune response in pigs recovering from SD includes reactivity with a 
range of outer membrane proteins (OMPs) of B. hyodysenteriae, varying in size from 
30 to 45 kDa (Sellwood et al., 1995; Smith et al., 1990; Wannemuehler et al., 1988). 
Likewise, the sera of pigs vaccinated with a B. hyodysenteriae bacterin and showing 
resistance to SD, reacted with a series of B. hyodysenteriae cell envelope proteins with 
molecular masses between 30 and 36 kDa (Chatfield et al., 1988). Although the major 
immunodominant antigens in terms of vaccine development are those located in the 
outer  membrane  of  B.  hyodysenteriae,  to  date  only  a  few  OMPs  have  been 
characterised, particularly compared to other species of pathogenic spirochaete such as 
Borrelia and Treponema (Trott et al., 2001). The first reported use of a recombinant 
protein from B. hyodysenteriae as a vaccine candidate (a 38 kDa flagellar protein) failed 
to  prevent  colonisation  in  experimentally  infected  pigs  (Gabe  et  al.,  1995).  In 
subsequent work, vaccination with a 29.7 kDa lipoprotein (Bhlp29.7) resulted in partial 
protection  in  experimentally  infected  pigs  (La  et  al.,  2004).  This  result  provided 
evidence  for  the  usefulness  of  OMPs  as  vaccine  subunits  in  combating  SD,  and 
encouraged the current search for other OMP components relevant to immunological 
protection. Moreover, given the existence of a range of OMPs, it is not realistic to 
expect to obtain solid protection based on a single molecule. Therefore it is likely that 
an effective vaccine would need to include a combination of multiple antigenic OMPs 
to elicit strong protective immunity.   - 120 - 
In  the  current  genomic  study,  six  novel  putative  OMPs  with  potential  as  vaccine 
subunits were identified. In order to incorporate as wide as possible a repertoire of 
antigenic sites (epitopes), and for reasons of economy, a set of four molecules was used 
in combination to assess their capacity to protect pigs from B. hyodysenteriae infection. 
To  ensure  sufficient  quantity  and  good  quality  of  this  new  vaccine,  four  molecules 
(NAV-H7, NAV-H17 C-terminal, NAV-H34 and NAV-H42) with the highest expression 
levels  (Table  2.7)  and  best  purity  (Figure  2.10)  were  selected  and  purified  in 
recombinant  form.  The  objective  of  the  present  study  was  to  combine  these  four 
recombinant  proteins  to  determine  their  efficacy  as  a  multicomponent  candidate 
vaccine  against  SD  in  a  pig  model.  Meanwhile,  recombinant  Bhlp29.7,  previously 
prepared  and  tested  in  our  laboratory  (La  et  al.,  2004),  was  used  in  parallel  as  a 
positive vaccine control in the pen trial. 
 
Since  the  antigenic  regions  of  NAV-H17  were  mainly  found  at  the  C-terminal,  and 
because of the abundance of the truncated form of the C-terminal in the expression 
system, the recombinant protein NAV-H17 in this and the following sections of the 
study will refer to its C-terminal, unless stated otherwise.  
 
3.2 3.2 3.2 3.2. MATERIALS AND METHODS . MATERIALS AND METHODS . MATERIALS AND METHODS . MATERIALS AND METHODS       
 
The  sources  of  commercial  reagents  and  kits  used  in  these  studies  are  listed  in 
Appendices  B.1  and  B.2.  The  formulation  of  all  buffers  and  solution  are  listed  in 
Appendix B.3.  
       
         - 121 - 
3.2.1. Permissions 3.2.1. Permissions 3.2.1. Permissions 3.2.1. Permissions       
       
The pig study was conducted with the approval of the Murdoch University Animal 
Ethics Committee. The maintenance and care of experimental animals complied with 
the  National  Health  and  Medical  Research  Council’s  guidelines  for  the  use  of 
experimental animals.  
 
3.2.2. Animals and diet 3.2.2. Animals and diet 3.2.2. Animals and diet 3.2.2. Animals and diet       
       
A total of 27 female pigs weaned at 3 weeks of age were purchased from a commercial 
SD-free herd in Western Australia, and were transported to the isolation animal house 
at  Murdoch  University.  The  animals  were  weighed  and  ear-tagged,  then  randomly 
assigned  to  three  groups  of  9:  unvaccinated control  group  (R1-9), Bhlp29.7  vaccine 
group (G1-9) and experimental vaccine group (OR1-9). The three groups of pigs each 
were subdivided into two, with three subgroups held together in a single pen in one 
room, and the other three subgroups held in a pen in an adjacent room (Fig 3.1). The 
rooms initially were held at 28°C, then the temperature was progressively reduced to 
22°C over the next four weeks. 
 
The  animals  were  fed  ad  libitum  on  a  commercial  pelleted  weaner  diet  without 
antibiotics  (Westfeeds,  WA).  The  food  ingredients  included  lupins,  dehulled  lupins, 
wheat, triticale, groats, canolameal, soyameal, fishmeal, meatmeal, bloodmeal, molasses, 
tallow, salt, enzyme, lysine, methionine, threonine, choline and vitamin/trace mineral 
premix (Table 3.1). 
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Table 3.1. Typical analysis of commercial diet. 
Nutrient   Nutrient   Nutrient   Nutrient          As Fed Basis As Fed Basis As Fed Basis As Fed Basis       
Crude Protein (min)  20.0% 
Digestible Energy(min)  14.5MJ/kg 
Added Salted (Max)  0.15% 
Available Lysine : DE  0.75 
Calcium (min)  0.80% 
Available phosphorous (min)  0.45% 
   
 
 
Fig 3.1. The author conducting the pig experiment in the Isolation Animal House at 
Murdoch University. 
                                    - 123 - 
3.2.3. Bacterial strains and culture conditions 3.2.3. Bacterial strains and culture conditions 3.2.3. Bacterial strains and culture conditions 3.2.3. Bacterial strains and culture conditions       
       
The  B.  hyodysenteriae  strain  BW1  was  recovered  from  frozen  stocks  held  at  the 
Reference Centre for Intestinal Spirochaetes, Murdoch University, and grown to mid-log 
phase  in  350  ml  of  Kunkle’s  pre-reduced  anaerobic  Trypticase  Soy  broth  (TSB) 
containing 2% foetal calf serum, 0.5% newborn calf serum, 0.002% cholesterol and 
0.1% resazurin (Kunkle et al., 1986). Cultures were grown at 37°C with shaking, and 
checked  for  growth  and  contamination  by  examination  under  a  phase  contrast 
microscope before use.  
       
3.2.4. Generation of the recombinant proteins for vaccination 3.2.4. Generation of the recombinant proteins for vaccination 3.2.4. Generation of the recombinant proteins for vaccination 3.2.4. Generation of the recombinant proteins for vaccination       
       
The four recombinant proteins NAV-H7, NAV-H17 C terminal, NAV-H34 and NAV-
H42 were used in combination as one vaccine for the pig protection study. Each was 
over-expressed in the E. coli system as a 6 × histidine-tagged fusion protein and purified 
in denaturation conditions as described in Chapter 2.  For each protein, 10-20 mg in 50 
ml elution buffer was produced.  After determining the purity by SDS-PAGE and the 
concentration by comparison with BSA standards, the samples were subjected to dialysis 
and freeze dried to obtain a powder. Prior to immunisation, the proteins were mixed in 
11 ml phosphate-buffer saline (PBS) to a final concentration of 0.5 mg/ml per protein, 
and then emulsified in an equal volume of Freunds’ Incomplete Adjuvant.  
 
Recombinant  His6-Bhlp29.7  was  provided  by  Dr  Tom  La (School  of  Veterinary  and 
Biomedical Science, Murdoch University), and acted as a positive control vaccine in the 
experiment.   - 124 - 
3.2.5.  3.2.5.  3.2.5.  3.2.5. Immunisation Immunisation Immunisation Immunisation and challenge of pigs  and challenge of pigs  and challenge of pigs  and challenge of pigs       
 
The  pig  challenge  studies  were  performed  as  described  by  La  et  al  (2004),  and 
commenced two weeks after the pigs were purchased. The pigs in the two vaccinated 
groups each received 2 ml of vaccine by deep intramuscular (im) injection into the neck 
muscles. The pigs in the Bhlp29.7 group were given 1 mg recombinant His6-Bhlp29.7, 
while the pigs in the experimental vaccine group each received 0.5 mg of each of the 
four  recombinant  proteins.  Four  weeks  later,  both  groups  received  a  second 
immunisation  using  the  same  dose  and  route.  The  non-vaccinated  group  acted  as 
controls. Three weeks after the second vaccination, all pigs were deprived of food for 
24  h  and  then  inoculated  with  approximately  1010  active  viable  cells  of  B. 
hyodysenteriae strains BW1 contained in 100 ml of Kunkle’s broth via stomach tube. 
Experimental challenge was repeated daily over five sequential days.  
       
3.2.6. Pig weights 3.2.6. Pig weights 3.2.6. Pig weights 3.2.6. Pig weights       
 
Pigs were weighed prior to the first vaccination (“pre-bleed”), just prior to the second 
vaccination  (“pre-boost”),  prior  to  the  first  day  of  challenge  (“pre-infection”)  and 
weekly thereafter. Pigs were removed from the experiment if they developed clinical 
signs, and consequently their weights were not recorded thereafter. 
       
3.2.7. Observation of clinical signs 3.2.7. Observation of clinical signs 3.2.7. Observation of clinical signs 3.2.7. Observation of clinical signs       
       
The pigs were evaluated daily for the presence of diarrhoea, mucus and/or blood in the 
faeces, depression and/or anorexia. The characteristics of the faeces in individual pigs   - 125 - 
were also assessed during rectal swabbing (section 3.2.8.1). 
 
3.2.8. Sample collection 3.2.8. Sample collection 3.2.8. Sample collection 3.2.8. Sample collection       
 
3.2.8.1. Swab samples and detection of   3.2.8.1. Swab samples and detection of   3.2.8.1. Swab samples and detection of   3.2.8.1. Swab samples and detection of  B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae       
       
Bacteriology swabs with alginate tips were used to collect faeces from the rectum of all 
pigs every 2-3 days, and also to swab the mucosal surface of the colonic and caecal 
walls  during  post  mortem.  These  swabs  were  used  to  streak  selective  agar  plates 
(Jenkinson  and  Wingar,  1981),  consisting  of  Trypticase  Soy  agar  (Becton  Dickinson 
Microbiology System, Cockeysville, MD, USA) containing 5% (v/v) defibrinated sheep 
blood, 400 µg/ml spectinomycin and 25 µg/ml each of colistin and vancomycin (Sigma, 
St. Louis, MO, USA). The plates were incubated for 5-7 days at 37°C in a jar with an 
anaerobic environment generated using a GasPak PlusTM disposable hydrogen + carbon 
dioxide generator envelope with a palladium catalyst (Becton Dickinson Microbiology 
System). The presence of low flat spreading growth of spirochaetes on the plate, and 
any haemolysis around the growth was recorded. The suspected areas of spirochaete 
growth were resuspended in phosphate buffered saline (PBS), and examined under a 
phase contrast microscope at 400 × magnification. Spirochaetes were identified as B. 
hyodysenteriae on the basis of strong β-haemolysis, microscopic morphology and results 
of a NADH oxidase (nox) PCR of cell growth on the plates. The pair of primers and 
PCR  condition  used  have  been  described  previously  (La  et  al.,  2003).  The  forward 
primer  (5’-ACTAAAGATCCTGATGATTTG-3’)  and  reverse  primer  (5’-
CTAATAAACGTCTGCTGC-3’)  targeted  a  354bp  fragment  of  the  nox  gene  of  B. 
hyodysenteriae. The PCR reaction was carried out in a 25 µl mixture consisting of 1 ×   - 126 - 
PCR buffer (containing 1.5 mM MgCl2), 0.5 U of HotStarTaq DNA polymerase, 0.2 mM 
of  each  dNTP,  0.5  µM  of  each  primer  and  2.5  µl  of  chromosomal  template  DNA 
purified from cell culture. The cycling conditions involved an initial activation step at 
95°C, followed by 31 cycles of denaturation at 94°C for 30 s, annealing at 52°C for 30 s, 
and primer extension at 72°C for 1 min. The amplified products were electrophoresis in 
a 1.5% (w/v) agarose gel in 1 × TAE buffer, stained by immersion in ethidium bromide 
(1 µg/ml), and viewed over UV light. 
       
3.2.8.2. Serum samples 3.2.8.2. Serum samples 3.2.8.2. Serum samples 3.2.8.2. Serum samples       
       
Pigs  were  bled  from  the  anterior  vena  cava  four  times  during  the  course  of  the 
experiment, commencing pre-bleed, pre-boost, pre-infection and at post-mortem. The 5 
ml blood samples were held at 4°C overnight, then the serum was removed, mixed 
with an equal volume of 100% glycerol, and stored at -20°C until used. 
       
3.2.9. Necropsy 3.2.9. Necropsy 3.2.9. Necropsy 3.2.9. Necropsy 
       
Necropsy was performed essentially as described by Hampson et al (2000). Dysenteric 
pigs were killed within 1-3 days of the first appearance of diarrhoea containing blood 
and/or mucus. All other pigs were removed for necropsy 30 days after the final day of 
experimental  challenge.  Slaughter  involved  stunning  with  a  captive  bolt  pistol, 
immediately followed by exsanguinations. The large intestine was removed and opened, 
then examined for gross pathological changes including the presence of haemorrhage, 
fibrin, mucus, oedema, necrosis, and hyperaemia. Swabs were taken from the wall of 
the caecum and mid-colon and plated on selective agar (as described in section 3.2.8.1).   - 127 - 
Fresh tissue from these two areas was placed into 10% (v/v) formalin, and after fixation 
and dehydration, sections (4 µm) were cut and stained with haematoxylin and eosin 
and with Steiner silver stain for subsequent histological examination. A 15 cm2 long 
section of the wall on the anti-mesenteric border of the proximal colon was excised, 
and  briefly  rinsed  in  PBS  to  remove  the  intestinal  contents.  The  mucosa  was  then 
scraped off with a scalpel blade and used to test for specific immunoglobulin content by 
ELISA and Western blot (see section 3.2.11). 
       
3.2.10. ELISA for serum antibodies 3.2.10. ELISA for serum antibodies 3.2.10. ELISA for serum antibodies 3.2.10. ELISA for serum antibodies       
 
Enzyme-linked immunoabsorbent assays (ELISA) were performed as described by La et 
al (2004) on the sera from the pen trial to determine the serum lgG and lgM responses. 
Microtitre plates (Sarstedt Technologies, SA, Australia) were coated with 100 µl per well 
of purified recombinant protein (0.5 µg/ml) or a whole-cell (WC) preparation of B. 
hyodysenteriae strain WA1 (1 µg/ml) in 0.1 M carbonate buffer (pH 9.6). The whole cell 
preparation was prepared as described in Chapter 2. Coating was allowed to occur at 
4°C overnight. Excess binding capacity was blocked with 150 µl of PBS containing 0.1% 
(w/v)  skim-milk powder for 1 h at room temperature with mixing, and then washed 
three times with 150 µl of PBS-T (Tween 20, 0.05%). Pig sera were diluted 200-fold in 
100  µl  of  PBS-T  containing  0.01%  skim-milk  powder  and  incubated  at  room 
temperature for 2 h. Plates were washed as above before adding 100 µl of goat anti-
swine lgG  or lgM conjugated with horse-radish peroxidase (Southern Biotechnology, 
Birmingham, AL, USA) diluted 10,000-fold in PBS-T containing 0.01% (w/v) skim-milk 
powder. After incubating for 1 h at room temperature, the plates were washed three 
times  and  100  µl  of  K-Blue  TMB  substrate  (ELISA  Systems,  Brisbane,  Qld,  Australia)   - 128 - 
added. The colour reaction was allowed to develop for 10 min before being stopped by 
the addition of 50 µl of 1 M sulphuric acid. The optical density (OD) of each well was 
measured at 450 nm on a microplate reader (BioRad Model 3550-UV).        
       
3.2.11. ELISA for colonic lgA and  3.2.11. ELISA for colonic lgA and  3.2.11. ELISA for colonic lgA and  3.2.11. ELISA for colonic lgA and lgG lgG lgG lgG       
       
Extraction and assaying of colonic lgA and lgG used a method adapted from Rees et al. 
(1989). The colonic epithelium was briefly rinsed to remove digesta, stripped off with a 
scalpel blade and resuspended in 4 ml of PBS containing 1% (w/v) BSA, 2 mM PMSF, 1 
mM EDTA and 0.2% (w/v) sodium azide. The suspensions were vortexed for 1 min at 
4°C to pellet the debris. The supernatant was removed, diluted 1:2 with PBS-T, and 100 
µl used for the ELISAs. The mucosal ELISAs were performed as for the serum ELISAs, 
except a goat anti-swine lgA-HRP (1: 5000 dilution, Southern Biotechnology) was used 
to detect the reactive mucosal lgA. 
 
3.2.12. Western blot analysis of serum lgG and colonic lgA 3.2.12. Western blot analysis of serum lgG and colonic lgA 3.2.12. Western blot analysis of serum lgG and colonic lgA 3.2.12. Western blot analysis of serum lgG and colonic lgA       
       
Serum and colonic antibody were analysed in Western blot using either a total of 100 
ng of each of the four recombinant proteins pooled or B. hyodysenteriae whole cell 
extract as antigen. The protocol was described in section 2.2.6.2 of chapter 2, except 
that for detecting the local lgA response, the secondary antibody was goat anti-swine 
lgA-HRP  (1:5000  dilution)  and  the  substrate  was  13-3’-
diaminobenzidinetetrahydrochloride  (5mg/ml,  Sigma)  and  hydrogen  peroxide 
(0.0003%, v/v) in 10 ml TBS. 
         - 129 - 
3.2.13. Data analysis 3.2.13. Data analysis 3.2.13. Data analysis 3.2.13. Data analysis       
       
Pigs were scored positive for clinical signs of SD if they had diarrhoea with fresh blood 
and/or  mucus  in  their  faeces.  Intestinal  lesions  were  considered  typical  of  SD  if 
haemorrhage, excess mucus, fibrin, and/or necrosis were observed in the caecum and/or 
colon. Lesion severity was classified as Normal: no lesion; Mild: patchy reddening in 
≤1/3  colon;  Severe:  lesions  >  1/3  colon  with  blood,  oedema  and  mucus.  SD  was 
defined as the presence of both positive clinical signs and typical lesion development. 
The same scoring system for comparing disease incidence was adopted as described by 
La et al (2004). Pigs that had mild localised lesions in the colon at post-mortem, but did 
not  have  clinical  signs,  were  scored  as  being  “healthy”.  Similarly  pigs  with  mild 
diarrhoea but no colonic lesions were recorded as “healthy”. 
  
3.2.14. Statistic analysis 3.2.14. Statistic analysis 3.2.14. Statistic analysis 3.2.14. Statistic analysis       
 
Microsoft Excel and SPSS for windows 14.0 were used for statistic analysis. Body weights 
and ELISA titers were expressed as the arithmetic mean and standard deviation, and 
statistical  differences  among  more  than  two  groups  were  assessed  using  one  way 
ANOVA. Continuous variables were compared by paired or unpaired Student’s t-test. 
Faecal excretion of B. hyodysenteriae, incidence of SD and association between onset of 
disease and the antibody titres were evaluated by Chi-square analysis. The number of 
pig  sampling  days  in  which  laboratory  culture  was  positive  or  negative  for  B. 
hyodysenteriae, or clinical signs were either observed or not observed, were compared 
for the three groups. Linear regression was used to compare body weights and antibody 
titres,  and  the  Pearson  correlation  coefficient  was  calculated  to  determine  the   - 130 - 
association  of  ELISA  reactivity  between  recombinant  proteins  and  the  whole-cell 
preparation. Significance was accepted at the 5% level (p<0.05).  
       
3.3. RESULTS 3.3. RESULTS 3.3. RESULTS 3.3. RESULTS       
       
3.3.1. Product of recombinant protein 3.3.1. Product of recombinant protein 3.3.1. Product of recombinant protein 3.3.1. Product of recombinant protein       
       
Purified proteins were almost free from contaminating components, and sufficient were 
produced for the planned vaccination in the trial. A total of 50 ml of each recombinant 
protein (ranging from 200 µg/ml to 400 µg/ml in concentration) was generated, and 5 
µl of each was subjected to SDS-PAGE (Figure 3.2).   
 
                           
Fig. 3.2. 10% SDS – polyacrylamide gel electrophoresis of purified recombinant proteins 
of B. hyodysenteriae, followed by Coomassie blue R-250 staining. Lane 1, Molecular 
weight marker. Lane 2, NAV-H7. Lane 3, NAV-H17 C-terminal. Lane 4, NAV-H34. Lane 
5, NAV-H42. Lanes 6-7, 5 µl BSA was used as a standard with 200 ng/µl and 100 ng/µl 
respectively.  
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3.3.2. Evaluation of weights 3.3.2. Evaluation of weights 3.3.2. Evaluation of weights 3.3.2. Evaluation of weights       
       
Before conducting the trial, the weights of the animals from the three groups were 
compared  by  One-Way  ANOVA,  and  no  significant  differences  were  detected. 
Therefore, the three groups could be considered appropriately balanced. During the 
experiment,  the  mean  body  weights  of  the  three  groups  showed  no  significant 
differences (p>0.05). A comparison of the mean weight among the three groups at 
eight different time points of the pig trial is shown in Figure 3.3.  
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Figure  3.3.  Comparison  of  the  mean  body  weights  in  the  three  groups  from  the 
beginning  to  the  end  of  the  trial.  Error  bars  indicate  the  standard  deviation.  Dpi 
represents days post infection. 
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The levels of systemic lgG and lgM antibodies against recombinant proteins and whole 
cell were analysed in respect to swine weights. High levels of lgG and lgM antibodies to 
both recombinant antigens and whole cell were present in pigs of different ages, and 
there was a significantly positive correlation between body weights and antibody titres 
(p<0.001).  The  association  between  body  weights  and  lgM  reactivity  against  B. 
hyodysenteriae whole cell preparations is shown in Figure 3.4. 
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Figure  3.4.  Comparison  of  the  whole-cell  lgM  reactivity  and  body  weights  in  non-
vaccinated pigs. 1 represents pigs from the control group, Bhlp29.7 group and vaccine 
group pre-bleed; 2 and 3 represent pigs from the control group pre-boost and pre-
infection respectively.   - 133 - 
3.3.3. Health status of pigs pre 3.3.3. Health status of pigs pre 3.3.3. Health status of pigs pre 3.3.3. Health status of pigs pre- - - -challenge  challenge  challenge  challenge        
       
All pigs were apparently healthy on arrival, and none shed B. hyodysenteriae in their 
faeces at any point prior to experimental infection. One animal in the Bhlp29.7 group 
died of meningitis soon after arrival, before vaccination was performed. One pig in the 
vaccine  group  died  of  pneumonia  2  days  after  the  second  vaccination.  All  other 
vaccinated pigs remained normal after vaccination, and adverse reactions to the vaccine 
were not noted. 
       
3.3.4. Systemic antibody responses 3.3.4. Systemic antibody responses 3.3.4. Systemic antibody responses 3.3.4. Systemic antibody responses       
       
Systemic antibody profiles were similar for the tested antigens and whole cell extract in 
the ELISAs (Figures 3.5-3.8 and 3.10). For the experimental vaccine group, serum lgG 
and lgM levels to all antigens showed substantial increases after the first vaccination, 
compared to pre-vaccination (p<0.01). A significant increase in titres was not detected 
after the second immunisation, and infection with live B. hyodysenteriae also did not 
further increase the antibody response (Tables 3.2 and 3.3). Indeed, in some of the 
vaccinated  pigs,  there  was  a  trend  for  antibody  titres  to  decline  after  the  second 
vaccination, but the change was not statistically significant (p>0.05) (Figure 3.10). In 
the Bhlp29.7 vaccine group, systemic antibody responses were also induced by the first 
vaccination, followed by a further increasing trend following secondary immunisation 
and bacterial challenge (Figures 3.9 and 3.10). The non-vaccinated pigs showed a trend 
to have increased circulating antibodies against the recombinant proteins or whole cell 
proteins throughout the course of the experiment (Tables 3.2 and 3.3). The average 
antibody titres were highest at the time of bacterial challenge, although the results were   - 134 - 
not uniform in all pigs (Figures 3.5 to 3.16). Over all groups, serum antibody levels did 
not correlate with development of disease (p>0.05). Some pigs (R4 and R8) which 
developed diarrhoea after inoculation had the highest serum lgG and lgM antibody 
levels (Figures 3.5 to 3.16). 
 
In the Bhlp29.7 and experimental vaccine groups, mean antibody levels after the first 
and second immunisation were higher than in the control group. After challenging with 
B. hyodysenteriae, there was no significant difference in either lgG or lgM reactivities to 
whole cell antigen amongst the three groups. The systemic humoral immune response 
to these proteins is illustrated in Figures 3.5 to 3.16 and summarized in Tables 3.2 and 
3.3. 
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Figure 3.5. Systemic lgG antibody titres in ELISA against NAV-H7 in individual pigs from 
the control and experimental vaccine groups. 
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Figure  3.6.  Systemic  lgG  antibody  titres  in  ELISA  against  NAV-H17  C-terminal  in 
individual pigs from the control and experimental vaccine groups. 
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Figure 3.7. Systemic lgG antibody titres in ELISA against NAV-H34 in individual pigs 
from the control and experimental vaccine groups. 
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Figure 3.8. Systemic lgG antibody titres in ELISA against NAV-H42 in individual pigs 
from the control and experimental vaccine groups. 
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Figure 3.9. Systemic lgG antibody titres in ELISA against His6-Bhlp29.7 in individual pigs 
from the control and Bhlp29.7 vaccinated groups. 
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Figure 3.10. Systemic lgG antibody titres in ELISA against B. hyodysenteriae whole-cell 
extracts in individual pigs from the control, Bhlp29.7 and experimental vaccine groups. 
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Table 3.2. Means and standard deviations of group lgG titres (OD values) to different 
ELISA antigens at four sampling times during the experiment. 
Antigen Antigen Antigen Antigen        Pre Pre Pre Pre- - - -bleed bleed bleed bleed        Pre Pre Pre Pre- - - -boost boost boost boost        Pre Pre Pre Pre- - - -infection infection infection infection        Post Post Post Post- - - -mortem mortem mortem mortem        F value F value F value F value       
 P value  P value  P value  P value       
in ANOVA in ANOVA in ANOVA in ANOVA       
NAV-H7    C:  0.22 ± 0.043  0.33 ± 0.081**  0.45 ± 0.094**  0.75 ± 0.361*  13.37  <0.001 
                 V:  0.27 ± 0.073  0.55 ± 0.060**##  0.50 ± 0.060  0.54 ± 0.051  36.71  <0.001 
             
NAV-H17  C:  0.32 ± 0.049  0.58 ± 0.073**    0.68 ± 0.067**  0.92 ± 0.220**  36.96  <0.001 
                V:  0.31 ± 0.060  1.14 ± 0.060**##  1.076 ± 0.18##  1.09 ± 0.213  35.29  <0.001 
             
NAV-H34  C:  0.43 ± 0.103  0.68 ± 0.118**  0.77 ± 0.102  1.18 ± 0.359**  21.04  <0.001 
                 V:  0.46 ± 0.073  1.73 ± 0.304**##  1.56 ± 0.268##  1.66 ± 0.316#  43.04  <0.001 
             
NAV-H42  C:  0.44 ± 0.070  0.74 ± 0.090**  0.93 ± 0.120**  1.13 ± 0.243*  35.13  <0.001 
                 V:  0.47 ± 0.110  1.48 ± 0.266**##  1.28 ± 0.223##  1.43 ± 0.270#  34.85  <0.001 
             
Bhlp29.7    C:   0.29 ± 0.064  0.39 ± 0.124*  0.44 ± 0.107   0.92 ± 0.45**  12.06  <0.001 
                  B:  0.32 ± 0.047  0.55 ± 0.108**#  0.70 ± 0.165*##  0.82 ± 0.256  13.52  <0.001 
             
Whole-cell C:  0.81± 0.090  1.14 ± 0.211**  1.30 ± 0.270  1.99 ± 0.477**  25.23  <0.001 
                 V:  0.88 ± 0.161  2.03 ± 0.182**##  2.01 ± 0.186##  2.00 ± 0.210  74.35  <0.001 
                 B:  0.91 ± 0.265  1.41 ± 0.28**#  1.54 ± 0.220  2.13 ± 0.360**   24.81  <0.001 
C: control group; B: Bhlp29.7 vaccine group; V: experimental vaccine group. 
* indicates p<0.05, ** indicates p<0.01, compared with previous time point within each group. 
# indicates p<0.05, ## indicates p<0.001, compared with control group at the same time point. 
   - 139 - 
NAV-H7 lgM response
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8
Control group                               Vaccine group  
A
n
t
i
b
o
d
y
 
t
i
t
r
e
s
 
(
O
D
 
v
a
l
u
e
)
Pre-bleed Pre-boost Pre-infection Post-mortem
 
Figure 3.11. Systemic lgM antibody titres in ELISA against NAV-H7 in individual pigs 
from the control and experimental vaccine groups. 
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Figure  3.12.  Systemic  lgM  antibody  titres  in  ELISA  against  NAV-H17  C-terminal  in 
individual pigs from the control and experimental vaccine groups. 
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Figure 3.13. Systemic lgM antibody titres in ELISA against NAV-H34 in individual pigs 
from the control and experimental vaccine groups. 
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Figure 3.14. Systemic lgM antibody titres in ELISA against NAV-H42 in individual pigs 
from the control and experimental vaccine groups.   - 141 - 
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Figure 3.15. Systemic lgG antibody titres in ELISA against His6-Bhlp29.7 in individual 
pigs from the control and Bhlp29.7 vaccinated groups. 
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Figure 3.16. Systemic lgM antibody titres in ELISA against B. hyodysenteriae whole-cell 
extracts in individual pigs from the control, Bhlp29.7 and experimental vaccine groups. 
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Table 3.3. Means and standard deviations of group lgM titres (OD values) to different 
ELISA antigens at four sampling times during the experiment. 
Antigen Antigen Antigen Antigen        Pre Pre Pre Pre- - - -bleed bleed bleed bleed        Pre Pre Pre Pre- - - -boost boost boost boost        Pre Pre Pre Pre- - - -infection infection infection infection        Post Post Post Post- - - -mortem mortem mortem mortem        F value F value F value F value       
 P value  P value  P value  P value       
in ANOVA in ANOVA in ANOVA in ANOVA       
NAV-H7    C:  0.15 ± 0.043  0.25 ± 0.093**  0.28 ± 0.069  0.49 ± 0.209*  12.84       <0.001   
                 V:  0.19 ± 0.096  0.43 ± 0.055**##  0.41 ± 0.036##  0.41 ± 0.044  25.19  <0.001   
               
NAV-H17  C:  0.15 ± 0.050  0.26 ± 0.113*    0.26 ± 0.076  0.51 ± 0.242*  10.36  <0.001   
                V:  0.19 ± 0.092  0.41 ± 0.049**##  0.40 ± 0.038##  0.40 ± 0.059  21.96  <0.001   
               
NAV-H34  C:  0.14 ± 0.051  0.24 ± 0.086**  0.28 ± 0.072  0.48 ± 0.215*  12.16  <0.001   
                 V:  0.18 ± 0.084  0.39 ± 0.051**##  0.39 ± 0.042##  0.39 ± 0.045  25.28  <0.001   
               
NAV-H42  C:  0.14 ± 0.047  0.25 ± 0.118*  0.31 ± 0.088  0.69 ± 0.288**  19.35  <0.001   
                 V:  0.17 ± 0.078  0.37 ± 0.065**#  0.37 ± 0.037  0.42 ± 0.065#  24.17  <0.001   
               
Bhlp29.7    C:   0.28 ± 0.076  0.45 ± 0.212*  0.44 ± 0.136  0.98 ± 0.573*  8.51  <0.001   
                  B:   0.33 ± 0.081  0.59 ± 0.246*#  0.70 ± 0.026#  1.06 ± 0.434*  8.93  <0.001   
               
Whole-cell C:  0.23 ± 0.067  0.50 ± 0.071**  0.55 ± 0.054  0.76 ± 0.157**  46.40  <0.001   
                 V:  0.21 ± 0.073  0.63 ± 0.038**##  0.67 ± 0.041##  0.67 ± 0.066  127.75      <0.001   
                 B:  0.29 ± 0.040  0.60 ± 0.104**#  0.59 ± 0.120  0.77 ± 0.212*  18.54  <0.001   
C: control group; B: Bhlp29.7 vaccine group; V: experimental vaccine group. 
* indicates p<0.05, ** indicates p<0.01, compared with previous time point within each group. 
# indicates p<0.05, ## indicates p<0.001, compared with control group at the same time point. 
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The  Pearson  correlation  test  identified  a  significantly  positive  correlation  between 
whole-cell  and  recombinant  protein  antibody  responses  in  unvaccinated  pigs  at 
slaughter (Table 3.4). Representative examples are shown in Figure 3.17.  
 
Table 3.4. Pearson correlation between each recombinant antigen and whole-cell ELISA 
reactivity in control pigs at post-mortem. 
Protein Protein Protein Protein        Serum Serum Serum Serum- - - -lgG lgG lgG lgG        Serum Serum Serum Serum- - - -lgM lgM lgM lgM        C C C Colonic olonic olonic olonic- - - -lgA lgA lgA lgA        Colonic Colonic Colonic Colonic- - - -lgG lgG lgG lgG       
NAV- H7  0.531*  0.793**  0.06  0.124 
         
NAV-H17 
 (C-terminal) 
0.758**  0.819**  0.58*  0.711** 
         
NAV-H34  0.751**  0.882**  0.576*  0.703** 
         
NAV-H42  0.583*  0.713**  0.03  0.717** 
         
Bhlp29.7  0.658**  0.956**  0.325  0.406 
* indicates p<0.05, ** indicates p<0.01 
       
Western  blot  analysis  of  swine  serum  from  the  experimental  vaccine  and  Bhlp29.7 
vaccine groups confirmed that the systemic antibody response was primary directed 
against the candidate proteins of B. hyodysenteriae used in the study (Figure 3.18), and 
His6-Bhlp29.7  (data  not  shown)  respectively.  Using  the  whole-cell  preparation  as 
antigen,  the  reactivity  of  the  serum  from  non-vaccinated  pigs  after  inoculation  was   - 144 - 
related to the production of the native form of the test antigens and Bhlp29.7 (Figure 
3.19).       
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Figure. 3.17. Examples of comparison of systemic antibody responses against vaccine 
antigens or whole-cell (WC) antigens in the non-vaccinated pigs at slaughter.  
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Figure 3.18. Western blot reactivity of serum from pigs in the experimental vaccine 
group to a mixture of the four recombinant proteins. Serum samples were taken from 
the individual pigs after primary immunisation (lanes 2-9), boost (lanes 10-13) and at 
post-mortem (lanes 14-16). The arrows indicate the position of the four recombinant 
proteins used in the experimental vaccine group. 
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Figure 3.19. Western blot reactivity of serum from pigs in the non-vaccinated control 
group to whole-cell preparation of B. hyodysenteriae WA1. Serum samples were taken 
from the individual pigs before (lanes 2-9) and after (lanes 10-17) inoculation with B. 
hyodysenteriae BW1. The arrows indicate the position of the four native proteins and 
Bhlp29.7 used for vaccination in this study.  
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3.3.5. Local antibody response 3.3.5. Local antibody response 3.3.5. Local antibody response 3.3.5. Local antibody response       
 
At slaughter, the local IgA response to the whole-cell preparation and to the candidate 
proteins except NAV-H7 were significantly higher in the experimental vaccine group in 
comparison with the control group (p<0.05) (Figure 3.20). The mean colonic lgG titres 
were also significantly higher in the vaccine group when NAV-H17, NAV-H34 and 
NAV-H42 were used as coating antigens (Figure 3.21). Colonic lgG and lgM responses 
also developed in the pigs immunised with Bhlp29.7 (Figure 3.22). An association 
between ELISA reactivity to the whole-cell preparation and to some of the recombinant 
proteins was again observed in the non-vaccinated pigs at slaughter (Table 3.4 and 
Figure 3.23). However, colonic lgA and lgG responses were not detectable in Western 
blot analysis using either whole-cell or recombinant proteins, and also the local 
antibody titres did not significantly correlate with development of disease (p>0.05). 
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Figure 3.20. Comparison of colonic lgA response in ELISA against recombinant proteins 
and  the  whole-cell  preparation  in  the  control  and  experimental  vaccine  groups  at 
slaughter. P-values are indicated in the bottom of the figure (Student’s t test).   - 148 - 
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Figure 3.21. Comparison of colonic lgG response in ELISA against recombinant proteins 
and  the  whole-cell  preparation  in  the  control  and  experimental  vaccine  groups  at 
slaughter. P-values are indicated in the bottom of the figure (Student’s t test). 
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Figure 3.22. Comparison of colonic antibody response in ELISA against Bhlp29.7 and 
the whole-cell preparation in the control and Bhlp29.7 vaccinated groups at slaughter. 
P-values are indicated under the X axis (Student’s t test).       
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Figure. 3.23. Examples of comparison of colonic antibody responses against vaccine 
antigens or whole-cell (WC) antigens  in the non-vaccinated pigs at slaughter.  
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3.3.6. Faecal excretion of  3.3.6. Faecal excretion of  3.3.6. Faecal excretion of  3.3.6. Faecal excretion of B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae B. hyodysenteriae       
 
Prior to the experimental infection, all rectal swabs were negative with respect to B. 
hyodysenteriae.  For  the  non-vaccinated  control  pigs,  excretion  of  B.  hyodysenteriae 
was  first  detected  in  two  pigs  (R1  and  R8)  10  days  after  the  end  of  experimental 
infection, and these two pigs developed SD within a few days. The first faecal samples 
positive for B. hyodysenteriae in the experimental vaccine group were also detected at 
10 days in two pigs (OR1 and OR4). However, swabs subsequently taken from OR1 and 
OR4 were negative until the end of the trial. Most of the pigs in the three groups were 
culture positive from the faeces at some point during the experimental period, and 
there was no significant difference in the faecal shedding of the bacteria at any stage 
(p>0.05)  (Table  3.5).  Overall,  the  number  of  positive  faecal  samples  in  the  three 
groups  were  16/81,  26/72  and  17/72,  and  these  differences  were  not  significant 
(X2=5.645, df=2, P=0.059). 
 
 
 
 
 
 
 
 
 
 
   - 151 - 
Table 3.5. Colonisation results for pigs in the three groups. Colonisation was determined by culture of faeces 
and PCR of the growth on plates. *Dpi: day post infection; PM: Post-mortem. +  and ￿ indicate culture positive 
and negative for B. hyodysenteriae, respectively. R1-9: non-vaccinated pigs; G1-8: the individual pigs in the 
Bhlp29.7  group;  OR1-8:  the  individual  pigs  in  the  experimental  vaccine  group.  Pigs  removed  from  the 
experiments due to development of clinical signs were not included for calculating sample positive ratios.  
Date  14-Nov  27-Nov  1-Dec  4-Dec  6-Dec  8-Dec  11-Dec  13-Dec  15-Dec  18-Dec  21-Dec 
Dpi  Na  5 dpi  10 dpi  13 dpi   15 dpi  17 dpi  20 dpi  22 dpi  24 dpi  27 dpi  PM 
R1  0  ￿  +  +  +  +           
R2  0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  +  ￿ 
R3  0  ￿  ￿  ￿  ￿  ￿  +  +  ￿  ￿  + 
R4  0  ￿  ￿  ￿  ￿  +  +   +       
R5  0  ￿  ￿  ￿  +  +           
R6  0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  +  +   
R7  0  ￿  ￿  ￿  ￿  ￿  +  +  ￿  ￿  + 
R8  0  ￿  +  +  +   +           
R9   0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  + 
Positive 
 ratio  0%  0%  22%  22%  33.30%  16.60%  50%  40%  20%  40%  78% 
G1  0  ￿  ￿  ￿  ￿  ￿  ￿  +  +  +  ￿ 
G2  0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
G3  0  ￿  ￿  ￿  ￿  +  ￿  ￿  +   +   
G4  0  ￿  +  +  +  +  ￿  +  +  +  + 
G5  0  +  +  +  +   +           
G6  0  +  ￿  +  +  +  +   +       
G7  0  ￿  ￿  ￿  ￿  ￿  +  +  +  +  + 
G8  0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
Positive 
 ratio  0%  25.00%  25.00%  37.50%  37.50%  42.90%  29%  50.00%  66.70%  60.00%  63% 
OR1  0  ￿  +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿ 
OR2  0  ￿  ￿  ￿  ￿  ￿  +  +  +  +  + 
OR3  0  ￿  ￿  ￿  +  +  +   +       
OR4  0  ￿  +  ￿  ￿  ￿  ￿  ￿  ￿  ￿  + 
OR5  0  ￿  ￿  ￿  +  ￿  ￿  ￿  ￿  +  + 
OR6  0  ￿  ￿  +  ￿  ￿  ￿  ￿  ￿  +  + 
OR7  0  ￿  ￿  ￿  ￿  ￿  +  +  +  +  + 
OR8  0  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  ￿  + 
Positive 
 ratio  0%  0%  25%  12.50%  25%  12.50%  37.50%  28.60%  28.50%  57.10%  87.50%   - 152 - 
3.3.7. Development of clinical signs, and lesions at post 3.3.7. Development of clinical signs, and lesions at post 3.3.7. Development of clinical signs, and lesions at post 3.3.7. Development of clinical signs, and lesions at post- - - -mortem mortem mortem mortem       
 
The appearance of clinical signs of SD always coincided with the prior occurrence of 
positive faecal cultures, although in some pigs positive cultures were not followed by 
disease development. Four of the nine non-vaccinated control group pigs developed 
clinical signs of SD, and were killed before the end of the experiment. Lesions of severe 
mucohaemorrhagic colitis were seen at post-mortem examination (a typical example is 
shown in Figure 3.25). Another pig (R2) in the control group had diarrhoea for only 
two days, and at necropsy there were only mild colonic lesions. According to the SD 
definition outlined in 3.2.13, this animal was scored as positive, making the number of 
positive animals 5/9 (56%) for the control group.  The median onset of clinical signs in 
the control group was 14 (9, 10, 14, 17, 21) days after infection. Three out of eight 
(38%)  pigs  in  the  Bhlp29.7  vaccine  group  developed  SD,  with  extensive 
mucohaemorrhagic colitis confirmed at post-mortem examination. For the experimental 
vaccine group, one pig developed diarrhoea 22 day after infection, and had localised 
mucohaemorhagic colitis in the upper 1/3 of the colon at post mortem (Figure 3.26). 
Another pig had extensive lesions in the middle half of the colon, but had not shown 
any clinical signs. The other 6 pigs remained healthy, and had no colonic lesion at post-
mortem (Figure 3.24). The incidences of disease in the three groups were therefore 
recorded as 5/9, 3/8 and 1/8, respectively, and these differences were not significant 
(X2=3.419, df=2, P=0.181). A summary of the clinical signs and severity of colonic 
lesions in the pigs at post-mortem is presented in Table 3.6. 
 
The cultures collected at post-mortem were positive in 19 out of 25 animals without 
regards to sampling location (caecum, colon and rectum) (Table 3.6), although some   - 153 - 
colonised pigs did not show clinical signs or colonic lesions. Histological abnormalities 
were  only  found  in  tissue  samples  taken  from  areas  showing  macroscopic  changes 
(Figure 3.27).  
 
 
 
 
 
Figure 3.24. A lack of macroscopic lesions in the colon of an experimental pig. The 
arrows indicate minor hyperaemia observed in the mid-portion of the colon. 
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Figure 3.25. Pathological changes in pig R4 from the control group, showing severe and 
extensive mucohaemorrhagic colitis extending from the caecum to the rectum.  
 
 
Figure  3.26.  Pathological  changes  in  pig  OR3  from  the  vaccine  group.  Localised 
mucohaemorrhagic colitis was present only in the upper one third of the colon.   - 155 - 
 
 
    
 
Figure.  3.27.  Histological  section  of  the  colon  of  a  B.  hyodysenteriae  -infected  pig, 
showing infiltration of a large number of inflammatory cells in the lamina propria, and 
focal  disruption  of  the  colonic  epithelium  with  discharge  of  inflammatory  cells 
(neutrophils) into the lumen (top right) (Magnification × 400). A and B demonstrate 
numerous spirochaetes found in the crypts and invading goblet cells (Magnification × 
1000). 
A 
A 
B 
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Table  3.6.  Clinical  signs,  post-mortem  culture  results  and  colonic  lesions  in  the 
experimental pigs.  
                        PM Culture PM Culture PM Culture PM Culture                 
Pig Pig Pig Pig        Clinical sign Clinical sign Clinical sign Clinical sign        Faeces Faeces Faeces Faeces        Colon Colon Colon Colon        Caecum Caecum Caecum Caecum        Lesion severity Lesion severity Lesion severity Lesion severity       
R1  Dys  +  +  +  Severe 
R2  Dys*  -  -  -  Mild 
R3  EOE  +  +  +  Normal 
R4  Dys  +  +  +  Severe 
R5  Dys  +  +  +  Severe 
R6  EOE  -  -  -  Normal 
R7  EOE  -  +  +  Normal 
R8  Dys  +  +  +  Severe 
R9  EOE  +  -  -  Normal 
G1  EOE  -  -  -  Normal 
G2  EOE  -  -  -  Normal 
G3  Dys  +  +  +  Severe 
G4  EOE  +  +  +  Normal 
G5  Dys  +  +  +  Severe 
G6  Dys  +  +  +  Severe 
G7  EOE  +  +  +  Mild 
G8  EOE  -  -  -  Normal 
OR1  EOE  -  -  -  Normal 
OR2  EOE  -  +  +  Normal 
OR3  Dys  +  +  +  Mild 
OR4  EOE  -  -  +  Normal 
OR5  EOE  -  -  +  Normal 
OR6  EOE  +  +  +  Normal 
OR7  EOE  +  +  +  Mild 
OR8  EOE  +  +  +  Normal 
R1-9:  non-vaccinated  pigs;  G1-8:  the  individual  pigs  in  Bhlp29.7  group;  OR1-8:  the  individual  pigs  in  the 
experimental vaccine group. * mild dysentery observed within two days. DYS = dysentery observed; EOE = 
end of experiment (no dysentery observed). + indicates culture positive, - indicates culture negative.   - 157 - 
3.4. DISCUSSION 3.4. DISCUSSION 3.4. DISCUSSION 3.4. DISCUSSION       
In previous studies, mice have been used as a convenient small animal model for SD 
(Hutto et al., 1998; Kennedy et al., 1997; Suenaga and Yamazaki, 1984; Zhang et al., 
1995). Unfortunately, inconsistent results have been obtained in protection studies using 
this in vivo model system (Murdoch University, unpublished data), Hence, in this study 
the  pig  was  used  as  the  most  representative  experimental  model  for  screening  for 
protective vaccine antigens in SD. In the first instance, for reasons of efficiency and 
economy, four highly expressed proteins were chosen and grouped into one vaccine to 
determine  whether  immunisation  with  these  could  alter  disease  progression  in  the 
natural host. A heterologous challenge was used to ensure that strain differences did not 
compromise protection.  
 
Serological responses to vaccination were used as a means of evaluating their efficacy. 
As determined by ELISA assays, the animals vaccinated with the novel antigens had 
increased serum antibody titres to these antigens after primary immunisation. However, 
a secondary response was not produced and inoculation did not increase the antibody 
response, although the titres after vaccination remained significantly higher than pre-
vaccination until the end of the experiment. This unusual serological response may be 
attributed to the use of several proteins in combination, or due to the high dose rates 
used. Unexpectedly, the non-vaccinated pigs also had elevated systemic lgG and lgM 
titres as their body weights increased, regardless of the coating antigens used in ELISAs, 
although the highest titres were achieved after bacterial challenge. Seroconversion in the 
control  pigs  may  indicate  that  the  experimental  pigs  had  been  exposed  to  other 
spirochaetes prior to the pen trial, even though the herd from which they originated   - 158 - 
was of high health status, and had no evidence of SD. Otherwise, if this antibody profile 
is  validated  in  normal  pigs  by  future  experiments,  the  age  category  should  be 
considered when developing a sensitively serological assay for diagnosing SD. At pre-
bleed, the serum titers in the three groups were not significantly different. Vaccination 
did lead to an obvious antibody response, in that at pre-boost and pre-infection titres in 
the two vaccinated groups were higher than in the unvaccinated control group. Local 
lgA and lgG levels were also on average higher at post-mortem in the Bhlp29.7 and 
experimental  vaccine  groups  than  in  the  control  group,  suggesting  that  the 
immunisation induced production of colonic lgA and lgG. The Western blot assay and 
the positive association between whole-cell and recombinant protein based ELISA titres 
confirmed that  vaccination  with  the  recombinant  antigens  resulted  in  production of 
high levels of specific antibodies 
 
Following  experimental  challenge,  some  of  the  animals  became  shedders  of  B. 
hyodysenteriae, and developed diarrhoea around one week after inoculation. Similar 
intervals  of  time  between  experimental  infection  and  onset  of  shedding  have  been 
described previously (Diego et al., 1995). The onset and duration of shedding in the 
three groups were not obviously different.  
 
Five out of nine (56%) non-vaccinated pigs were clinically affected in this experimental 
challenge. This represents a reasonable number compared to some other studies (Hyatt 
et al., 1994; Jacobson et al., 2004; Jonasson et al., 2004; La et al., 2004), but it would 
have been preferable to obtain a 100% incidence. Only one (13%) pig immunised with 
the  tested  antigens  developed  clinical  signs  of  SD.  This  was  much  less  than  in  the 
unvaccinated control group and the Bhlp29.7 group (38%). Moreover, the onset of   - 159 - 
clinical signs was much earlier in pigs in the control group than in the vaccinated pigs. 
Unfortunately, due to the small numbers of control pigs contracting SD, the apparent 
relative protection achieved by vaccination in this study was not significant. Bhlp29.7 
used as a positive control previously had showed partial protection (La et al., 2004), 
but had little obvious effectiveness in this trial. Dysenteric pigs in the control group had 
severe and extensive lesions in their large intestines at post-mortem. In contrast, the pig 
with clinical signs in the experimental vaccine group showed localized lesions, whilst 
another pig had colonic lesions but no clinical signs. Since this trial was finished 30 days 
after the infection, it is possible that more pigs in the control groups and vaccine groups 
may have developed SD later. Examination at post–mortem showed 19/25 (76%) pigs 
had started to shed B. hyodysenteriae (Table 3.6). Therefore, it could be anticipated 
that more animals would have developed disease if they had been kept for longer. 
       
Results  from  this  study  indicate  that  the  four  recombinant  antigens  can  generate 
systemic and colonic antibody responses, and vaccination tended to delay the onset of 
clinical signs and attenuate lesion development in pigs. Further trials involving large 
numbers of pigs are now needed to determine whether the antigens used either singly 
or  together  in  different  combinations  offer  significant  protection.  In  addition, 
comparative evaluation of alternate dose rates and delivery routes, and design of novel 
antigen delivery systems and more potent adjuvants would certainly be helpful. This 
would enhance the immunogenicity of the recombinant antigens, and in turn provide 
optimal levels of protection against SD. Unfortunately, there was insufficient time and 
the financial resources available were too limited to allow such studies to be conducted 
within the framework of the current thesis. 
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4.1. INTRODUCTION 4.1. INTRODUCTION 4.1. INTRODUCTION 4.1. INTRODUCTION       
 
Swine dysentery (SD) mainly affects swine in the grower/finisher period, and causes 
economic losses through reduced growth rates and poorer food conversion, cost of 
medication, and mortality (Harris and Lysons, 1992). Recovered pigs continue to shed B. 
hyodysenteriae  in  their  faeces  for  the  same  time,  and  are  an  important  source  of 
infection for susceptible pigs (Hampson et al., 1997). Early diagnosis, treatment and 
isolation  of  infected  pigs  from  the  rest  of  the  herd  are  important  measures  for 
preventing the within-herd spread of the disease. On the other hand, prevention of 
transmission of disease between herds requires a proper understanding of the disease 
status of herds supplying and receiving pigs. 
 
Current  diagnostic  methods  rest  on  observation  of  clinical  signs  and  detecting  B. 
hyodysenteriae in the faeces by culture (Harris et al., 1999; Jensen, 1997) or by PCR 
(Atyeo et al., 1998; Atyeo et al., 1999; La et al., 2003). However, culturing is time-
consuming,  and  co-infection  with  other  Brachyspira  species  often  makes  accurate 
diagnosis rather difficult (Hudson et al., 1976; Joens and Harris, 1980). On the other 
hand, PCR tests on faeces also can be limited because of the complex and expensive 
procedure of bacterial DNA extraction, and the possibility of there being PCR inhibitors   - 161 - 
or contamination. In general, these tests are not capable of detecting asymptomatic 
animals, and cannot be readily applied as a routine screening method. 
 
Enzyme-linked immunosorbent assays (ELISAs) have the potential to be used as rapid, 
sensitive  and  reproducible  procedures  for  quantifying  serum  antibodies  to  B. 
hyodysenteriae  in  individual  swine,  and  hence  providing  indirect  evidence  of  the 
disease status of an individual pig or the herd of origin. The availability of reliable 
ELISAs would help determine the presence of SD, provide clinical guidance for medical 
intervention, and could be used to help study the pathogenesis or progression of the 
disease  in  a  herd  by  reflecting  dynamic  changes  in  humoral  immunity.  Previously 
published ELISA assays using sonicated whole cells or LPS as plate-coating antigens are 
sensitive enough to allow detection of SD at a herd level, if sufficient pigs are tested 
(Joens et al., 1982; Smith et al., 1991; Wright et al., 1989). However, due to the many 
cross-reactivities  between  B.  hyodysenteriae  and  other  related  spirochaetes,  false-
positive reactions hampered further development of these assays into a clinical test for 
the  detection  of  individual  infected  animals,  even  when  they  are  coupled  with 
immunoblotting (La and Hampson, 2001). Additionally, LPS-based ELISAs require an 
understanding of the LPS- serogroups of B. hyodysenteriae that are liable to be present 
in a given geographical area, so that an appropriate panel of LPS types can be used as 
ELISA antigen (Mhoma et al., 1992). 
 
The use of recombinant protein-based serological tests should improve sensitivity and 
specificity, provided that the target antigens are immunodominant and devoid of any 
non-specific moieties such as are present in whole-cell preparations. Development of 
novel  ELISAs  containing  such  purified  and  highly  specific  antigens  therefore  should   - 162 - 
improve ELISA performance, and their use should assist in diagnosing SD. Recent work 
in our laboratory showed that the use of recombinant Bhlp29.7 in a whole molecule Ig 
ELISA  could  identify  infected  herds,  but  not  necessarily  individual  infected  pigs  (La, 
2007). As a number of immunoreactive molecules of B. hyodysenteriae were identified 
in  the  studies  described  in  Chapter  two,  here  they  were  further  evaluated  as  ELISA 
antigens.  Hence,  the  purpose  of  the  present  study  was  to  choose  appropriate 
recombinant B. hyodysenteriae antigens for use as class-specific reagents in ELISAs for 
serodiagnosis of SD. These would be assessed for their use in correctly classifying the 
disease status of individual herds when tested with a statistically relevant collection of 
sera from fattening pigs at slaughter, as well as being assessed for their likely usefulness 
in identifying individual pigs that had been exposed to B. hyodysenteriae. In developing 
this  test,  this  study  included  two  steps:  firstly,  a  small  subset  of  sera  was  used  to 
determine which antigens were the most useful for detection of serological evidence of 
SD; secondly, the ELISAs based on the selected antigens were further optimised and 
evaluated on a large set of sera to determine their potential for screening the disease 
status of herds and individual pigs. 
       
4.2. MATERIALS AND METHODS  4.2. MATERIALS AND METHODS  4.2. MATERIALS AND METHODS  4.2. MATERIALS AND METHODS        
       
4.2.1. Serum samples 4.2.1. Serum samples 4.2.1. Serum samples 4.2.1. Serum samples       
 
For the initial antigen selection study, a total of 120 swine sera including 50 from three 
SD-free farms (A2, A4 and A5) and 70 from six infected farms (Table 4.1) were used to 
evaluate  their  reactivities  with  all  antigens.  The  serum  samples  were  obtained  from 
finisher pigs at slaughter, and were collected by veterinarians responsible for the health   - 163 - 
status of the farms. All animals (approximately 22 weeks old) were healthy at the time 
of slaughter, but they originated from herds either considered to be free of SD (A series 
farms)  or  where  SD  had  been  diagnosed  (B  series  farms).  In  subsequent  analysis  of 
recombinant  proteins  NAV-H8,  NAV-H42  and  Bhlp29.7  to  measure  serum  IgM 
response in ELISA, the serum sample size was expanded to 707, including 421 from pigs 
on 5 SD-free farms (A1-A5) and 286 from potentially infected pigs on 5 infected farms 
(B1, B3-B6).  Because of the small number of serum samples (10), farm B2 was not used 
for further testing in this second phase. Serum was separated into aliquots of 500 µl and 
stored at -20°C until used. The numbers of sera and the identity and status of the farms 
are shown in Table 4.1.  
 
Two  hyperimmune  sera  were  produced  in  two  14-week-old  experimental  pigs  by 
vaccinating  them  twice  intramuscularly  at  a  three  week  interval  with  formalinised 
bacterins from B. pilosicoli strain 1648 and B. innocens strain B256T, respectively, in 
Freund’s incomplete adjuvant. These sera were used for assessing any cross-reactivity 
problems in the experiment. Similarly a positive reference serum was produced by twice 
intramuscularly  immunising  a  14-week-old  pig  with  a  B.  hyodysenteriae  B78T 
formalinised bacterin in Freund’s incomplete adjunct. 
 
Eight swine sera from the experimentally challenged control pigs from the previous pig 
vaccine trial (Chapter three) were used as positive samples for protein optimisation. 
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Table  4.1. Sources of field serum samples used in the study. 
Category Category Category Category        Herd identity Herd identity Herd identity Herd identity        Location Location Location Location        No. of sera No. of sera No. of sera No. of sera available  available  available  available       
A1  Queensland  132 
A2  Victoria  236 
A3  Western Australia  12 
A4  Victoria  20 
Non-infected 
Herds 
A5  Victoria  21 
B1  Victoria  127 
B2  Western Australia  10 
B3  Queensland  39 
B4  Queensland  40 
B5  Queensland  40 
Infected 
Herds 
B6  Queensland  40 
* subsets of these sera from herds A2, A4 and A5, and B1 through B6 were used in the 
initial screening experiment. For more details see Table 4.4 in the results section. 
       
4.2.2. Antigen coating 4.2.2. Antigen coating 4.2.2. Antigen coating 4.2.2. Antigen coating       
       
Eight antigens were tested in this study, including six novel proteins (NAV-H7, NAV-H8, 
NAV-H12,  NAV-H17  C-terminal,  NAV-H34  and  NAV-H42),  Bhlp29.7  and  sonicated 
whole cells of B. hyodysenteriae WA1. The recombinant protein Bhlp29.7 was provided 
by Dr. Tom La (Murdoch University). The whole–cell antigen was used as a control in 
the study. Details of production of the other recombinant proteins and whole-cells of B. 
hyodysenteriae were described in Chapter two.    - 165 - 
4.2.3. ELISA assays for determining total specific  4.2.3. ELISA assays for determining total specific  4.2.3. ELISA assays for determining total specific  4.2.3. ELISA assays for determining total specific IgG IgG IgG IgG and   and   and   and IgM IgM IgM IgM       
       
The ELISA assays for IgG and IgM anti-B.hyodysenteriae antibodies were performed as 
previously described in Chapter 3, except that 1% (w/v) bovine serum albumin (BSA; 
Sigma) was used to block non-specific binding instead of 0.01% skim-milk. The working 
concentrations were 0.5 µg/ml for recombinant proteins and 1 µg/ml for whole-cells at 
a  serum  dilution  of  1:200.  Mixtures  of  different  antigens  consisted  of  recombinant 
proteins at 0.5 µg/ml each. After optimising the serum concentration, the field sera 
were  diluted  at  1:  400  for  the  NAV-H42  IgM  ELISAs  and  1:200  for  NAV-H8  and 
Bhlp29.7  IgM  ELISAs  for  large  scale  testing.  All  assays  were  performed  twice  on 
different days to confirm the reproducibility of the results, and the mean values were 
adopted  as  the  final  data.  Sera  were  analysed  for  IgG  and  IgM  titres  using  the 
corresponding conjugates, as described in Chapter 3. 
 
4.2.4 4.2.4 4.2.4 4.2.4. . . .       Optimisation Optimisation Optimisation Optimisation of the protein and serum concentration in NAV  of the protein and serum concentration in NAV  of the protein and serum concentration in NAV  of the protein and serum concentration in NAV- - - -H8 and NAV H8 and NAV H8 and NAV H8 and NAV- - - -H42  H42  H42  H42 
IgM IgM IgM IgM ELISAs  ELISAs  ELISAs  ELISAs       
       
Purified antigens NAV-H8 and NAV-H42 were analysed in ELISA coating buffer (0.1M 
sodium carbonate, pH 9.3) in a two fold serial dilution. The extreme concentration was 
2µg/ml,  diluted  to  0.0156  µg/ml.  A  pool  of  hyperimmune  sera  from  eight  pigs 
experimentally challenged with B. hyodysenteriae BW1 (derived from the vaccine study 
described in Chapter 3) and sera from eight healthy pigs from the A2 group were used 
to optimise the protein concentration.  
 
Using  the  optimal  antigen  concentration,  the  serum  concentration  was  subsequently   - 166 - 
determined  to  maximally  differentiate  the  positive  from  the  negative  samples.  Ten 
positive and 10 negative samples from the B1 and A1 groups respectively were used in a 
two-fold serial dilution (from 1: 25 to 1: 1600). 
 
La (2007) previously had determined the optimal protein and serum concentrations of 
the  recombinant  Bhlp29.7  to  be  30ng/well  at  a  1:200  serum  dilution,  and  these 
concentrations were used in the further analysis of Bhlp29.7. 
       
4.2.5. 4.2.5. 4.2.5. 4.2.5. Expression  Expression  Expression  Expression of ELISA antibody titres and   of ELISA antibody titres and   of ELISA antibody titres and   of ELISA antibody titres and determination of  determination of  determination of  determination of cut cut cut cut- - - -off values off values off values off values       
 
As the results arising from the same plate could be readily compared, the raw antibody 
titres were used in determining the optimal concentration of coating antigens for the 
NAV-H8 and NAV-H42 IgM ELISA assays.        
  
To  avoid  plate-plate/day-day  variation,  the  ELISA  values  were  standardised  using  a 
hyperimmune serum. The positive control serum was incorporated into each plate to 
generate  a  linear  relationship  between  the  predicted  antibody  titres  and  the 
corresponding  observed  serum  titres,  a  procedure  described  as  the  standard  serial-
dilution method (Kurkjian et al., 2005). Regression analysis was performed to produce 
a  six  parameter  standard  curve  from  which  an  equation  was  derived  that  allowed 
conversion of the absorbance reading of the single working dilution directly into the 
predicted antibody titres.  
 
The highest concentration (1:50) in the standard curve was assigned a value of 1000 
concentration  units  (CU),  with  subsequent  1:2  dilutions  expressed  in  CU  (500CU,   - 167 - 
250CU, etc). The optical density (OD) for each test serum specimen was determined by 
subtracting the negative control without serum samples, and subsequently comparing to 
the standard curve and reported CU values.  
 
The cut-off values for detection of IgG and IgM antibodies were established from the 
CU of the normal healthy pigs examined, using the mean plus three standard deviations 
as the cut-off (expressed as mean + 3SD). In further analysis of the NAV-H8, NAV-H42 
and Bhlp29.7 IgM ELISAs,  the mean + 2SD was also used as a second cut-off  to study 
specificity and sensitivity at the pig level, and 2.5 times the mean value of all negative 
pigs (n=421) was used as a third cut-off for herd level detection. For diagnostic study at 
the herd level using the first and second cut-offs, if one pig gave a positive titre, the 
herd was regarded as positive. If the third cut-off was applied, the herd was diagnosed 
as positive when the herd mean antibody value was above the defined negative value 
(2.5 times the mean of all the negative herds). An individual pig serum was deemed 
positive if its titre exceeded the diagnostic cut-off value (Mean + 2 or 3 SD). 
       
4.2.6. St 4.2.6. St 4.2.6. St 4.2.6. Statistical analysis atistical analysis atistical analysis atistical analysis       
       
Positive/negative  results  were  correlated  to  known  herd  health  status  to  establish 
sensitivity/specificity  at  the  herd  level.  The  detection  ratio  was  determined  at  the 
individual pig level as the number of positive sera identified by the ELISAs/total number 
of sera from the infected herd tested. The specificity at the pig level was defined as the 
number of negative sera identified/total number of sera from negative farms tested. The 
data were analysed using SPSS for window XP. Linear regression was used to convert 
OD  values  to  predictive  ELISA  titres  and  to  identify  the  association  between  ELISA   - 168 - 
reactivities  for  the  NAV-H8,  NAV-H42  and  Bhlp29.7  IgM  ELISAs.  The  Pearson 
correlation coefficient was calculated to evaluate reproducibility of the ELISAs. Statistical 
differences  among  more  than  two  groups  were  assessed  using  one  way  ANOVA. 
Variables within and between groups were compared by Student’s t-test. Seropositive 
rates  among  different  recombinant  antigen  groups  were  evaluated  by  Chi-square 
analysis. A P-value<0.05 was considered significant. 
       
4.3. RESULTS 4.3. RESULTS 4.3. RESULTS 4.3. RESULTS       
       
4.3.1. Standardis 4.3.1. Standardis 4.3.1. Standardis 4.3.1. Standardisation of ELISA titres ation of ELISA titres ation of ELISA titres ation of ELISA titres       
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Figure. 4.1. Representation of the relationship between the observed antibody titres of the positive 
control serum sample obtained from serial dilution in a NAV-H34 IgM ELISA and their corresponding 
concentration units. The equation (y= 495.70X - 184.46) produced was used to convert OD value of 
the swine sera at a single working dilution (1:200) into predictive ELISA titres.   - 169 - 
A typical example of a standard curve obtained by serial dilution of the positive control 
serum  in  a  NAV-H34-based  ELISA,  showing  a  regression  line  and  a  corresponding 
equation with a correlation coefficient of 0.988 (p<0.001), is presented in Figure 4.1.  
       
4.3. 4.3. 4.3. 4.3.2.  2.  2.  2. IgG IgG IgG IgG response  response  response  response 
 
In the initial attempt to detect serum IgG responses to the recombinant antigens in 
ELISA assays, NAV-H7 was recognised as the most promising antigen as it could detect 4 
out of six infected herds (66.7% sensitivity) based on the defined cut-off (Mean + 3SD). 
The other antigens presented low sensitivity (ranging from 0% to 33.3%) at the herd 
level  (Table 4.2).  Nevertheless,  the  sensitivity could  be  improved  by  combining the 
antigen results, for example combining the results for NAV-H7 and NAV-H8 would 
result in 5 of the 6 (83.3%) infected herds being detected. Of the 70 positive sera tested, 
18 (25.7%) demonstrated reactivities to one or more antigens.  The numbers of positive 
samples with the different antigens were 11 for NAV-H7, 3 for NAV-H8, 1 for NAV-H12, 
0 for NAV-H17, 4 for NAV-H34, 0 for NAV-H42, 1 for Bhlp29.7 and 5 for the whole-
cell  preparation.  Accordingly,  the  detection  ratios  at  the  pig  level  varied  for  the 
different antigens from 15.7% (NAV-H7) to 0% (NAV-H17) (Table 4.2). Only the NAV-
H7, NAV-H8, NAV-H34 and whole cell ELISAs were completely specific, not incorrectly 
identifying any sera from the negative herds as being positive. The detailed results of 
the IgG-ELISA using the different antigens to examine the individual serum samples are 
presented later in Table 4.4, together with results for the IgM-ELISAs. 
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Table 4.2. Comparative results for reactivities of positive (B series) and negative test 
sera to recombinant antigens and whole cells of B. hyodysenteriae in IgG ELISAs. 
H H H Herd erd erd erds s s s       
(No. of sera) (No. of sera) (No. of sera) (No. of sera)       
NAV NAV NAV NAV- - - -H7 H7 H7 H7        NAV NAV NAV NAV- - - -H8 H8 H8 H8        NAV NAV NAV NAV- - - -H12 H12 H12 H12       
NAV NAV NAV NAV- - - -H17 H17 H17 H17       
C C C C- - - -terminal terminal terminal terminal       
NAV NAV NAV NAV- - - -H34 H34 H34 H34        NAV NAV NAV NAV- - - -H42 H42 H42 H42        Bhlp29.7 Bhlp29.7 Bhlp29.7 Bhlp29.7        Whole cell Whole cell Whole cell Whole cell       
B1 (20)  6  2  0  0  4  0  0  1 
B2 (10)  0  1  0  0  0  0  0  4 
B3 (10)  2  0  0  0   0  0  0  0 
B4 (10)  0  0  0  0   0  0  1  0 
B5 (10)  1  0  1  0   0  0  0  0 
B6 (10)  2  0  0  0   0  0  0  0 
Negative (50)  0  0  1  1   0  1  1  0 
Sensitivity 
(Herd level) 
 
66.7%   33.3%   16.7%  0%  16.7%   0%   16.7%  33.3%  
% positive 
(Pig level) 
 
15.7%   4.3%   1.4%  0%   5.7%   0%   1.4%  7.1%  
Specificity 
(Pig level) 
100%   100%  98%  98%  100%  98%  98%  100%  
The total number of sera reacting positively to each antigen is recorded in the table, and sensitivity, % positive 
and specificity are calculated based on these data. The defined cut-off was mean + 3SD. 
       
4.3.3.  4.3.3.  4.3.3.  4.3.3. IgM IgM IgM IgM response  response  response  response       
 
In analyses for IgM antibodies, NAV-H8, NAV-H42 and Bhlp29.7 were identified as the 
reagents with the highest sensitivity (83.3%, 100% and 83.3% respectively) at the herd 
level (Table 4.3). The other proteins, except NAV-H7 and whole-cell antigens, showed 
some improvement in identifying SD infected herds, compared with their performance 
in  IgG  ELISAs  (Table 4.3).  At the  individual pig  level,  52.9%  (37/70)  of the  serum 
samples from the SD herds tested at a single serum dilution of 1:200 were positive with 
one or more recombinant antigens. The number of serum specimens positive for the 
whole-cell  antigens  was  much  lower  than  for  most  of  the  recombinant  proteins   - 171 - 
investigated.  Seropositive  rates  among  different  recombinant  antigen  groups  were 
highly variable, and ranged from 4.3% for NAV-H17 truncated protein to 42.9% for 
NAV-H42  antigens  in  the  IgM  ELISA  (Table  4.3).  Differences  in  these  values  were 
statistically significant (p<0.01). Of the recombinant antigens, NAV-H8, NAV-H42 and 
Bhlp29.7 reacted with more sera than the other antigens, with 30%, 42.9% and 27.1% 
detection  ratios  respectively,  and  combinations  of  these  results  covered  all  detected 
positive sera (Table 4.4). Only NAV-H12 and NAV-H34 were not 100% specific at the 
herd  level,  as  each  reacted  with  one  serum  sample  from  a  pig  in  herd  A5  (serum 
samples A5-1 and A5-2, respectively). 
 
Table 4.3. Comparative results for reactivities of test sera to recombinant antigens and 
whole cells of B. hyodysenteriae in IgM ELISA. 
Herds Herds Herds Herds              
(No. of sera) (No. of sera) (No. of sera) (No. of sera)       
NAV NAV NAV NAV- - - -H7 H7 H7 H7        NAV NAV NAV NAV- - - -H8 H8 H8 H8        NAV NAV NAV NAV- - - -H12 H12 H12 H12       
NAV NAV NAV NAV- - - -H17 H17 H17 H17       
C C C C- - - -terminal terminal terminal terminal       
NAV NAV NAV NAV- - - -H34 H34 H34 H34        NAV NAV NAV NAV- - - -H42 H42 H42 H42        Bhlp29.7 Bhlp29.7 Bhlp29.7 Bhlp29.7        Whol Whol Whol Whole cell e cell e cell e cell       
B1 (20)  4  14  2  2  9  13  6  1 
B2 (10)  2  1  0  0  2  2  0  0  
B3 (10)  0  2  0  0  1  3   2  0  
B4 (10)  0  0  0  0  0  3  3  0  
B5 (10)  2  3  1  1  2  8  6  2  
B6 (10)  0  1  0  0   0  1  2  0 
Negative (50)  0  0  1  0  1  0  0  0 
Sensitivity 
(Herd level) 
 
50%   83.3%   33.3%   33.3%   66.7%   100%   83.3%  33.3%  
% positive 
(Pig level) 
 
11.4%   30%   4.3%   4.3%   20%   42.9%   27.1%  4.3%  
Specificity 
(Pig level) 
100%   100%   98%   100%  98%   100%  100%  100%  
The total number of sera reacting positively to each antigen is recorded in the table, and sensitivity, % positive 
and specificity are calculated based on these data. The defined cut-off was mean + 3SD. 
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Table  4.4.  IgG  and  IgM  ELISA  results  for  the  investigated  antigens  tested  alone  and  in 
different combinations (IgM) with 120 individual sera. 
Sampl Sampl Sampl Sample* e* e* e*        NAV NAV NAV NAV- - - -H7 H7 H7 H7        NAV NAV NAV NAV- - - -H8 H8 H8 H8        NAV NAV NAV NAV- - - -H12 H12 H12 H12        NAV NAV NAV NAV- - - -H17 H17 H17 H17        NAV NAV NAV NAV- - - -H34 H34 H34 H34        NAV NAV NAV NAV- - - -H42 H42 H42 H42        Bhl Bhl Bhl Bhlp29.7 p29.7 p29.7 p29.7        WC WC WC WC       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H42 H42 H42 H42       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
B1-1  +  [+]      +  [+]        [+]    [+]   
B1-2  +  + [+]      +          [+]  [+]  [+]  [+] 
B1-3    [+]      [+]  [+]      [+]  [+]  [+]  [+]  [+] 
B1-4            [+]  [+]             
B1-5  + [+]  [+]    [+]  + [+]  [+]  [+]      [+]  [+]  [+]  [+] 
B1-6                    [+]  [+]     
B1-7                           
B1-8                        [+]   
B1-9  + [+]  [+]    [+]  +  [+]        [+]  [+]  [+]  [+] 
B1-10    [+]      [+]  [+]    +    [+]  [+]  [+]   
B1-11  +                         
B1-12  + [+]  [+]  [+]      [+]  [+]  [+]    [+]  [+]  [+]  [+] 
B1-13            [+]        [+]    [+]   
B1-14    [+]                [+]       
B1-15    [+]  [+]    [+]  [+]  [+]      [+]  [+]  [+]  [+] 
B1-16    [+]      [+]  [+]  [+]      [+]  [+]  [+]   
B1-17    [+]      [+]            [+]     
B1-18    + [+]      [+]  [+]        [+]  [+]  [+]  [+] 
B1-19  [+]  [+]      [+]  [+]  [+]      [+]  [+]  [+]  [+] 
B1-20    [+]      [+]  [+]        [+]  [+]  [+]   
B2-1                +           
B2-2                +  [+]      [+]   
B2-3                           
B2-4  [+]        [+]  [+]               
B2-5                +           
B2-6                           
B2-7                           
B2-8                           
B2-9                           
B2-10  [+]  + [+]      [+]  [+]    +  [+]    [+]  [+]  [+] 
B3-1  +  [+]        [+]  [+]             
B3-2                          + 
B3-3  +  [+]      [+]  [+]        [+]  [+]  [+]  [+] 
B3-4            [+]  [+]          [+]   
B3-5                           
B3-6                           
B3-7                             - 173 - 
Sampl Sampl Sampl Sample* e* e* e*        NAV NAV NAV NAV- - - -H7 H7 H7 H7        NAV NAV NAV NAV- - - -H8 H8 H8 H8        NAV NAV NAV NAV- - - -H12 H12 H12 H12        NAV NAV NAV NAV- - - -H17 H17 H17 H17        NAV NAV NAV NAV- - - -H34 H34 H34 H34        NAV NAV NAV NAV- - - -H42 H42 H42 H42        Bhl Bhl Bhl Bhlp29.7 p29.7 p29.7 p29.7        WC WC WC WC       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H42 H42 H42 H42       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
B3-8                           
B3-9                           
B3-10                           
B4-1              +[+]             
B4-2            [+]  [+]      [+]      [+] 
B4-3            [+]               
B4-4                           
B4-5            [+]  [+]          [+]   
B4-6                           
B4-7                           
B4-8                           
B4-9                           
B4-10                           
B5-1  + [+]  [+]  + [+]  [+]  [+]  [+]  [+]  [+]  [+]  [+]  [+]  [+]  [+] 
B5-2            [+]               
B5-3  [+]  [+]      [+]  [+]  [+]  [+]      [+]  [+]  [+] 
B5-4            [+]  [+]             
B5-5            [+]  [+]      [+]       
B5-6                           
B5-7            [+]               
B5-8    [+]        [+]  [+]      [+]    [+]   
B5-9                           
B5-10            [+]  [+]      [+]    [+]  [+] 
B6-1              [+]             
B6-2  +          [+]               
B6-3  +  [+]                [+]  [+]  [+]   
B6-4              [+]             
B6-5                           
B6-6                           
B6-7                           
B6-8                    [+]    [+]   
B6-9                           
B6-10                           
False positive results: 
A5-1      +[+]  +    +  +      [+]       
A5-2          [+]                 
+ indicates seropositive based on cut-off of mean + 3 SD. The results for the IgM ELISA are shown in 
parentheses, and  IgG responses are not determined for testing combination of different antigens.  
* For herd identity see Table 4.1. WC = whole cell.         - 174 - 
4.3.4. Combination of different antigens for  4.3.4. Combination of different antigens for  4.3.4. Combination of different antigens for  4.3.4. Combination of different antigens for IgM IgM IgM IgM reactions  reactions  reactions  reactions       
       
In attempting to enhance the performance of the ELISA assays, the four novel antigens 
with the best sensitivity and the highest detection ratios for individual sera (NAV-H7, 
NAV-H8, NAV-H34 and NAV-H42) referred to in Table 4.3 were randomly assigned 
into five different combination groups and subsequently pooled as ELISA plate coating 
antigens to detect systemic IgM.  The best group was found to be a NAV-H8 and NAV-
H42 mixture, with 100% specificity at the herd level and identifying 35.7% positive 
samples (Table 4.5). However, compared with the IgM ELISAs established using single 
molecules,  such  as  NAV-H42  with  100%  sensitivity  at  the  herd  level  and  a  42.9% 
positive rate at the pig level (Table 4.3), or the separate use of NAV-H8 and NAV-H42 
lgM ELISAs that could identify 48.6% (34/70) sera from the positive herds (Table 4.4),  
the combination did not achieve the desired improvement over the unmixed individual 
antigens. The detailed results of IgM-ELISA using mixtures with different antigens studied 
to examine the serum samples are recorded in Table 4.4.  
 
4.3.5 4.3.5 4.3.5 4.3.5. Specificity . Specificity . Specificity . Specificity at the pig level in the s  at the pig level in the s  at the pig level in the s  at the pig level in the small scale testing stage mall scale testing stage mall scale testing stage mall scale testing stage       
 
In the initial test using a small range of samples, 48 of the 50 negative control serum 
samples were constantly negative in the IgG and IgM ELISA. Of the false positive sera, 
one (A5-1) had a positive antibody response to four antigens in IgG ELISA and two 
antigens in IgM ELISA, and the other (A5-2) produced a false-positive result in the IgM 
ELISA using recombinant NAV-H34 (Table 4.4). All investigated antigens could correctly 
identify 98%-100% negative samples. 
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Table 4.5. Comparative results for reactivities of test sera to different combination of 
recombinant antigens of B. hyodysenteriae in IgM ELISA. 
Herd Herd Herd Herds  s  s  s        
(No. of sera) (No. of sera) (No. of sera) (No. of sera)       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
       NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H7 H7 H7 H7       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
           NAV NAV NAV NAV- - - -H34 H34 H34 H34       
NAV NAV NAV NAV- - - -H8 H8 H8 H8       
       NAV NAV NAV NAV- - - -H42 H42 H42 H42       
B1 (20)  1  15  13  8  14 
B2 (10)  2  0  1  1  2 
B3 (10)  0  1  1  1  2 
B4 (10)  0  1  0  1  1 
B5 (10)  1  4  2  3  4 
B6 (10)  0  2  1  0  2 
Negative (50)  0  1  0  0  0 
Sensitivity 
(Herd level) 
 
50%   83.3%   83.3%   83.3%   100%  
% positive 
(Pig level) 
 
5.7%   32.9%   25.7%   20%   35.7%  
Specificity 
(Pig level) 
100%   98%   100%   100%   100%  
The total number of sera reacting positively to each antigen is recorded in the table, and sensitivity, % positive 
and specificity are calculated based on these data. The defined cut-off was mean + 3SD. 
 
4.3.6 Optimisatio 4.3.6 Optimisatio 4.3.6 Optimisatio 4.3.6 Optimisation of protein concentration n of protein concentration n of protein concentration n of protein concentration       
       
The recombinant proteins NAV-H8 and NAV-H42 were tested separately at various 
concentrations for their maximum effect on the ability of the IgM ELISA to differentiate 
between positive and negative sample. The concentrations giving optimal performance 
were  determined  to  be  25ng/well  for  NAV-H8  (Figure  4.2.  A)  and  12.5ng/well  for 
NAV-H42 (Figure 4.2. B).         - 176 - 
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Figure 4.2. Evaluation of varying concentrations of recombinant NAV-H8 (A) and NAV-
H42 (B) at a single serum dilution of 1:200 in an IgM ELISA. 
A 
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Varied serum concentrations in NAV-H42 lgM ELISA
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Figure 4.3. Optimisation of serum concentration in NAV-H8 (A) and NAV-H42 (B) IgM 
ELISAs at the concentrations of 25ng/well and 12.5ng/well, respectively. The bar represents 
the mean antibody titres of the negative (A1, n = 10) or positive (B1, n = 10) groups. The 
curve refers to differences between two groups, calculated from the mean titres of positive 
groups / mean titres of negative group. 
A 
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4.3.7. Optimis 4.3.7. Optimis 4.3.7. Optimis 4.3.7. Optimisation of serum concentration ation of serum concentration ation of serum concentration ation of serum concentration       
 
Using the optimised concentrations, NAV-H8 and NAV-H42 were incubated with serial 
dilutions  of  positive  and  negative  sera  (from  1:25  to  1:3200).  The  optimum  serum 
concentration for the IgM ELISA which showed the maximum difference between the 
positive and negative groups was determined to be 1:200 for NAV-H8 (Figure 4.3. A) 
and 1:400 for NAV-H42 IgM (Figure 4.3. B).  
       
4.3.8. Further large scale evaluation of NAV 4.3.8. Further large scale evaluation of NAV 4.3.8. Further large scale evaluation of NAV 4.3.8. Further large scale evaluation of NAV- - - -H8, NAV H8, NAV H8, NAV H8, NAV- - - -H42 and Bhlp29.7 in IgM ELISA H42 and Bhlp29.7 in IgM ELISA H42 and Bhlp29.7 in IgM ELISA H42 and Bhlp29.7 in IgM ELISA       
 
Using  the  optimised  antigen  and  serum  concentrations,  NAV-H8,  NAV-H42  and 
Bhlp29.7  were  further  evaluated  in  the  IgM  ELISA  with  the  serum  sample  numbers 
extended to 707, including 421 sera from the five negative farms (A series) and 286 sera 
from the five infected farms (Table 4.1; less the 10 sera from herd B2, which were not 
tested). 
 
4.3.8.1.  4.3.8.1.  4.3.8.1.  4.3.8.1.  Specif Specif Specif Specificities  at  the  herd  and  pig  levels  with  the  NAV icities  at  the  herd  and  pig  levels  with  the  NAV icities  at  the  herd  and  pig  levels  with  the  NAV icities  at  the  herd  and  pig  levels  with  the  NAV- - - -H8,  NAV H8,  NAV H8,  NAV H8,  NAV- - - -H42  and  H42  and  H42  and  H42  and 
Bhlp29.7 IgM ELISAs in large scale testing Bhlp29.7 IgM ELISAs in large scale testing Bhlp29.7 IgM ELISAs in large scale testing Bhlp29.7 IgM ELISAs in large scale testing       
 
Using mean + 3SD of the negative herd titres as a cut-off, 11 samples from three of the 
negative herds (A1, A2 and A5) yielded false positive results by one or other of the 
three assays (Table 4.6 and Figures 4.10-4.12), which gave rise to a herd specificity of 
60% for NAV-H8 and NAV-H42, and 80% for Bhlp29.7. The second cut-off (Mean + 
2 SD) had lower specificity, and therefore its potential use for a herd test will not be 
discussed in the remainder of the thesis. When the third cut-off (2.5 times the mean   - 179 - 
value of the negative sera) was introduced, the mean values from each negative herd 
were below the defined cut-off values for each of the three ELISA assays, giving 100% 
specificity at the herd level. A typical example is shown for the NAV-H8 IgM ELISA in 
Figure 4.4, where it can also be seen that none of the negative herds had a mean that 
exceeded the overall cut-off value.  
 
The specificity at the individual pig level for the negative groups was also examined 
using cut-off values either 3SD or 2SD above the mean value. The diagnostic specificity 
was 98.3%, 99.5% and 99.5% for NAV-H8, NAV-H42 and Bhlp29.7 respectively if the 
threshold was set at the high stringency level (Mean + 3SD) (Table 4.6). More than 
96% of the negative samples were below the second cut-off (Mean + 2SD) regardless of 
the  assays  tested.  Serum  sample  A5-1  demonstrated  high  antibody  titres  in  all  three 
assays, and yielded apparently false positive reactivities to NAV-H42 (Figure 4.11) and 
Bhlp29.7 (Figure 4.12), as well as to NAV-H8 (Figure 4.10) if the second cut-off (Mean 
+ 2SD) was used. When the second cut-off was applied to all three assays, 39 sera had 
false positive results, and among these 28.2% (11/39) were reactive to at least two 
antigens. 
 
For  the  purpose  of  addressing  the  apparent  cross-reactivity  problems,  two  serum 
samples from pigs experimentally vaccinated with B. pilosicoli and B. innocens bacterins, 
respectively, were analysed. Both serum samples were classified as seronegative based 
on the diagnostic reference lines in the IgM ELISAs, regardless of the tested antigens 
(Figures 4.10-4.12). 
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4.3.8.2. Sensitivity at the herd level and detection ratio at  4.3.8.2. Sensitivity at the herd level and detection ratio at  4.3.8.2. Sensitivity at the herd level and detection ratio at  4.3.8.2. Sensitivity at the herd level and detection ratio at the  the  the  the pig level pig level pig level pig level       
       
The three molecules again demonstrated a good capacity to identify infected herds in 
IgM ELISAs, with 100% sensitivity based on the first cut-off (Mean + 3 SD) (Table 4.6). 
When the third cut-off was used (2.5 times the negative mean), the sensitivity at the 
herd  level  was  100%  for  NAV-H8  (Figure  4.4),  60%  for  NAV-H42  and  40%  for 
Bhlp29.7.  
 
Using mean + 3SD, NAV-H8 and NAV-H42 identified more positive individuals [21.7% 
(62/286) and 20.3% (58/286) respectively], than Bhlp29.7 with 9.1% positive (26/286) 
(Table 4.6 and Figures 4.5-4.7). Among the sera tested in the NAV-H8 and NAV-H42 
IgM ELISAs, 37 (12.9%) were reactive to both antigens, and a total of 84 (29.4%) sera 
were reactive to either NAV-H8 or NAV-H42. Based on the second cut-off (Mean + 2 
SD)  (Table  4.6),  the  %  positive  for  both  ELISA  assays  were  59.4%  (170/286)  and 
44.4%  (127/286)  respectively.  Moreover,  98  (34.3%)  sera  were  identified  and 
classified as positive in both assays, and 202 (70.6%) of the sera from the positive herds 
were reactive to either NAV-H8 or NAV-H42. 
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Table  4.6.  Summarised  results  for  reactivities  of  707  sera  to  recombinant  NAV-H8, 
NAV-H42 and Bhlp29.7 in IgM ELISA using cut-off values of 3SD and 2SD above the 
mean. 
Herd Herd Herd Herds  s  s  s        
(No. of sera) (No. of sera) (No. of sera) (No. of sera)       
NAV NAV NAV NAV- - - -H8 H8 H8 H8        NAV NAV NAV NAV- - - -H42 H42 H42 H42        Bh Bh Bh Bhlp29.7 lp29.7 lp29.7 lp29.7       
B1 (n = 127)  11 (53)  21 (60)  15 (34) 
B3 (n = 39)  8 (24)  2 (3)  3 (11) 
B4 (n = 40)  6 (28)  4 (4)  1 (3) 
B5 (n = 40)  22 (37)  18 (31)  6 (7) 
B6 (n = 40)  15 (28)  13 (29)  1 (6) 
A1 (n = 132)  2 (5)  0 (0)  0 (1) 
A2 (n = 236)  5 (7)  1 (9)  0 (3) 
A3 (n = 12)  0 (0)  0 (0)  0 (0) 
A4 (n = 20)  0 (0)  0 (0)  0 (0) 
A5 (n = 21)  0 (2)  1 (1)  2 (11) 
Sensitivity 
(Herd level) 
 
100% (100%)  100% (100%)  100% (100%) 
% positive 
(Pig level) 
 
21.7% (59.4%)  20.3% (44.4%)  9.1% (21.3%) 
Specificity 
(Herd level) 
 
60% (40%)  60% (60%)  80% (40%) 
Specificity 
(Pig level) 
98.3% (96.7%)  99.5% (97.6%)  99.5% (96.4%) 
The total number of sera reacting positively to each antigen is recorded in the table, and the data in parentheses 
are calculated based on mean + 2SD cut-off.  
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Figure  4.4.  Diagnostic  sensitivity  and  specificity  at  herd  level  using  the  third  cut-off 
method (2.5 times the mean of all the negative sera) in the NAV-H8 IgM ELISA. For 
group identity see Table 4.1. The solid line represents the cut-off established at 2.5 times 
the mean value of all the pigs from the uninfected herds (153.3 CU), and the mean 
value of the negative pigs is shown with a broken line (61.7 CU). The short line within 
the boxplot represents the mean value of each group. 
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Figure 4.5. Diagnostic and detection sensitivity and specificity in the different groups 
using the NAV-H8 IgM ELISA. For group identity see Table 4.1. Group BP and BI are 
hyperimmune serum against B. pilosicoli and B. innocens respectively. The solid and 
broken lines represent the cut-offs established for mean + 3SD and 2SD respectively. 
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Figure 4.6. Diagnostic and detection sensitivity and specificity in the different groups 
using the NAV-H42 IgM ELISA. For group identity see Table 4.1. Group BP and BI are 
hyperimmune serum against B. pilosicoli and B. innocens respectively. The solid and 
broken lines represent the cut-offs established for mean + 3SD and 2SD respectively. 
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Figure 4.7. Diagnostic and detection sensitivity and specificity in the different groups 
using the Bhlp29.7 IgM ELISA. For group identity see Table 4.1. Group BP and BI are 
hyperimmune serum against B. pilosicoli and B. innocens respectively. The solid and 
broken lines represent the cut-offs established for mean + 3SD and 2SD respectively. 
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4.3.8.3  4.3.8.3  4.3.8.3  4.3.8.3 Comparison of o Comparison of o Comparison of o Comparison of overall antibody titres between the negative and positive herds verall antibody titres between the negative and positive herds verall antibody titres between the negative and positive herds verall antibody titres between the negative and positive herds 
 
The antibody titres in the positive (infected) herds were significantly higher than in the 
negative (non-infected) herds. The differences were about 2.88 fold in the NAV-H8 IgM 
ELISA, 2.38 fold in the NAV-H42 ELISA, and 1.91 fold in the Bhlp29.7 IgM ELISA (Figure 
4.8 ). 
 
 
Figure 4.8. Comparison of antibody titres between sera from the negative and positive 
herds using NAV-H8, NAV-H42 and Bhlp29.7 IgM ELISAs. The bar represents the mean 
value in each group and the error bars are the 95% CI. 
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Further analysis of the antibody pattern in each herd demonstrated that amongst both 
positive and negative groups there were significant differences regardless of the three 
plate coating antigens (P<0.001) (Figure 4.9 A-C). Within the negative and positive 
groups, there also were significant differences between herds (P<0.001), and some of 
the ELISA values determined in the three assays were outside the normal distribution 
range (Figure 4.10).  
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Figure 4.9. Antibody profiles in the different groups using the NAV-H8 (A), NAV-H42 
(B) and Bhlp29.7 (C) IgM ELISAs. Groups A1-A5, negative control herds; groups B1-B6, 
infected herds. 
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Figure 4.10. Distribution of ELISA values using NAV-H8 (A), NAV-H42 (B) and Bhlp29.7 
(C) IgM ELISAs in the five negative herds. 
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4.3.8.5. Association of the three EL 4.3.8.5. Association of the three EL 4.3.8.5. Association of the three EL 4.3.8.5. Association of the three ELISA systems ISA systems ISA systems ISA systems       
 
The ELISA values produced from the three IgM assays were highly correlated (p<0.001) 
(Figures 4.11-4.13). The best correlation was between the NAV-H8 and NAV-H42 IgM 
ELISAs, in particular in the positive subgroup (Figures 4.11 and 4.12). 
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Figure 4.11. Correlation of reactivity of NAV-H8 and NAV-H42 IgM ELISAs for all sera, and 
as positive and negative subgroups. 
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Figure 4.12. Correlation of reactivity of NAV-H8 and Bhlp29.7 IgM ELISAs for all sera, and 
as positive and negative subgroups. 
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Figure 4.13. Correlation of reactivity of Bhlp29.7 and NAV-H42 IgM ELISAs for all sera, and 
as positive and negative subgroups. 
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4.3.9 4.3.9 4.3.9 4.3.9. Reproducibility . Reproducibility . Reproducibility . Reproducibility       
       
The  reproducibility  of  the  results  was  checked  by  duplicating  the  assays  in  different 
plates  on  different  days.        Correlation  coefficients  ranged  between  0.71  and  0.83 
(p<0.001). 
 
4.4. DISCUSSION 4.4. DISCUSSION 4.4. DISCUSSION 4.4. DISCUSSION       
 
It is important to be able to detect exposure to B. hyodysenteriae at both the herd and 
pig level. As far as herd detection is concerned, the diagnostic test should be able to 
correctly  discriminate  positive  from  negative  herds,  as  this  would  help  ensure  the 
infected herds were treated properly and promptly, and that movement of infected 
stock  to  other  farms  was  stopped.  In  the  meanwhile,  the  test  should  give  a  100% 
specificity – correctly identify all uninfected herds. If the test is not 100% specific it 
could  lead  to  significant  costs  for  unnecessary  medical  treatment  and  quarantine 
procedures  in  herds  that  were  incorrectly  diagnosed  with  SD.  On  the  other  hand, 
detection of individually infected pigs would be very useful to help reduce the spread of 
B.  hyodysenteriae  within  and between herds.  The  potential  use  of  the  recombinant 
antigens for development of ELISAs in detecting infected herds and individual pigs were 
studied in this chapter. However, the study was limited by the fact that the field sera 
were not all well-characterised. Although the negative herds were chosen from farms 
without reported SD, their health status was not confirmed by culture. On the other 
hand,  the  positive  sera  were  from  farms  with  SD  observed  by  veterinarians  and 
confirmed  by  culture.  This  implies  that  the  animal  group  had  been  exposed  to  the 
disease,  but  the  individual  pigs  from  which  serum  samples  were  obtained  had  not   - 194 - 
necessarily been infected. For comparative purposes, a whole-cell ELISA (Joens et al., 
1982; Smith et al., 1991; Wright et al., 1989) and a Bhlp29.7 ELISA (La, 2007), both of 
which have been reported as sensitive lgG ELISAs for herd tests, were incorporated into 
this study to investigate them further in class-specific ELISAs, and to compare them with 
the use of the novel recombinant antigens.  
 
Unfortunately, there was insufficient time to test all eight available antigens with all of 
the available sera. A decision was made to screen the antigens using a subset of 120 sera 
in the first instance.  All the recombinant proteins were coated on the ELISA plates at a 
constant  concentration  of  0.5  µg/ml  at  a  1:200  single  serum  dilution,  and  were 
evaluated for their usefulness in IgG and IgM ELISAs. The cut-off value was established 
from 50 pigs in the negative groups, originating from three farms. The mean plus three 
or two standard deviations were adopted as ELISA cut-offs, providing confidence levels 
of 99% or 95%, respectively for data with a normal distribution. For this stage of 
screening, the higher stringency cut-off (Mean + 3SD) was applied, but with this some 
of  the  tests  only  achieved  80%  and  99%  specificity  at  the  herd  and  pig  level, 
respectively. However, due to the small number of negative samples used to set up the 
cut-off, specificity was not a major concern at this stage. The focus of the investigation 
at this phase was on antigen selection, and evaluation of the usefulness of the antigen 
depended on the combinative assessment of diagnostic sensitivity at the herd level and 
% positive identified at the pig level. The IgG responses demonstrated that NAV-H7 
was the best molecule, with the capacity to detect the majority of the infected herds. 
Although antibodies to the other peptides were detected less frequently in ELISAs, these 
molecules could be used as adjunct indicators along with NAV-H7 for herd surveillance. 
Unfortunately, relatively few pigs from the infected herds were detected as positive by   - 195 - 
these antigens in the IgG ELISA. However, considerable improvement for most of the 
tested  antigens  was  obtained  when  the  IgM  ELISA  was  used.  This  study  therefore 
showed  that  detection  of  IgM  reactions  was  more  useful  than  IgG  for  identifying 
infected  animals.  Using  sera  from  the  vaccine  study,  IgM  was  still  the  predominant 
antibody class in the experimental pigs at 21 days post-challenge (Chapter three, Table 
3.3). Similarly, Smith et al (1991) observed a strong ELISA positive response when whole 
B. hyodysenteriae cells were used as the coating antigen to measure IgM antibodies in 
the  period  up  to  2  weeks  post-infection.  In  the  current  study  the  positive  serum 
specimens were collected from animals that were likely to have had exposure to B. 
hyodysenteriae approximately 4-10 weeks prior to sampling. Although it is not clear 
how long serum IgM lasts during the progression of the disease, it is likely that within-
herd infection continues and consequently more pigs become exposed and develop a 
detectable IgM response with time. Generally IgM is accepted as the primary antibody 
response occurring early in bacterial infection (Wood, 2001), and a number of ELISAs 
targeting this molecules have been established to detect infected hosts in the early stage 
of disease (Ehlers et al., 2006; Marangoni et al., 2005; Rawstron et al., 2004). On the 
basis of the present results, on the known immunological properties of IgM, and the 
likely SD prevalence on different farms, it appears that IgM ELISAs could be used as 
sensitive assays to detect herds with SD, and also could have considerable potential to 
be applied to identify individual infected pigs. Certainly, follow-up studies are needed 
to monitor the duration of the systemic IgM response in pigs with SD in order to help 
evaluate and perfect this screening system. 
 
Of  the  recombinant  antigens  analysed  for  IgM  antibodies,  NAV-H8,  NAV-H42  and 
Bhlp29.7 were found to be best for detecting infected herds, with sensitivities of 83.3%,   - 196 - 
100% and 83.3% respectively. Furthermore, the three molecules also seemed to be the 
most promising antigens for identifying individual infected pigs in IgM ELISAs. For both 
the IgG and IgM responses, the whole-cell preparation was less useful than most of the 
purified antigens, with low numbers of pigs recorded as being infected, although it has 
previously been proposed that the whole cell IgG ELISA can aid in diagnosing SD (Joens 
et al., 1982; Wright et al., 1989). This discordance in results may be due to different 
strains prepared as coated antigens, different clinical sample type and size used, the time 
point  of  sample  collection  after  infection  and  the  cut-off  value  adopted.  Generally 
speaking, the whole-cell ELISA did not seem particularly useful as an assay for detection 
of evidence of SD. Nevertheless, the assay may be useful for monitoring progression of 
the disease at the herd level. 
 
In the expectation of improving the level of detection, mixtures of the recombinant 
antigens were used to determine if the sensitivities and specificities were comparable to 
or better than those in single antigen format. Unfortunately, the ELISA performance did 
not  seem  to  be  improved.  This  problem  could  be  related  to  the  use  of  a  high 
concentration of coated antigens or of combined fusion proteins as antigen, as these 
might decrease sensitivity by interference when the antibody-antigen complex is formed 
in the plate wells. In addition, from the point of view of repeatability and specificity, 
serological tests based on a single, well defined immunogen might be advantageous 
over  assays  based  on  multiple  antigen  mixtures.  As  a  consequence,  a  panel  of  key 
antigens should be identified and tested separately to provide definitive evidence of 
their usefulness, and increase the sensitivity of detection.  
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In the next phase of the study effort was focused on the optimisation and analysis of 
NAV-H8, NAV-H42 and Bhlp29.7 in IgM ELISAs using a large number of serum samples. 
These  three  molecules  were  selected  as  they  seemed  to  be  the  best  choice  for 
developing serological assays, based on the preliminary studies. 
 
In  a  previous  serological  survey  of  SD  using  an  LPS-based  ELISA,  the  within  herd 
prevalence  of  infection  was  estimated  at  10%  (Mhoma  et  al.,  1992).  Thus  it  was 
suggested that a sample size of at least 40 sera should be chosen for herd diagnosis to 
achieve an appropriate confidence of 95% of detecting an individual infected pig (La, 
2007; Mhoma et al., 1992). This level of confidence of course assumes that the infection 
is uniformly distributed in the herd, and that the test used is highly sensitive. Due to the 
availability of only 10 sera, one of the positive herds (B2) used in the initial screening 
was  discarded  for  further  antigen  evaluation:  this  small  number  of  samples  had  the 
potential to underestimate the sensitivity of the ELISA system as a herd test. The assays 
for  the  three  molecules  were  re-established  with  optimal  antigen  and  serum 
concentrations.  The new cut-offs (Mean + 3SD or 2SD) were established using 421 
swine sera from 5 SD-free herds, and then used to screen the 286 serum samples from 
the  5  SD  infected  herds.  When  the  mean plus  3  SD  value  was  applied  as  a  cut-off 
criterion, 100% sensitivity at the herd level was achieved in the three assays. However, 
the  ELISAs  only  had  60-80%  specificity  at  the  herd  level,  which  obviously  would 
present important practical problems if used in field situations.  
 
In reviewing the vaccine study reported in Chapter 3, the increase in systemic antibody 
titres was about 1.2-2.5 fold before and after experimental challenge in the control pigs, 
and varied from antigen to antigen. A similar increase has been demonstrated by other   - 198 - 
researchers using ELISAs based on either B. hyodysenteriae whole-cells (Diego et al., 
1995; Joens et al., 1982; La et al., 2004), LPS (Mhoma et al., 1992) or recombinant 
Bhlp29.7 (La et al., 2004) with sera from experimentally infected pigs. Moreover, the 
extent of change in titres after experimental challenge that was seen when using the 
recombinant ELISAs (Chapter 3) was highly correlated with the current performance of 
these proteins using field sera (partial data not shown). If this positive relationship can 
be confirmed in future experiments, this system could be developed as a convenient 
approach to testing the efficacy of antigens as seroconversion indicators, and would be 
particularly useful for our laboratory which is involved in screening a large number of 
candidate  vaccine  antigens.  Consistent  with  this  observation,  when  comparing  the 
positive  and  negative  herds,  differences  were  2.88-1.91  fold  using  the  three  antigen 
based IgM ELISAs, and the extent of this difference also was associated with the overall 
performance of these assays. It seems clear that pigs infected with B. hyodysenteriae 
either naturally or experimentally tend not to exhibit a particular high serum antibody 
response  when  compared  to  other  pathogenic  infection,  which  typically  show  an 
increase  of  more  than  4-10  fold,  and  for  which  successful  ELISA  assays  have  been 
developed (Boesen et al., 2005; Kroll et al., 2005; Lower et al., 2001; Wielkopolska et 
al., 2002). The relative low antibody titres in pigs with SD probably reflect the fact that 
the  infection  is  localised  to  the  large  intestine,  and  there  is  no  general  invasion  or 
spirochaetaemia. 
 
The typical methods for establishing cut-offs in serological assays use the mean value of 
negative controls plus a multiple of the standard deviation of the negative control. The 
major disadvantage of this method is the assumption of a normal distribution of titres 
among  the  uninfected  individuals.  Since  antibody  titres  were  highly  variable  within   - 199 - 
negative groups (discussed later), this method was considered not to be particularly 
suitable  for  herd  detection,  as  false  positive  results  would  occur.  To  overcome  this 
problem, a third cut-off was established based on the mean value of the sera from the 
negative  herds.  Any  herds  with  a  mean  value  greater  than  the  cut-off  would  be 
regarded as positive. An important advantage of this method is that certain doubtful 
(false positive) samples do not have a disproportionate influence on the group value if 
the  group  size  is  big  enough.  Furthermore,  herd  surveillance  could  be  set  up  by 
monitoring  this  mean  value  (and  range),  and  comparing  it  over  time  with  the  set 
threshold. A “herd profile” could be set up on infected herds, and monitored regularly 
to assess the effectiveness of control measures. In the current study, the criterion for 
identifying an infected herd was defined as 2.5 times the mean value of the sera from 
the negative herds. In the NAV-H8 IgM ELISA, the positive threshold was set at 154 CU, 
and it correctly discriminated all negative and positive herds (ie 100% sensitivity and 
specificity). The NAV-H8 IgM ELISA therefore could be used with confidence to detect 
infected  herds.  When  using  this  criterion  the  other  two  assays  also  showed  100% 
specificity, but unfortunately they had low sensitivity. However, as this cut-off method 
was set up in a somewhat arbitrary manner, further optimisation is needed to improve 
the sensitivity of NAV-H42 and Bhlp29.7 IgM ELISA, and to confirm the usefulness of 
the NAV-H8 IgM ELISA as a herd test when used in this format.  
 
At the pig level, use of the mean + 3SD or 2SD was still useful to explore the capacity of 
each  antigen  to  detect  individual  infected  pigs,  as  more  than  95%  of  pigs  from 
uninfected farms had values below the cut-offs. Overall, using the first more stringent 
cut-off,  the  examined  antigens  (NAV-H8,  NAV-H42  and  Bhlp29.7)  had  a  detection 
ratio at the individual pig level of 21.7%, 20.3% and 9.1% respectively. Therefore, the   - 200 - 
assays  using  NAV-H8  and  NAV-H42  appeared  to  be  more  sensitive  in  detecting 
potentially infected animals. In addition, 12.9% of the sera were identified as positive 
by both assays, and ELISA values from both assays were highly correlated, particularly in 
screening the positive groups. Simultaneous application of both assays identified 29.4% 
of  the  animals  from  the  uninfected  herds  as  being  positive,  whilst  70.6%  positive 
animals were identified using the second cut-off value. These results demonstrated that 
the NAV-H8 and NAV-H42 IgM ELISAs could be used together to help confirm the 
disease status or to increase diagnostic sensitivity at the individual pig level.  
 
For the three ELISA antigens, considerable variations in antibody responses were noted 
within and across each group. Variation among and within positive groups is easy to 
understand  as  infected  animals  generally  developed  higher  antibody  titres  than 
uninfected ones, and the numbers of positive animals are likely to be different in each 
herd depending on their degree and timing of exposure, and extent of disease. The 
differences  also  could  arise  from  the  variable  expression  of  proteins  by  different  B. 
hyodysenteriae  strains,  and  the  host  immune  responses  to  different  proteins. 
Additionally,  in  some  of  the  positive  pigs  without  measurable  IgM  antibodies,  class 
switching of the anti-B. hyodysenteriae antibodies to IgG may have occurred. It was 
intriguing that noticeable difference also existed among and within the negative groups. 
Pig age has been found to be related to antibody level (Chapter 3), but such influence 
should be minimal, as all pigs were in the same age range in the study. The difference 
was mainly due to a small number of serum samples that had much higher titres than 
others. These samples were dispersed outside of the normal distribution of the data, 
and hence would be regarded as false positive results even if a high cut-off was applied 
(Mean + 3SD). The apparent cross-reactivity with these control pigs posed a problem in   - 201 - 
achieving specificity. One important issue was that the health status of the control pigs 
from these apparent uninfected farms was not confirmed by culture. It is possible that 
certain pigs from the “negative” farms may have had prior unknown exposure to B. 
hyodysenteriae.  On the other hand, because different samples were cross-reactive to 
different antigens, false positive serological results to B. hyodysenteriae may be due to 
cross-reactivity with antibodies to other bacteria harbouring the gene fragments. In this 
case the specificity can be improved by simultaneous application of different antigen 
based ELISAs, and only scoring a serum sample as positive if it reacts with two or more 
recombinant  antigens.  Cross-reactivity  is  most  likely  to  be  due  to  colonisation  with 
other  Brachyspira  species,  which  have  been  shown  to  share  antigens  with  B. 
hyodysenteriae (Lee et al., 2000). Furthermore, in Western blot, these proteins had 
been found to react with hyperimmune sera to B. pilosicoli and B. innocens (Chapter 2). 
Because of difficulty in obtaining field sera from herds without SD but with known 
infection with B. hyodysenteriae-related bacteria, such cross-reactivity therefore cannot 
be  ruled  out  at  this  stage.  However,  the  preliminary  analysis  of  hyperimmune-sera 
against B. pilosicoli and B. innocens, which were categorized as negative based on the 
defined cut-off points, helps support the likely specificity of these particular antigens in 
the differentiation of infection with other Brachyspira species in the ELISAs.  
 
In conclusion, the serological results suggested that different cut-off methods should be 
used to set up ELISAs for herd and individual pig tests. The newly developed IgM ELISA 
using  recombinant  NAV-H8  is  promising  as  a  diagnostic  tool  for  confirming  natural 
infections with B. hyodysenteriae at the herd level, and monitoring progression of the 
disease within a herd. On the other hand, both the NAV-H8 and NAV-H42 IgM ELISAs 
have potential to be used for detecting individual infected pigs. Interestingly, NAV-H8 is   - 202 - 
annotated as Tolc, involving haemolysin secretion, and NAV-H42 is a putative flagellar 
protein, both of which appear to be associated with important phenotypic features of 
pathogenic  B.  hyodysenteriae.  Hence,  their  potential  usefulness  is  worthy  of  further 
investigation. Future research directions will be discussed in Chapter 5. 
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5.1. INTRODUCTION 5.1. INTRODUCTION 5.1. INTRODUCTION 5.1. INTRODUCTION       
       
This study is the first to report on the application of a “reverse vaccinology” approach 
to  the  identification  of  potential  candidate  components  for  a  subunit  Brachyspira 
hyodysenteriae vaccine. Although the approach of “mining” genomic sequence to help 
identify vaccine candidates now has been successfully applied to a number of human 
bacterial pathogens, to date it has not been widely applied to bacterial pathogens of 
animals. 
 
The main aim of the study was thus to use a reverse vaccinology approach to identify a 
small subset of surface exposed antigens of B. hyodysenteriae, and to test them for their 
efficacy as vaccine components in pigs. In addition, a second aim was to test these 
molecules to determine whether they could be used as a basis for serological tests to 
identify infected pigs and/or herds. Both of these project aims were achieved in the 
study.  
       
5.2. BIOINFORMATIC ANALYSIS 5.2. BIOINFORMATIC ANALYSIS 5.2. BIOINFORMATIC ANALYSIS 5.2. BIOINFORMATIC ANALYSIS       
 
The general principle for selecting vaccine components is that the candidates should be 
highly  immunogenic,  expressed  in  vivo  and  conserved.  Bacterial  outer-membrane 
proteins  are  known  to  be  accessible  to  the  host  immune  system,  and  therefore  are 
considered  as  major  targets  for  designing  vaccine  subunits.  With  the  availability  of   - 204 - 
various bioinformatics tools, putative surface-oriented molecules easily can be identified 
from in silico analysis. However, in the first screening stage, only a proportion of ORFs 
from the whole genomic sequence can be analysed. The computer-based approach used 
in the current study facilitated the selection process, and allowed unbiased identification 
of a small number of candidate genes. Genomic mining strategies currently consist of 
predicting  a  function  and  cellular  location/surface  features,  although,  unfortunately, 
none of the computer programmes currently available can give a definitive prediction. 
Hence, the final selection of suitable candidates depends on the overall evaluation of 
the information obtained. In this section of the study, partial genomic sequences of B. 
hyodysenteriae were utilized so as to complete my PhD project within the required 
timeframe.  Nineteen  putative  ORFs  were  selected  as  candidate  genes  encoding 
potential outer membrane proteins or disease-related factors. 
 
5.3. DISTRIBUTION OF PUTATIVE ORFS 5.3. DISTRIBUTION OF PUTATIVE ORFS 5.3. DISTRIBUTION OF PUTATIVE ORFS 5.3. DISTRIBUTION OF PUTATIVE ORFS       
       
The  next  part  of  the  study  was  undertaken  to  ensure  that  the  selected  ORFs  were 
present  throughout  all  or  most  strains  of  the  species,  and  not  just  restricted  to  the 
sequenced strain. In many cases, one of the major obstacles for the development of 
effective vaccines is that they often only impart immunity to the serotypes included in 
the vaccine. In the case of B. hyodysenteriae, there are 11 LPS serogroups (Hampson et 
al., 1990; Hampson et al., 1991), and immunity is largely serogroup specific (Hampson 
et al., 1997). Hence bacterin vaccines for B. hyodysenteriae have had limited success. In 
addition, B. hyodysenteriae is a recombinant species (Trott et al., 1997), with extensive 
exchange of genetic alleles within and between members of the genus (Zuerner et al., 
2004),  and  this  could  result  in  the  absence  of  certain  ORFs  in  certain  strains,  or   - 205 - 
expression of variant proteins. Furthermore, different pathogenic isolates are distributed 
in  different  geographical  locations.  Fortunately,  with  the  nearly  complete  genomic 
sequence now available, it was possible to identify potentially effective vaccine subunits 
likely to be distributed throughout the genetically diverse species. Preliminary screening 
then was set up to identify conserved sequences by examining the distribution of the 
selected  candidate  genes  amongst  23  strains  of  B.  hyodysenteriae  (involving  7 
serogroups),  originating  from  different  geographic  regions.  The  selection  criterion 
established was that if a gene could be amplified by PCR from more than 90% of B. 
hyodysenteriae  strains  investigated,  it  would  be  considered  ubiquitous  in  B. 
hyodysenteriae and would be taken into the next step of the overall process. In total, 
17 out of 19 candidate genes met this criterion and were selected for further work. The 
conserved nature of these genes and their products suggests that they have important 
functions in the spirochaete. Based on in silico analysis, the translated products of these 
putative genes were annotated as transport, translocase, flagellin-related, enzyme or 
unknown outer-membrane proteins. Nevertheless, their functions need to be clarified 
by further experiments. Their distribution in other Brachyspira spp. was not investigated, 
as  their  presence  in  these  spirochaetes  should  not  cause  a  problem  for  vaccine 
development. 
 
5.4. GENE CLONING AND PREP 5.4. GENE CLONING AND PREP 5.4. GENE CLONING AND PREP 5.4. GENE CLONING AND PREPARATION OF RECOMBINANT PROTEINS ARATION OF RECOMBINANT PROTEINS ARATION OF RECOMBINANT PROTEINS ARATION OF RECOMBINANT PROTEINS       
 
In modern vaccinology, gene cloning and protein purification act as a standard platform 
for further evaluating the efficacy of candidate molecules as components of vaccines. An 
E. coli mediated expression system was employed in the study, as this system is easy to 
manipulate, and has high growth rates and low nutritional requirements. However, not   - 206 - 
all gene products could be purified in native form in this bacterial system, which is a 
known problem with the existing protein expression technology (Ross et al., 2001). 
Although correct folding is important for eliciting a protective immune response, the use 
of denatured peptides for screening the immunogenicity of some of the antigens did not 
present a problem at this stage of this study. Another potential problem with the E. coli 
system is that genes with low G+C content (typical of B. hyodysenteriae) are difficult to 
express. Consistent with this, of the 19 cloned genes, 5 could not be expressed. In the 
future it would be useful to attempt to express these genes using different expression 
systems or truncated regions of the proteins. Finally, 14 recombinant fusion proteins 
originating from 12 genes were obtained either in a native conformation or precipitated 
as  inclusion  bodies.  This  still  represented  a  substantial  number  of  potential  vaccine 
components for further testing, given the time constraints of the project. 
       
5.5. IMMUNOGENICITY SCREENING 5.5. IMMUNOGENICITY SCREENING 5.5. IMMUNOGENICITY SCREENING 5.5. IMMUNOGENICITY SCREENING AND SEQUENC  AND SEQUENC  AND SEQUENC  AND SEQUENCE  E  E  E ANALYSIS ANALYSIS ANALYSIS ANALYSIS       
 
Immunogenicity  studies  are  a  crucial  element  in  the  process  of  screening  antigens. 
Usually, a series of convalescent sera from individuals infected with different bacterial 
strains are reacted with the selected antigens. In this way immunogenic proteins with 
conserved epitopes can be identified using techniques such as immunoblotting. Due to a 
lack of well-defined sera, the current study deviated from this classical approach in that 
a range of sera from pigs in different stages of exposure to B. hyodysenteriae were 
tested  with  the  candidate  proteins.  To  address  potential  sequence  variability  of  the 
selected antigens among different B. hyodysenteriae strains, the whole coding region of 
each of the candidate genes was sequenced and subjected to multiple alignments to 
verify the level of homology among the different alleles. From the above studies, seven   - 207 - 
fusion proteins derived from six genes reacted with the tested sera, and the antigen 
sequences  were  highly  conserved  in  the  investigated  B.  hyodysenteriae  strains.  The 
immunogenicity and expression of the antigens were further verified by analysing post-
immunisation sera against each recombinant protein.  
 
To further rationally reduce the number of candidate proteins for use in vaccines, it is 
recommended that additional studies be undertaken to assess the immunogenicity and 
confirm the computer-predicted surface location of each polypeptide. In the current 
study an agglutination assay was used to assess antibody binding, but other methods 
such as ELISA and flow cytometry/immunofluoresence assays could be used to measure 
antibody titres of post-immunisation sera, and to determine the ability of these antisera 
to bind to the surface of live bacteria. In addition, the availability of reliable small 
animal  models  and  in  vitro  assays  for  testing  the  efficacy  of  candidate  antigens  is 
essential  when  attempting  to  select  protective  antigens  from  a  large  number  of 
candidates. Therefore, priority should be given to establishing such systems. In fact, a 
mouse model has been developed for B. hyodysenteriae colonisation in our laboratory, 
based on models developed elsewhere. It was not used in the current study because 
inconsistent results have been encountered when it has been used in previous vaccine 
studies at Murdoch University (unpublished data). Discordance in results for the mouse 
and the pig might be due to different intestinal environments in the two species, or the 
influence of other factors such as diet, age, administration routes and infectious dose 
used. Many of these variables have not been fully standardised. 
 
In conclusion, 19 ORFs were identified from in silico analysis as outer-member proteins 
and/or virulence factors. After screening by a variety of assays in the laboratory, the   - 208 - 
candidates were reduced to six gene products that were immunoreactive, conserved 
and expressed in vivo.  
 
5.6. PROTECTION STUDY IN  5.6. PROTECTION STUDY IN  5.6. PROTECTION STUDY IN  5.6. PROTECTION STUDY IN PIGS PIGS PIGS PIGS       
 
An  advantage  of  the  current  study  was  that  the  natural  host  species  of  B. 
hyodysenteriae (the pig) was available for evaluation of the vaccines. Using the pig 
directly thus avoided the complications and uncertainties of using an animal model such 
as the mouse. The disadvantage of using pigs is that they are expensive and difficult to 
work with, particularly as they grow considerably during the course of a vaccine trial. 
Vaccination,  infection  and  monitoring  are  also  time-consuming.  Because  of  these 
constraints on time, and on our funding, a decision was made to test the potentially 
synergic effects of four proteins as a combined vaccine. If positive results were obtained, 
individual evaluation of each component could then be undertaken to locate the best 
targets,  followed  by  re-formulation  of  more  rational  antigen  combinations. 
Unfortunately, this second phase was beyond the scope of the current study. 
 
Humoral  immunity  has  been  given  extensive  attention  in  studies  of  SD,  and  is 
commonly regarded as one of the important parameters for assessing vaccine efficacy 
(Twigg,  2005).  The  vaccine  was  administrated  by  the  intramuscular  route,  which  is 
easily implemented for purified proteins, and was shown to elicit both systemic and 
mucosal  antibody  responses.  Mucosal  immunity  provides  a  first  line  of  defence  in 
preventing colonisation and invasion by intestinal pathogens (Csencsits et al., 2002), 
hence it was thought important to evaluate this. Although an immune response at the 
colonic mucosal surface was induced in this study, efforts should be made to maintain   - 209 - 
this to provide long-term protection. This could be done for example by development 
of local antigen delivery systems such as using plant delivery, with prolonged feeding of 
recombinant  protein  expressed  in  the  plant  tissues,  and/or  the  use  of  potent 
adjuvants/immunomodulators to stimulate more prolonged mucosal immunity, and/or 
the  use  of  alternative  administration  routes  such  as  nasal  or  oral  immunisation. 
Numerous researchers have suggested that cell-mediated immunity in SD is likely to be 
important in the pathogenesis and mechanisms of protection in the colon (Jonasson et 
al., 2004; Jonasson et al., 2006; Waters et al., 1999a; Waters et al., 2000). As a result, 
analysis  of  local  (colonic)  cell-mediated  immunity  in  pigs  will  provide  additional 
information in regards to the efficacy of the antigens. Again, examining this aspect was 
beyond the scope of the current study. 
 
Each pig in the experimental vaccine group was immunised with 1 mg of each of the 
four recombinant proteins in total. This dosage was mainly established by reference to a 
previous pig experiment that used 2 mg of recombinant Bhlp29.7 for each animal, and 
which achieved a 50% reduction in SD development (La et al., 2004). However, this 
dose  rate  is  rather  high  in  comparison  with  other  pig  studies  which  used  vaccine 
subunits with 0.03-0.2mg/per pig (Gabe et al., 1995; Terzić et al., 2003a; Terzić et al., 
2003b). In practice, the use of too high a dose of antigen does not necessarily increase 
the immune response (Palache et al., 1993a; Palache et al., 1993b). Another potential 
problem  with  multicomponent  vaccines  is  that  their  use  can  affect  the  resultant 
antibody  profile  (Brown  et  al.,  2005).  As  observed  in  the  experimental  vaccinated 
animals,  a  secondary  “boost”  response  was  not  induced  following  the  second 
immunisation.  Consequently,  understanding  the  impact  of  each  component  on  the 
immune response, and using optimal concentrations of individual components will be   - 210 - 
critical in defining the composition of an effective vaccine formulation (Brown et al., 
2005). These studies need to be undertaken with each of the four vaccine candidate 
antigens. 
 
The  results  from  this  vaccine  trial  demonstrated  that  the  multicomponent  vaccine 
delayed  the  progression  of  the  disease  and  alleviated  lesion  development. 
Unfortunately, although fewer vaccinated pigs than unvaccinated controls developed 
disease, significantly protective efficacy could not be demonstrated, apparently mainly 
due to the small group size used in the study. In this context, it is noteworthy that the 
positive  control  group  vaccinated  with  Bhlp29.7  also  did  not  obtain  significant 
protection. In part, this apparent lack of efficacy also might be associated with a heavy 
experimental challenge caused by housing vaccinated and unvaccinated pigs together. 
Additionally,  as  mentioned  earlier,  the  correct  conformation  of  each  antigen  is 
important for protective immunity, and the tested antigens were prepared in denatured 
form. In follow-up experiments, the candidate antigens should be expressed in native 
conditions and then evaluated using a larger number of animals.  
 
In the end, parenteral vaccine efficacy heavily relies on administration with adjuvants in 
order to stimulate effective immune responses. Adjuvants have an absolutely essential 
function  for  the  development  of  B-  and  T-  cell  responses  by  triggering  antigen-
presenting cells to upregulate co-stimulatory molecules, to process and present antigens, 
migrate  to  lymph  nodes,  and  secrete  cytokines  that  induce  appropriate  Th1  (cell-
mediated)  or  Th2  (antibody-dominated)  responses  (Hackett  and  Harn,  2006).  The 
adjuvant used in this study was oil-based, and its development was based on empirical   - 211 - 
approaches. Further studies should include consideration of the use of other adjuvants, 
including those that boost mucosal immunity. 
       
5.7. DEVELOPMENT OF  5.7. DEVELOPMENT OF  5.7. DEVELOPMENT OF  5.7. DEVELOPMENT OF A  A  A  A SEROLOGIC SEROLOGIC SEROLOGIC SEROLOGICAL ASSAY FOR  AL ASSAY FOR  AL ASSAY FOR  AL ASSAY FOR SD SD SD SD       
 
In addition to vaccine development, six immunoreactive proteins (NAV-H7, NAV-H8, 
NAV-H12, NAV-H17, NAV-H34 and NAV-H42) defined from genomic screening were 
investigated for their potential usefulness for establishing novel ELISAs for the serological 
diagnosis of SD at the herd and individual pig level.  
 
Colonisation  by  B.  hyodysenteriae  induces  a  strong  immunologic  response,  hence 
infected animals can be discriminated from uninfected animals by measuring circulating 
antibody titres against specific antigens (La and Hampson, 2001). However, to date 
there has been a lack of availability of species-specific and highly immunogenic proteins 
to establish reliable serological assays for detecting evidence of SD. The ELISA has been 
recommended  as  a  standard  serological  assay  whenever  it  is  applicable.  Although  a 
number of B. hyodysenteriae surface associated proteins previously have been identified 
and characterised, their suitability as plate coating antigens in ELISAs have not been 
established. In the current study, the use of the six novel proteins and two previously 
reported  ELISA  antigens  (whole-cell  and  Bhlp29.7)  were  compared.  Two  antigens 
(NAV-H8  and  NAV-H42)  were  subsequently  selected  as  promising  discriminatory 
antigens in IgM ELISAs. 
 
Room still exists for further improvement in the lgM ELISAs based on the NAV-H8 and 
NAV-H42 recombinant proteins. First, optimisation of the assay conditions (eg. pH, ion   - 212 - 
concentration,  incubation  time  and  temperature)  might  increase  sensitivity.  Second, 
multiple  antigenic  regions  have  been  identified  in  both  NAV-H8  and  NAV-H42  by 
computer  predictions.  Using  truncated  parts  containing  key  epitopes  or  preparing 
monoclonal antibodies as  a blocking  agent  in  a  competitive  ELISA  test  are likely  to 
improve  these  assays  for  detecting  B.  hyodysenteriae-specific  antibodies.  Third,  the 
recombinant  NAV-H42  was  purified  in  denaturating  conditions.  As  the  correct 
conformation of an antigen is important for generating an immunologic response, an 
ELISA based on the native protein should be assessed in parallel. 
 
The major limitation of this study was the uncertain disease status of some of the herds, 
which made the interpretation of the serological results difficult. Negative sera were 
examined on a herd basis, and it is possible that some of the animals had come from 
herds with unrecognised exposure to B. hyodysenteriae, which would decrease the test 
specificity and sensitivity. On the other hand, the positive sera used in this study were 
from infected herds, but individual pig sera tested may not necessarily have been from 
infected animals. This then would hamper accurate assessment of the assays at the pig 
level.  Therefore,  to  accurately  judge  the  ELISA  system’s  performance  and  to  set  up 
universal assays for different laboratories, a large number of negative and positive sera, 
individually confirmed by other independent tests such as culture and PCR, should be 
obtained and tested. Also sera from pigs of different age groups should be examined to 
establish reasonable baselines, as antibody titres varied with age (Chapter three). Finally, 
potential cross-reactivity should be re-assessed by testing a range of field sera from pigs 
exposed  to  other  bacteria  that  are  related  to  B.  hyodysenteriae.  If  applicable,  pre-
adsorption of the sera with related bacteria could be done to improve ELISA specificity, 
since this should reduce the occurrence of cross-reactive results. A problem with this   - 213 - 
approach could be the reduction of genuine antibody titres, so this procedure might be 
best reserved for individual sera where cross-reactivity is suspected to be a problem. 
Equally, such suspect sera could be tested for specific antibody content by Western blot 
analysis against a panel of recombinant antigens. 
       
5.8. SUMMARY 5.8. SUMMARY 5.8. SUMMARY 5.8. SUMMARY       
       
The  reverse  vaccinology  approach  applied  in  this  study  demonstrated  its  power  by 
identifying  useful  target  antigens  for  SD  vaccine  and  diagnostic  development.  The 
project  aims  thus  were  considered  to  be  achieved.  Six  molecules  were  identified  as 
promising  proteins,  of  which  four  that  were  evaluated  in  a  combination  induced 
systemic  and  local  antibody  responses  and  alleviated  disease  progression  in 
experimentally infected pigs. In the serological study, two antigens showed potential for 
detecting individual infected pigs, and one could be used as the basis of an apparently 
robust herd test.  
 
Future experimental use of the recombinant proteins described in this thesis should help 
consolidate  our  knowledge  on  the  pathogenesis  and  seroepidemiology  of  B. 
hyodysenteriae, and provide additional information in relation to the efficacy of these 
antigens as vaccine subunits and/or as diagnostic antigens. Currently, a gene knock-out 
system for B. hyodysenteriae has been established in our laboratory. Specific genes are 
being inactivated to investigate the functions of the molecules, and the virulence of the 
mutant strains also will be tested, as such strains have the potential to be used as live 
attenuated vaccines. Furthermore, to maximum use of the entire genomic sequence of B. 
hyodysenteriae,  microarray  analysis  and  proteomics  are  being  incorporated  into  the   - 214 - 
platform  of  reverse  vaccinology  to  extend  and  validate  all  the  candidate  genes 
identified in our laboratory.  
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B78T               ....................................................................................................  
N5503/92           ....................................................................................................  
155.18             ....................................................................................................  
WA1                ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           TGCTCAAGAATTATTAAATTGGTATACAAAAAATGGATCTACTTCTACTTTAGAAGCTTGTCAGTCTGAAGTTCAAACTCGTCCTTTTGTTACAACAGAA  
ACK300/8           ....................................................................................................  
B78T               ....................................................................................................  
N5503/92           ............................................................................................T.......  
155.18             ....................................................................................................  
WA1                ....................................................................................................  
Clustal Consensus  ******************************************************************************************** *******  
 
                           910       920       930       940       950       960       970       980       990       1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           GAAATCAAAAATATAAAAACAGGTGATTCTGTAAGAATAACAGCTGACTTCTTTGCAAGCCAGTCTTTAATAACAGAGGATAAATTAACTGTTGTTGACC    - 252 - 
ACK300/8           ....................................................................................................  
B78T               ....................................................................................................  
N5503/92           ....................................................................................................  
155.18             ....................................................................................................  
WA1                ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1010      1020      1030        
                   ....|....|....|....|....|....|....|... 
V2809/87           AAAATGTAGATACTGAATTATTAGGTAAAGCATTAAAT  
ACK300/8           ......................................  
B78T               ......................................  
N5503/92           ......................................  
155.18             ......................................  
WA1                ......................................  
Clustal Consensus  **************************************  
 
 
 
A.2. CLUSTAL X (1.83) multiple sequence alignment in NAV-H8 
 
                            10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGAAAATAAGTGTTAAAATAATTTTATGTTCTATTGTATTTATAAATATTTTATATGGTCAAACAAATACTTTGACTTATGCTGCTTATATGGAAACTA  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TAAGAGATCAAATACCAGAACTAAAAATAAATGCTGTAACAGAAACTAATGCTCAGATGAATTTACTTAGTGCTGAAAGTTCAGGAGATGTAAATTTATC  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TGCACAGTTTGGAGCAGTAGGTAAATACGGAAGTTTATCAAGCGGATACACTAGTACTACAGCTAGCCCAAGTGTCAATGCCGCAGGAATACAGGCTGGA  
WA1                .................................................................................................... 
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ................................................................................................A...  
Clustal Consensus  ************************************************************************************************ ***  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATTGGACTAGGTTCTTTAATACCTTATACAGGAACTAAATGGTCTGTTAATTTAACTCATACTTCTTTTTTAGGCGGTAAATTAAATATGCCTGGAGGTC  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               .............................................................................A......................  
Clustal Consensus  ***************************************************************************** **********************  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           AGTCTGTAGATTTTAATAATTATCAGCCTTCATTAACATTAGAAGTAACTCAGCCTCTTTTAAGAAATTTTTTCGGTACTTTAGATAAATATCCTATAAA  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               .................................................................................................... 
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           AGATGCTGAATATGCTCTTGCTATAGCTAAGCTTCAAAGAAAATTAGATGATGCCAGCGTTATTGTTTCATATCAGAAAATTTATTATCAATGGATAATG  
WA1                ....................................................................................................  
NAVH8-D94.00498    ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TACGAAAAACTTCTTGCTTATTACAGAAACATGTATATAACTGCTAAAAGATTTGAAAATCAGATGAGAGACAGATACAATAACGGACTTATAGATAATG  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ACTCTTATCAGAACGCAAGAACACAAACTATGGTTTACAGTGATTATTATGCACAGAATCAGGTTTACTTAGATAGTCTTTTAGCAACTGTAAGTTTCTT  
WA1                .......................................................A............................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................    - 253 - 
Clustal Consensus  ******************************************************* ********************************************  
 
                           810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TATGCCTGTAACTAATATAAAGCCGGATCATACTACTTGGGATGCTTATTTAGATTTAGGAAGCAATATGCAGATGGAGGCAGTTCCTTTCGCTGATAGT  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           910       920       930       940       950       960       970       980       990       1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATAAACGGACAAATAGCATATCAATCTAAAATAAGAGCTGAATATACTCTTGATGCTATGAAAAACGGTACATTACCTAATTTAGACTTTGTAGGAAGTG  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ............................................................................................G.......  
B204               ............................................................................................G.......  
Clustal Consensus  ******************************************************************************************** *******  
 
                           1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TAAGTCTTAATGGTCTTAGTCCTAATACTGAAGGATATTTTAAATCTTTCGGCAGTATGACAAATGTTGATTTCTTTGCCGGAGTGCAGTTCTCTTATCC  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               .........................C.....................................................T....................  
B204               .........................C.G...................................................T....................  
Clustal Consensus  ************************* * *************************************************** ********************  
 
                           1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATTAGGAAACAGAGCAAATAAAGCACAATATCAAATGGCTGAAAACTCATTATATGGAATAATAGCTCAATATGATCAATTAGAAAAAGATTTTAATACT  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ................................................T...................................................  
B204               .........T......................................T...................................................  
Clustal Consensus  ********* ************************************** ***************************************************  
 
                           1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           CAATTACAGACATATATTTCTAAATTTAATGCTTACAAAAATTTAATAGCAAGCAAACAAATGCAGATAAGAGCAATTAATTCAAGAATAGCTACTCAGC  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               ....................................................................................................  
B204               ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TTCAAAAACTTGATCAAGGACGTTTAGAAATCGATGATTTACTTACATCAAGGTTGGAACTTGTAGCTACTCAGACAGAGCTTTTGAATCTTCAGTACGA  
WA1                ....................................................................................................  
D94.00498          ....................................................................................................  
B78T               ....................................................................................................  
B169               .........................G..........................................................................  
B204               .........................G..........................................................................  
Clustal Consensus  ************************* **************************************************************************  
 
                           1410      1420      1430      1440      1450    
                   ....|....|....|....|....|....|....|....|....|....|.. 
D90.8506           ATTTATAACGACTATATTTGATTACAGAGCTTTGCTTGCCATAGATTATGAA  
WA1                ....................................................  
D94.00498          ....................................................  
B78T               ....................................................  
B169               ....................................................  
B204               ....................................................  
Clustal Consensus  ****************************************************  
 
 
 
A.3. CLUSTAL X (1.83) multiple sequence alignment in NAV-H12 
 
                            10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           ATGAAAGTTTTTATTAGTGCGGATATTGAAGGAATTACCACAACTACACAATGGCCTGATACAGATGCAGGAAGTTTAACTTATAAAGATCATGCACTTC  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ...............................................C....................................................  
Q4662.4            .................................................................................................... 
D94.00498          ....................................................................................................  
Clustal Consensus  *********************************************** ****************************************************  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           AAATGACTAAAGAAGTTAAAGCGGCATGCGAGGGAGCTATTGATGCTGGAGCAAAAGAAATATTTGTAAAAGATGCCCATGACTCTGCTATGAATATATT  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ...................................................................................................C  
Q4662.4            .................................................G..........................G.......................  
D94.00498          .................................................G..........................G.......................  
Clustal Consensus  ************************************************* ************************** **********************   
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           TCAAACTGCTTTGCCTGAATGCGTGAAAATACATAGAAGATGGAGCGGAGATCCTTATTCTATGATAGAAGGTATTGATGAGAGCTTTGATGCTATAATG    - 254 - 
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ....................................................................................................  
Q4662.4            ....................................................................................................  
D94.00498          ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           TTTATTGGATATCATAATGCAGCTTCTATTGGAAATAATCCGCTTTCTCATACTATGAATACTAGAAATGTTTATGTGAAGCTTAATGAAGTATTAGCAA  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ...............................................G....................................................  
Q4662.4            ...............................................G....................................................  
D94.00498          .............................C......................................................................  
Clustal Consensus  ***************************** ***************** ****************************************************  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           GTGAATTTATGTTTTTTAGTTATGCGGCAGCTTATAGAAAAGTGCCTACAGTATTTTTATCAGGAGATAAAGGATTATGCGAAGTAGCACAAAATATGCA  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           .C.........................................A........................................................  
Q4662.4            .C.........................................A........................................................  
D94.00498          .C.......................T.................A........................................................  
Clustal Consensus  * *********************** ***************** ********************************************************  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           GCCTAATCACCCTAATTTAGTAACTCTTCCTGTTAAAGAGGGTGTAGGTTATTCTACTATAAATTACTCTCCTAATTTAATGGTTAAAATGATTAAAGAG  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ...........................................A................C.....T..A........G....................A 
Q4662.4            ...........................................A................C.....T..A........G....................A  
D94.00498          ...........................................A................C.....T..A........G.....................  
Clustal Consensus  ******************************************* **************** ***** ** ******** ********************   
 
                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           AAAACTAAAGAGGCATTGAGTCAAGATTTTAAAGGTAAATTATTAAAACTTCCTAATCATTTTAAATTAGAGATTTGTTATAGGGAACATGGATACGCTC  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           ......................................G.............................................................  
Q4662.4            ......................................G.............................................................  
D94.00498          ................................G...................................................................  
Clustal Consensus  ******************************** ***** *************************************************************  
 
                           710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
V2809/87           ATAAAGTATCATTCTATCCTGGAGCTAAAAAAATTAATGATACTACGGTAATTTTTGAAAATAATGACTATTATGAAATACTAAGAGCCTTGAAATTTAT  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
D90.8506           .......G............................................................................................  
Q4662.4            .......G............................................................................................  
D94.00498          ....................................................................................................  
Clustal Consensus  ******* ********************************************************************************************  
 
                      805        
                   ....| 
V2809/87           ATTA                                                                                                  
155.9              ....                                                                                                  
WA1                ....                                                                                                  
D90.8506           ....                                                                                                  
Q4662.4            ....                                                                                                  
D94.00498          ....                                                                                                  
Clustal Consensus  ****         
 
          
 
A.4. CLUSTAL X (1.83) multiple sequence alignment in NAV-H17 
 
                  10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               ATGGGAGCAATGGACTTAGTATTCAAATTAATATTCGGCTCTAAAGAACAAAATGACGCTAAAATATTAAAACCTATAGCAGAAAAAACATTAACCTTTG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AAGAAGAGATAAAAAAATTAAGCAATGAAGAACTTACAAATAAAACAAAAGAATTCAGGGAAAGAGTAGAAAAATACATAGGATGCAAAACAGAAGAATT  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AGATTTAAGCAAAGAAGAAAATAAGAAAAAACTTCAGAATATATTAGATGAAATACTTCCAGAGGCATTTGCTGTGGTTCGTGAGGCTAGTATAAGAACT  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................    - 255 - 
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               ACAGGAATGAGACACTTTGATGTTCAGGTTATGGGTGGAGCAGTACTTCATCAGGGAAGAATTGCCGAGATGAAAACAGGTGAAGGTAAAACTCTTGTTG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ...................................A........................................................A.......  
D90.8506           ...................................A........................................................A.......  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  *********************************** ******************************************************** *******  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               CTACCCTTGCTGTTTATCTTAATGCTTTAACAGGATTAGGAGTGCATGTTGTTACAGTAAACGATTACCTCGCTAAAAGGGACGCTGAATGGATGACTCC  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TATATATTCTATGCTTGGTATAAGCGTAGGAATACTTGATAATACAAGACCCCATTCACCTGAAAGAAGAGCCGTTTATAACTGCGATGTTGTTTATGGT  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               ACTAACAATGAGTTTGGATTCGACTATTTAAGAGATAATATGGTAACTAGAAAAGAGGATAAAGTTCAAAGAAAATTCTACTTTGCCATAGTCGATGAGG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TAGACAGTATTTTGATAGATGAAGCTAGAACTCCTCTTATCATATCAGGACCTGCGGAAAAAAACATAAAAATGTACTATGAAATTGATAGAATCATACC  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TATGCTTAAACAGGCTGAAGTTGATGAGAGAATGCGTGAGGTAGCAGGCACTGGTGATTATGTATTAGATGAAAAAGATAAAAACGTATACCTTACAGAA  
Q4662.4            ....................................................................................................  
B169               ................................................................C.T.................................  
B78T               ................................................................C.T.................................  
D90.8506           ................................................................C.T.................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  **************************************************************** * *********************************  
 
                           910       920       930       940       950       960       970       980       990       1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               GAAGGGGTACACAAAGTAGAAAAACTCCTTAATGTTGAAAACTTGTACGGAGCTCAAAGCAGTACAATAGTTCACCATGTTAATCAGGCATTGAAAGCTC  
Q4662.4            .....C..............................................................................................  
B169               .....C...........................................................T..................................  
B78T               .................................................................T................................A.  
D90.8506           .....C...........................................................T................................A.  
WA1                .....C..............................................................................................  
V2809/87           .....C..............................................................................................  
Clustal Consensus  ***** *********************************************************** ******************************** *  
 
                           1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               ATAAAGTATTCAAAAAAGACGTTGATTATATGGTTACCGACGGAGAAGTTTTGATTGTAGATGAGTTTACAGGCCGTGTGCTTGAAGGAAGAAGATACAG  
Q4662.4            ....................................................................................................  
B169               .........................................................................A.....A.....G......C.T.....  
B78T               .........................................................................A.....A.....G......C.T.....  
D90.8506           .........................................................................A.....A.....G......C.T.....  
WA1                ...................T................................................................................  
V2809/87           ...................T................................................................................  
Clustal Consensus  ******************* ***************************************************** ***** ***** ****** * *****  
 
                           1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               CGACGGACTTCACCAAGCAATAGAAGCTAAAGAAAAAGTTGCTATACAAAATGAATCTCAAACTTATGCTACAATTACATTCCAGAACTATTTCAGAATG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................    - 256 - 
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TATCCTAAACTTTCTGGTATGACAGGTACTGCTGAAACAGAGGCTGAAGAGTTTTATAAAATATATAAATTAGACGTTGCTGTTATACCTACTAATAAGC  
Q4662.4            ....................................................................................................  
B169               ..................................................A..C...............C.T..T.........................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ************************************************** ** *************** * ** *************************  
 
                           1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               CTATAGCAAGACAGGATTTATCAGACAGAATATACAGAACAAGAAAAGCTAAATTTGAGGCTTTGGCAAAATATATTAAAGAACTTCAGGATGCCGGAAA  
Q4662.4            ....................................................................................................  
B169               ..............................................G...........A.........................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ********************************************** *********** *****************************************  
 
                           1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               ACCTGCTCTTGTAGGTACTGTATCAGTTGAAATGAACGAAGAATTATCAAAAGTATTCAAAAGACATAAAATTAATCATGAAGTATTGAATGCTAAAAAC  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               CACTCAAGAGAGGCTGCAATAATAGCACAGGCAGGAGAGCCTGGAGCTGTTACACTTGCTACAAACATGGCAGGCCGTGGTACAGATATTGTGCTTGGAG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1610      1620      1630      1640      1650      1660      1670      1680      1690      1700         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               GAAACCCTGTTGCTAAAGGTGTTGCTGAAATAGAGCAAATACTTGTACTTATGAGAGATAAAGCTTTCAAAGAGAGAGACCCTTACAAAAAAGAGGAATT  
Q4662.4            .............................................................G......................................  
B169               .............................................................G......................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ************************************************************* **************************************  
 
                           1710      1720      1730      1740      1750      1760      1770      1780      1790      1800         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AACAAAGAAAATAAAATCAATAGACCTTTATAAAGAGGCTTTTGTAAGAAGCGTAATATCTGGAAAAATAGAAGAAGCTAAAGAATTGGCTCAAAAAAAT  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               .......................................................................................A............  
D90.8506           .......................................................................................A............  
WA1                .......................................................................................A............  
V2809/87           .......................................................................................A............  
Clustal Consensus  *************************************************************************************** ************  
 
                           1810      1820      1830      1840      1850      1860      1870      1880      1890      1900         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AATGCCGATGAAATGATAGAAAAAATTGACAGAATAATACAAATAAATGAAAAAGCTAAAATAGATAAGGAAAGAGTACTTGCTGCAGGCGGTTTGCATG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               .......................G..............T..G..................G.T.....................................  
D90.8506           .......................G..............T..G..................G.T.....................................  
WA1                .......................G..............T..G..................G.T.....................................  
V2809/87           .......................G..............T..G..................G.T.....................................  
Clustal Consensus  *********************** ************** ** ****************** * *************************************  
 
                           1910      1920      1930      1940      1950      1960      1970      1980      1990      2000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TTATAGGAAGTGAAAGACATGAGGCAAGACGTATTGATAATCAGCTTAGAGGTAGAAGCGGAAGACAGGGAGACCCTGGACTAAGCGTATTTTTCTTATC  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ..................................................................................T.................  
V2809/87           ..................................................................................T.................  
Clustal Consensus  ********************************************************************************** *****************  
 
                           2010      2020      2030      2040      2050      2060      2070      2080      2090      2100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TCTTGAAGATGATTTAATGCGTTTATTCGGAGGTGAGAGAGTTTCTAAAATGATGCTTGCTATGGGAATGGGCGAAGAAGAAGAGCTAGGACATAAATGG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................    - 257 - 
D90.8506           ....................................................................................................  
WA1                G.............................C..C..............G.......................T...........A..T..G.........  
V2809/87           G.............................C..C..............G.......................T...........A..T..G.........  
Clustal Consensus   ***************************** ** ************** *********************** *********** ** ** *********  
 
                           2110      2120      2130      2140      2150      2160      2170      2180      2190      2200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               CTTAATAAATCAATAGAAAATGCTCAGAGAAAAGTTGAAGGCAGAAACTTTGATATAAGAAAGCATTTGCTTGAGTATGATGATGTTATGAATCAGCAGC  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           2210      2220      2230      2240      2250      2260      2270      2280      2290      2300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               GTATGGCTGTTTACGGTGAAAGAGATTATATACTTTACTCTGATGATATATCTCCTAGAGTAGAAGAAATTATATCTGAAGTTACTGAAGAGACTATTGA  
Q4662.4            .................................................................................................... 
B169               ....................................................................................................  
B78T               ................C..G................................................................................  
D90.8506           ................C..G................................................................................  
WA1                ................C..G.....C..........................................................................  
V2809/87           ................C..G.....C..........................................................................  
Clustal Consensus  **************** ** ***** **************************************************************************  
 
                           2310      2320      2330      2340      2350      2360      2370      2380      2390      2400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AGATATAAGCGGAAATAAAAAGAATGTTGATGCTTTAGAAGTAACTAAATGGCTTAACAGTTATTTGATAGGTATAGATGAAGATGCAGCCAATAAAGCT  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               .......................................................................................G..A.........  
D90.8506           .......................................................................................G..A.........  
WA1                .......................................................................................G............  
V2809/87           .......................................................................................G............  
Clustal Consensus  *************************************************************************************** ** *********  
 
                           2410      2420      2430      2440      2450      2460      2470      2480      2490      2500         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               GTAGAAGGCGGAGTTGATAATGCTGTAAAAAATCTTACTAACCTATTATTAGAAGCATACAGAAAAAAAGCATCTGAAATAGATGAAAAAATATTCAGAG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ..........................G.........................................................................  
D90.8506           ..........................G.........................................................................  
WA1                ..........................G.........................................................................  
V2809/87           ..........................G.........................................................................  
Clustal Consensus  ************************** *************************************************************************  
 
                           2510      2520      2530      2540      2550      2560      2570      2580      2590      2600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AAGTAGAGAAAAACATATTCCTTTCAATAATAGATAACAGATGGAAGGATCATTTATTTGCTATGGATAGTTTAAGAGAAGGTATAGGACTTAGAGGATA  
Q4662.4            .................................................................................................... 
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           2610      2620      2630      2640      2650      2660      2670      2680      2690      2700         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               TGCTGAGAAAAACCCTCTTACAGAATACAAACTCGAAGGATATAAGATGTTTATGGCTACTATGAATGTTATACATAATGAGCTTGTAAACTTGATAATG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           2710      2720      2730      2740      2750      2760      2770      2780      2790      2800         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               AGAGTAAGAATAATACCTAATTCATTTGATACTATTGAAAGAGAAAGTGCATTTGACGGAGGCGTTGAAGAAAAAAGCAGTGCTAGTGCTATGAATGGAG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           2810      2820      2830      2840      2850      2860      2870      2880      2890      2900         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
B204               GAAATGCTCAAGCTATTCAAAGCAAAGTAAAAAATGCACAGCCTAATGTTAAAATGGCTCAGAAAATAGGAAGAAATGATCCTTGTCCTTGCGGAAGCGG  
Q4662.4            ....................................................................................................  
B169               ....................................................................................................  
B78T               ....................................................................................................  
D90.8506           ....................................................................................................  
WA1                ....................................................................................................  
V2809/87           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           2910      2920      2930      2940         
                   ....|....|....|....|....|....|....|....| 
B204               AAAGAAATATAAGCATTGCCATGGGAAGGATAATCCTCAG                                 
Q4662.4            ........................A...............                                                              
B169               ........................................                                                              
B78T               ........................A...............                                                                - 258 - 
D90.8506           ........................A...............                                                              
WA1                ........................................                                                              
V2809/87           ........................................                                                              
Clustal Consensus  ************************ ***************   
 
 
 
A.5. CLUSTAL X (1.83) multiple sequence alignment in NAV-H34 
 
                            10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGGGAGTCAAAAAGTATTTCTTTTTATTGCTAGTCTTATTAGCTATGAATAGTATATATGCATTTGCAAATCAAAATATTATAAGAGTACAATTAACAG 
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGTAAAAGCACCATATACTATTAATATCAAAGGACCATATAAAGCATACAATTATAAATATGAAAGTGAAATTATATCTGCTCTTACCAATGAAACTGT  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           AATGGTAGTTGAAAACAGATTAGGATTAAAAGTTAATGAAGTAGGAGTTTATAAAGAAGGTATAGTATTTGAAACTCAGGATGGATTTACTTTAAATGGT  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATTGAATATTATGGTTCTTTAATGTTTATTCCATATAATGATACAATGATAGTTGTTAATGAACTTAATATTGAAGATTATGTTAAAGGAGTACTTCCTC 
D94.00498          .................................................................................................... 
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGAAATGTCTCCTGATTGGCCTATGGAAGCTTTAAAAGCTCAGGCAGTAGCAGCTAGAACTTATGCTATGTATCATATATTAAAAAATGCTAATAAACT  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           .................................................................................................... 
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           TCCTTTTGATGTTGATAATACTACAAAATATCAAGTTTATAATGGTAAAGAAAAAATGAATTGGTCTGTAGAACAGGCAGTTGATAGAACTAGATATGAG 
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATTGCTGTTTATAAAGGAAAAGTTATAGCTACATATTTCAGTGCTTTATGCGGCGGACATACTGATAGTGCTGAAAATGTATTTGGTGTTGCTGTTCCTT  
D94.00498          ....................................................................................................  
Q4662.4            .................................................................................................... 
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATTTGGGCGGTGTTGCTTGTCCTTACTGCAATGCTCAGATTAAGCCTTGGACTAATGCTTTGAGTTATAATGAGCTTAATAATGATTTAGCTAATTATTC  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|   - 259 - 
D90.8506           TGTACATGCTACTGAAAAATCTTCTATAGGTATAAGTACTGATCCTAAATCTGGAAAAGCTACTAATATAAAAATAGATAATAATGATATTACTTCAAGA  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              .................................................................................................... 
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           910       920       930       940       950       960       970       980       990       1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           GATTTCAGAACTACTCTTTCTCCTAGATTAGTACCTTCACTTAACTTCACTATTAAAAAAGTTGATAACGGTATTATAATCACTGGAAAAGGAAGTGGAC 
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGGAGTAGGTATGTGTCAGTGGGGTGCTTACGGTATGGCACAAGTAAAAAAAGATTATAAAGAGATTTTAAAATTCTATTATAACGGAGTTGATATCGT  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           1110      1120      1130      1140      1150         
                   ....|....|....|....|....|....|....|....|....|....| 
D90.8506           AGATTATAATAGAGTTAATAAAGAGTTTGAACCCGATGTATGGGGAAAT                        
D94.00498          .................................................                                             
Q4662.4            .................................................                                                     
V2809/87           .................................................                                                     
155.9              .................................................                                                     
WA1                .................................................                                                     
ACK300/8           .................................................                                                     
Clustal Consensus  *************************************************                          
 
 
 
A.6. CLUSTAL X (1.83) multiple sequence alignment in NAV-H42 
 
                            10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           ATGAATATGAAAAGATTAAGTATCTTGATAACAATGTTAATTCTAACTGTTGCATTCTTGTTGTTTGCCCAAGATGCGGCTCAAACAGGTGAGCAAACTA  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           CTCAAAATCAGGGTGAAAATGGTAATAACTTCGTAACTGAAGCTATCACTAACTACTTAATAGATGATTTTGAATTTGCTAATACTTGGCAAGCTTCTAT  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           GCCTAGAGATTACGGTGTAGTTAGCATCATTCGTCGTGAAGGCGGTCCAGCTGATGTTGTAGCTGAAGGTGCTGAAAATAATAAATATATTTTAGGTGCT  
D94.00498          ....................................................................................................  
Q4662.4            .................................................................................................... 
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           AAAGTAGAGTACTTCAGAACAGGTTATCCTTGGTTCTCTGTTACTCCTCCTAGACCTGTTAAAATACCTGGTTATACTAAAGAACTTAGTGTTTGGGTAG  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           CTGGTCGTAACCATAATAATAGAATGAGTTTCTATGTTTATGATGTAAACGGTAAGCCTCAAGCAGTTGGTAATGAAGCTCTTAACTTTATGGGTTGGAA  
D94.00498          ....................................................................................................  
Q4662.4            .................................................................................................... 
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................    - 260 - 
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           AAACATTACTGTACAAATTCCTGCTAATATAAGACAAGAAGAATTCAGAGGACAAGTTGAACAAGGTATTAGCTTTATGGGTATACATGTTAAAGTTGAT 
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
D90.8506           CCTAGAGATTCTTATGGTAAATATTATATATACTTCGATCAATTAATGGCTAAGACTGATATGTACTTAGAAACTTATAGAGAAGAAGATGACCCATTAG  
D94.00498          ....................................................................................................  
Q4662.4            ....................................................................................................  
V2809/87           ....................................................................................................  
155.9              ....................................................................................................  
WA1                ....................................................................................................  
ACK300/8           ....................................................................................................  
Clustal Consensus  ****************************************************************************************************  
 
                           710         
                   ....|....| 
D90.8506           ATACTTGG                                                               
D94.00498          ........                                                                                     
Q4662.4            ........                                                                                              
V2809/87           ........                                                                                              
155.9              ........                                                                                              
WA1                ........                                                                                              
ACK300/8           ........                                                                                              
Clustal Consensus  ********                                                                                                                                                                           
 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   - 261 - 
APPENDIX B APPENDIX B APPENDIX B APPENDIX B       
 
 
B.1. Source of laboratory instruments B.1. Source of laboratory instruments B.1. Source of laboratory instruments B.1. Source of laboratory instruments       
 
 
Equipment Equipment Equipment Equipment        Supplier Supplier Supplier Supplier       
ELISA reader  EFLAB, Finland 
GeneAmp PCR System 2400 Version 2.10  Applied Biosystems, USA 
GS Gene Linker UV Chamber  BioRad Laboratories, USA 
Milli-Q Ultrapure Water System  Millipore, Australia 
Mini-Protein dual slab cell  Bio-Rad Laboratories, USA 
Phase Contrast Microscope  Olympus, Japan 
Polaroid 545i Camera  Polaroid Corporation, USA 
Rotary mixer  Ratek Instruments Pty Ltd, Australia 
Shimadzu Spectrophotometer UV-100-02  Ramsay Surgical Ltd, Australia 
Sonicator  Heat Systems, New York, USA 
Soval RC 24 Centrifuge  Dupont, USA 
Techo Thermal Cycler PHC-3 
Dri-block Cycle  Techo Ltd, England 
Uv-1201 UV-Vis Spectrophotometer  Shimadzu Corporation, Japan 
Water bath  Perth Scientific Equipment, Australia 
 
       
B.2. Source of laboratory chemicals and reagents B.2. Source of laboratory chemicals and reagents B.2. Source of laboratory chemicals and reagents B.2. Source of laboratory chemicals and reagents       
 
 
Reagent Reagent Reagent Reagent        Supplier Supplier Supplier Supplier       
Acetic acid  Ajax Chemical, Australia 
Agar 
Becton Dickinson Microbiology 
Systems, USA   - 262 - 
Reagent Reagent Reagent Reagent        Supplier Supplier Supplier Supplier       
Agarose  Bio-Rad Laboratories, USA 
Ammonium persulfate  Bio-Rad Laboratories, USA 
Bacto-Tryptone 
Becton Dickinson Microbiology 
Systems, USA 
Bacto-Yeast Extract 
Becton Dickinson Microbiology 
Systems, USA 
Beta-mercaptoethanol  Bio-Rad Laboratories, USA 
Bromophenol blue  Bio-Rad Laboratories, USA 
5-bromo-4 chloro-3-indolyl phosphate (BCIP)  Sigma Chemical Company, USA 
Calcium chloride  Chem-Supply, Australia 
Chloroform  BDH Chemical, Australia 
Coomassie brilliant blue-250  Bio-Rad Laboratories, USA 
Commercial dye-binding       assay Kit  Bio-Rad Laboratories, USA 
Dimethylformamide  Sigma Chemical Company, USA 
DNA sequencing kit   Applied Biosystems, USA 
dNTP  Pharmacia, UK 
Ethanol  BDH Chemical, Australia 
Ethylenediaminotetre-acetic acid  
tetra-sodium salt (EDTA) 
Ajax Chemical, Australia 
Ethidium bromide  Boehringer Mannheim, West Germany 
d-Glucose  BDH Chemical, Australia 
Gel Drying kit  Promega, USA 
Glutamine  ICN Biomedicals, USA 
Glycerol  BDH Chemical, Australia 
Hyodrochloric acid (HCl)  BDH Chemical, Australia 
IPTG (isopropyl-B-D-thiogalactopyranoside)  Progen Industies LTD, Australia 
Imidazole  QIAGEN, Australia 
Isoamyl-alcohol  Ajax Chemical, Australia   - 263 - 
Reagent Reagent Reagent Reagent        Supplier Supplier Supplier Supplier       
Isopropanol (propan-2-ol)  Fisons Pty Ltd, Australia 
100 and 250bp ladder  Promega, USA 
Lysozyme  Boehringer Mannheim, West Germany 
Kanamycin  Progen Industies LTD, Australia 
Magnesium chloride  BDH Chemical, Australia 
Magnesium sulfate  Chem-Supply, Australia 
Methanol  BDH Chemical, Australia 
Ni-NTA Agarose  QIAGEN, Australia 
Nitro blue tetrazolium chloride (NBT)  Sigma Chemical Company, USA 
Potassium acetate  Ajax Chemical, Australia 
Potassium dihydrogen orthophosphate (KH2PO4)  Ajax Chemical, Australia 
di-Potassium hydrogen orthophospate (K2HPO4)  Ajax Chemical, Australia 
Prestained Marker Proteins  Promega, USA 
Primers  Geneworks, Australia 
Proteinase K  Boehringer Mannheim, West Germany 
QIAprep Spin Miniprep Kit  QIAGEN GmbH, Germany 
QIAquick spin PCR purification kit (50)  QIAGEN GmbH, Germany 
Restriction enzymes  Promega, USA 
RNAse  Boehringer Mannheim, West Germany 
SDS  Bio-Rad Laboratories, USA 
Sodium actetate (CH3COONa)  BDH Chemical, Australia 
Sodium hydroxide (NaOH)  BDH Chemical, Australia 
Sodium carbonate (NaHCO3)  Chem-Supply, Australia 
Sodium chloride  Ajax Chemical, Australia 
Sodium dihydrogen orthophosphate (NaH2PO4)  Chem-Supply, Australia 
di-Sodium hydrogen orthophospate (Na2HPO4)  Chem-Supply, Australia 
Streptomycin  Sigma Chemical Company, USA   - 264 - 
Reagent Reagent Reagent Reagent        Supplier Supplier Supplier Supplier       
Sulphuric acid  Ajax Chemical, Australia 
Temed  ICN Biomedicals, USA 
TRIS  Bio-Rad Laboratories, USA 
Trypticase soy agar (BBL) 
Becton Dickinson Microbiology 
Systems, USA 
Trypticase soy Broth (BBL) 
Becton Dickinson Microbiology 
Systems, USA 
Tween-20  Bio-Rad Laboratories, USA 
Urea  Ajax Finechem, Australia 
Whatman no. 3 filter paper  Whatman International Ltd, UK 
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Alkaline phosphatase (AP) staining solutions: Alkaline phosphatase (AP) staining solutions: Alkaline phosphatase (AP) staining solutions: Alkaline phosphatase (AP) staining solutions:         
Development buffer  100 mM Tris.Cl, pH 9.5;  
100 mM NaCl; 5 mM MgCl2 
   
NBT stock solution  5% NBT in 70% dimethylformamide 
(store at -20°C) 
   
BCIP stock solution 
5% BCIP in 100% dimethylformamide 
(store at -20°C) 
   
Staining solution  66 µl NBT and 33 µl BCIP stock 
solutions in 10 ml development  
buffer (prepare before use) 
   
Blocking Solution for Western Blotting  Skim Milk 5g in 100 ml of TBS   - 265 - 
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Carbonate Buffer (0.1M)  Na2CO3  6.36 g 
  NaHCO3 11.72 g 
 
Make to 400ml with distilled water,  
autoclave, pH 9.8 
   
Gel Overlay Buffer of SDS-PAGE  95% (v/v) I-butanol 
  5% (v/v) distilled water 
   
LB liquid medium  1% Bacto tryptone  
  0.5% Bacto yeast extract 
  0.5% NaCl in distilled water 
   
Loading buffer of SDS-PAGE  10 ml glycerol 
  2.9 ml of 2.5% bromophenol blue 
  0.2% ml of 10% SDS 
  2 ml of 100mM EDTA 
 
Make to 20 ml using distilled water,  
pH 7.5 
   
PBS (10 X )  NaCl 80 g 
  KCl 2g 
  Na2HPO4 14.4g 
  KH2PO4 2.4 g 
 
Make up to 1L with distilled water,  
Autoclave 
   
Protein purification buff Protein purification buff Protein purification buff Protein purification buffers under  ers under  ers under  ers under        
Denaturing conditions: Denaturing conditions: Denaturing conditions: Denaturing conditions:   
Buffer B  13.8 g NaH2PO4 · H2O 
1.2 g Tris base 480.5 g  
PH to 8.0 using NaOH   - 266 - 
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Make up to 1 L with distilled water 
   
Buffer C  13.8 g NaH2PO4 · H2O  
1.2 g Tris base 480.5 g  
PH to 6.3 using HCl 
Make up to 1 L with distilled water 
   
Buffer D  13.8 g NaH2PO4 · H2O  
1.2 g Tris base 480.5 g  
PH to 5.0 using HCl 
Make up to 1 L with distilled water 
Protein purification buffers under  Protein purification buffers under  Protein purification buffers under  Protein purification buffers under        
native conditions: native conditions: native conditions: native conditions:   
Lysis buffer  6.90 g NaH2PO4 · H2O 
17.54 g NaCl  
0.68 g imidazole  
PH to 8.0 using NaOH 
Make up to 1 L with distilled water 
   
Wash buffer  6.90 g NaH2PO4 · H2O 
17.54 g NaCl  
1.36 g imidazole 
PH to 8.0 using NaOH 
Make up to 1 L with distilled water 
   
Elution buffer  6.90 g NaH2PO4 · H2O 
17.54 g NaCl 
17.00 g imidazole 
PH to 8.0 using NaOH 
Make up to 1 L with distilled water 
     - 267 - 
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10% SDS  20 g SDS 
 
Bring final volume to 200 ml with 
Oasis water 
   
4 X  Separating Gel Buffer (1.5 M Tris PH 8.8)  36.3 g Tris base (fw: 121) 
  About 160 ml dH2O 
  PH to 8.8 with concentrated HCl 
  Bring final volume to 200 ml 
   
8 X Stocking Gel Buffer (1 M Tris PH 6.8)  24.2 g Tris base (fw: 121) 
  About 160 ml dH2O 
  PH to 6.8 with Concentrated HCl 
  Bring final volume to 200 ml 
   
Sulfuric Acid (H2SO4 1M)  Sulfuric Acid (95-97%) 5.6 ml 
  ddH2O to 100 ml 
 
Note: Dilute by adding slowly sulfuric 
acid to 80 ml water and mix, adjust 
final volume to 100 ml 
   
50 x TAE  242g/L Tris base 
  57.1 ml/L glacial CH3OOH 
  10ml/L 0.5M EDTA (pH 8.0) 
   
TMB (Tetramethyl benzidine) ELISA substrate  Distilled H2O 10ml 
  0.2 M Na acetate 9.9ml 
  0.2 M Citric acid  0.1 ml 
  H2O2  2.6 µl 
 
TMB 100 mg/ml in 100% DMSO  
260ml 
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Transfer buffer for Western blotting  10 mM NaHCO3 
  3 mM Na2CO3 
  20% v/v methanol 
  PH to 9.9 
   
Tris Buffered saline (TBS)  20 mM Tris 
  500 mM NaCl 
  PH to 7.5 with 1 M HCl 
 
 
 
 